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Abstract
Chemokines have a diverse array of effects on the functions of lymphocytes 
and other immune cells. CXCR6 is a relatively newly discovered chemokine 
receptor, originally thought only to be expressed on a specific-subset of T- 
lymphocytes. It has since bepn identified on a number of cell types, and is not only 
able to function as a human immunodeficiency virus coreceptor, but has been 
implicated in the trafficking of T-lymphocytes in certain inflammatory diseases. The 
ligand for CXCR6, CXCL16, has a novel structure among the members of the CXC 
chemokine family, it that it possesses a mucin-like stalk which enables it to be both 
membrane bound or soluble.
There has currently been little work into the signal transduction mechanisms 
through which CXCR6 and CXCL16 elicit their effects; the aims of this project were 
to identify signal transduction molecules downstream of CXCR6 and determine 
whether CXCR6 is coupled to similar pathways utilised by other chemokine 
receptors. The results indicate that although CXCR6 is implicated in trafficking T- 
lymphocytes, levels of in vitro chemotaxis are very low. However, activation CXCR6 
is able to induce polymerisation of actin which is Goi-mediated, and dependent on 
phosphatidylinositol-3 kinase, protein kinase C, Rho, Rac and Cdc42. CXCR6 
ligation also has an additive effect on the CD3-mediated production of tumour 
necrosis factor-a and mterferon-y, through a pathway not utilised by CXCR4. The 
ability of CXCL16 to induce production of pnoinflammatory cytokines may indicate 
that CXCR6, found at high concentrations in areas of inflammation, may not only be 
involved in trafficking the cells but also in the pathogenesis of the inflammation.
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1.1 The Immune System - an overview
The immune system is similar to other elements of mammalian physiology in 
being composed of specialised cells with specific functions (figure 1). The 
granulocyte-monocyte lineage gives rise to a number of cells involved in the innate 
immune response. Neutrophils, eosinophils and basophils, termed granulocytes 
because of the presence of cytotoxic granules in the cytoplasm giving a distinct 
appearance. They circulate in the blood and migrate into tissues when an 
inflammatory stimulus is detected. The exception to this is the mast cell which bears 
similar morphology to basophils and is mainly resident in tissues. Granulocytes are 
involved in different areas of the immune response with neutrophils predominant in 
the removal and killing of bacteria and fungi and eosinophils predominant in the 
control of infection by parasites. The exact role of basophils and mast cells is less 
well defined, but these cells are significant in the pathogenesis of allergic 
responses. Monocytes have a very short half-life spending approximately 24 hours 
in the blood before migrating into the tissue; tissue-resident monocytes are termed 
macrophages. They also contain some cytotoxic granules, are involved in the 
processing and presentation of antigens and, like neutrophils, are able to ingest and 
destroy pathogens by phagocytosis. Dendritic cells are bone marrow derived cells 
which are particularly important in the presentation to, and activation of, naive T- 
lymphocytes.
Lymphocytes, the major constituents of the adaptive immune system, are 
divided into two subtypes, B-lymphocytes and T-lymphocytes. The main functions 
of B-lymphocytes are the recognition of antigen through surface receptors known as 
antibodies and the presentation of the antigen to T-lymphocytes. Plasma cells are 
non-circulating, differentiated B-lymphocytes whose primary function is to produce 
antibody. T-lymphocytes are pivotal cells in the immune response and are able to 
influence many aspects of immunity. Their functions include the stimulation of B^  
lymphocytes providing a signal to mature into plasma cells and release of soluble 
factors responsible for recruitment, growth, expansion and development of other 
cells.
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Figure 1. The development of blood cells from pluripotent stem cells to mature 
circulating and tissue forms.
HSC, haemopoietic stem cell; LSC, lymphoid stem cell; ESC, erythroid stem cell; GM, 
granulocyte-monocyte common precursor; B, bone-marrow derived lymphocyte; NK, natural 
killer cell (large granular lymphocyte); T, thymus derived lymphocyte, (based on Peakman 
& Vergani, 1997)
T-lymphocytes are defined by the presence of several cell surface markers; 
the receptor for antigen, the TCR (T cell receptor), is present on all T-lymphocytes 
and forms a complex with CD3, composed of five different transmembrane protein 
chains, which transduces to signals from the TCR to initiate cell activation. These 
surface markers are important in T-lymphocyte development (figure 2) (Haks et al, 
1999). Bone marrow-derived precursor cells (thymocytes) enter the thymus where 
they generate cytoplasmic forms of the a and p TCR chains. These are then 
rearranged and are expressed on the surface of the cell; failure to do this will result 
in cell death. The cell then expresses CD3 as well as CD4 and CD8 , accessory 
proteins with affinity for class II and class I MHC (major histocompatability complex) 
molecules respectively; these are important in the recognition of antigen and 
subsequent activation of the T-lymphocyte through the TCR. The double positive
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cell is exposed to self-antigen peptides resulting in four possible outcomes: (i) no 
affinity of the TCR for peptides presented by either class I or II MHC molecules, the 
cell receives no positive signal and cell death occurs; (ii) the TCR has high affinity 
for peptide-MHC complex is potentially dangerous if the cell were to encounter this 
in the periphery, these cells do not continue either; (iii) the TCR has moderate 
affinity for a peptide presented by class I MHC resulting in positive selection of the 
cell which loses the CD4 molecule from the cell surface; (iv) the TCR has moderate 
affinity for a peptide presented by class II MHC resulting in positive selection of the 
cell which loses the CD8 molecule from the cell surface. These T-lymphocytes then 
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Figure 2. Thymic selection and development of T-lymphocytes.
T-lymphocyte precursors (thymocytes) enter the thymus. Cells expressing a T cell receptor 
(TCR) which recognise and have moderate affinity for self MHC (major histocompatibility 
complex) molecules are selected and exit the thymus. These cells can be further developed 
into effector T-lymphocytes either T helper (Th) CD4+ cells or T cytotoxic (Tc) CD8 + cells. 
Thymocytes not selected undergo apoptosis. (based on Peakman & Vergani, 1997)
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Exposure of CD4+ T-lymphocytes to specific cytokines during their maturation can 
produce T helper (Th) cells (HayGlass et al, 1997; Romagnani, 1996). Th cells are 
defined by their cytokine profiles; Th1 cells secrete interferon-y (IFN-y) and 
interleukin 2 (IL-2), while Th2 cells produce IL-2, interleukin 4 (IL-4), interleukin 5 
(IL-5), interleukin 6 (IL-6) and interleukin 10 (IL-10). Major functions of these two 
subsets of T-lymphocytes differ with Th1 cells involved in the activation of 
macrophages and other cytotoxic cells and Th2 cells important in the activation and 
maturation of B-lymphocytes.
Natural killer cells are the third member of the lymphocyte family, 
morphologically similar to T-lymphocytes. Unlike both B- and T-lymphocytes they 
are able to kill tumour and virally infected cells without prior sensitisation.
The immune response is divided into two parts determined by the speed 
and specificity of the reaction (reviewed in Parkin & Cohen, 2001; Rollinghoff etal, 
1997). The innate immune system, present from birth, is the main, first-line defence 
against invading organisms; it typically involves the activation of neutrophils, 
monocytes, macrophages and complement. In contrast, the adaptive immune 
system, based on the development of lymphocytes which respond selectively to 
antigens, is acquired following exposure to pathogens and has both specificity and 
memory. While the mechanisms of immunity are highly efficient in protecting the 
body against antigen, inappropriate or over-activation of the responses are 
detrimental and can give rise to hypersensitivity and autoimmune disorders, like 
asthma, rheumatoid arthritis or multiple sclerosis (Vandenbulcke et al, 2006). It is 
thus essential that the system is strictly controlled; central to this is the appropriate 
recruitment of leukocytes to sites of inflammation. This is a tightly regulated process 
involving molecules expressed on the vascular endothelium including integrins, 
selectins, cadherins, connexins and chemoattractants (C5a, formyl peptide, 
prostaglandins) which direct leukocyte traffic (Worthylake etal, 2001). Of particular 
importance in the trafficking and activation of leukocytes are the members of the 
chemokine family (Wong & Fish, 2003).
Chapter 1: Introduction 15
1.2 Chemokines and Chemokine Receptors
1.2.1 Chemokines
Chemokines (chemotactic cytokines) are low molecular weight proteins 
involved primarily in chemoattraction and regulation of leukocyte trafficking. They 
are classified into families according to both structural and genetic properties 
(Zlotnik, et al, 2000). All chemokines contain at least 3 p-pleated sheets and an a- 
helix in the carboxyl-terminus. Most chemokines contain 4 conserved amino- 
terminal cysteine residues, the positioning of the two nearest the amino-terminal 
denote the sub-family to which the chemokine belongs (Figure 3) (Rollins, 1997).
Chromosomal
Family __________ Structure________________Locus
CXC —^ — ....■—» 'W m sm  14q12-21
cc — u— — » i ■—» i» i7qi 1.2-12
















m m m f
CX3C . 16
ClwmoMM Mucin SMk Cytoplaatnlc
Domain
Figure 3. Structural relationship between chemokine families. The genes of the 
individual chemokine families generally cluster to specific chromosome locations. The basic 
structure of chemokines consists of 3 p-pleated sheets (P1-3) and an a-helix. The 
conserved cysteine residues indicated are the basis for the nomenclature of this superfamily 
(X denotes any amino acid). The CX3C chemokine has an additional structure not found in 
other chemokine families (with the exception of CXCL16). The mucin stalk spans the 
plasma membrane and has a small N-terminal cytoplasmic domain. (Rollins, 1997)
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The majority of chemokines are soluble, however the CX3C chemokine 
(CXsCLI/fractalkine), while containing the general features of the other chemokine 
families, also contains a membrane embedded stalk heavily substituted with mucin­
like carbohydrates (Bazan etal, 1997). A recently discovered chemokine, CXCL16, 
has also been found to have this structure; however it can also be cleaved into a 
soluble form which is also active (Matloubin, etal, 2000).
ELR Chemokines
The tripeptide ELR (Glu-Leu-Arg) motif, immediately preceding the first 
cysteine residue at the amino-terminal, is a common feature of many CXC 
chemokines which act through CXCR1 and/or CXCR2 allowing further classification 
of the CXC chemokines. ELR-positive chemokines are potent neutrophil 
chemoattractants and function as potent angiogenic factors, able to stimulate 
endothelial cell chemotaxis. ELR-negative chemokines have anti-angiogenic 
properties; they inhibit endothelial cell chemotaxis induced by ELR-positive 
chemokines (Strieter et al, 1995; Murphy, 1996)
Inducible and Constitutive Chemokines
A more flexible system for categorising chemokines is dependent on a more 
functional characteristic; the regulation of their production from cells (Mantovani, 
1999; Zlotnik, 2000). Chemokines constitutively (constitutive/ homeostatic) 
expressed in specific organs are believed to have more of a housekeeping role; a 
specific function involving leukocyte trafficking under normal conditions (figure 4). 
Inducible (inflammatory) chemokines are strongly upregulated in peripheral tissues 
following an immune or inflammatory stimulus indicating a role in the development 
of immune or inflammatory responses (figure 5). The genes which encode inducible 
chemokines are located in two major clusters on chromosomes 4 and 17 for CXC 
and CC chemokines respectively; whereas genes for constitutive chemokines are 
sited alone or in small clusters on chromosomes. It has been suggested that 
chemokines located on different chromosomes to the major clusters are probably 
older in evolutionary terms and have been conserved because of their specific 
functions. They are also less likely to share receptors or have overlapping functions 
with other chemokines. In contrast, the functional diversity of the chemokines 
located within the major clusters may be less significant; their main role is likely to 
be the attraction of neutrophils or monocytes, and probably display some 
promiscuity to receptors (Zlonik etal, 2000).
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This classification of chemokines does have limitations; some chemokines 
are constitutively produced, but are also upregulated under inflammatory 
conditions. For example, CCL19 (EBI(EBV-induced gene)1 ligand chemokine/ ELC) 
is constitutively expressed on stromal cells where it is involved in trafficking naive T 
cells and maturing DC into secondary lymphoid organs, however it can also be 
upregulated along with CCL21 (secondary lymphoid tissue chemokine/ SLC) at 
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Figure 4. Functional classification of chemokines.
Depending on the regulation of their production, many chemokines can be categorized 
either as inducible chemokines that are associated with inflammatory and immune 
responses or constitutive chemokines which regulate normal leukocyte trafficking. Some 
chemokines, however, play a pivotal role in both homeostasis as well as in inflammatory 
responses.
1.2.2 Chemokine Receptors
Chemokine receptors are a family of heptahelical G-protein coupled 
receptors (GPCR); typically 340-370 amino acids in length and contain the 
conserved amino acid sequence, DRYLAIV, in the second intracellular loop. This 
motif, exposed following ligation of the receptor by its activating chemokine, is 
known to be involved in G-protein coupling (Murphy, 2002). The nomenclature of 
this family of receptors is based on the structure of their activating chemokines; 
which display some promiscuity between receptors (Table 1). The reason a 
chemokine can activate a number of receptors is not fully understood; although it 
may enable the regulation of different leukocyte subpopulations in acute or chronic 
inflammatory responses.
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Receptor High Affinity Ligands Functional Expression on Immune Cells
CCR1 CCL3,5,7,14,15,16,23 memory T cells
CCR2 CCL2,7,12,13 monocytes, DC, NK, basophils, PMN
CCR3 CCL5,7,8,13,15,24,26 T cells (Th2>Th1), eosinophils, basophils, mast cells
CCR4 CCL17.22 T cells (Th2>Th1)
CCR5 CCL3,4,5 progenitors, Th1, monocytes, macrophages, DC
CCR6 CCL20 memory T cells, DC
CCR7 CCL19.21 T cells, B cells, DC
CCR8 CCL1.4 Th2 cells
CCR9 CCL25 a 4p7+ T cells, DC, macrophages, thymocytes
CCR10 CCL27 CLA+ cells
CCR11 CCL2,8,13 n.a.
CXCR1 CXCL2,3,5,6,7,8 PMN, mast cells, monocytes, macrophages
CXCR2 CXC L1,2,3,5,6 ,7,8 PMN, mast cells, monocytes, macrophages
CXCR3 CXCL9,10,11 T cells (Th1>Th2), B cells, NK
CXCR4 CXCL12 most progenitor cells, T cells, B cells, PMN, 
monocytes, macrophages, DC
CXCR5 CXCL13 B cells, memory T cells
CXCR6 CXCL16 T cells
CX3CR1 CX3CLI PMN, monocytes, NK, T cells
XCR1 XCL1.XCL2 T cells
Table 1. Chemokine receptor-ligand pairs and expression profile
Chemokine receptors are expressed on a wide variety of immune cells. The majority of 
receptors can be activated by a number of chemokines initiating different functional 
responses depending on the activating ligand and environment of the cell. NK, natural killer 
cell; DC, dendritic cell; PMN, polymorphonuclear cell (neutrophil); CLA, cutaneous 
lymphocyte antigen.
The most widely expressed chemokine receptor is CXCR4, present on T 
lymphocytes, neutrophils, monocytes, B lymphocytes and blood-derived dendritic 
cells as well as a number of non-haemopoetic cells. CXCR1 and CXCR2, although 
expressed on most leukocytes, appear only to be functionally active on neutrophils, 
monocytes/macrophages and mast cells (Murphy et al, 2000; Nilsson et al, 1999). 
CXCR3, CXCR5 and CXCR6 are primarily expressed on lymphocytes although 
have been identified on other cell types (Forster et al, 1994; Qin et al, 1998; 
Unutmaz et al, 2000). CCR1, CCR2, CCR4, CCR5, CCR6 , CCR7, CCR8 , CCR9 
and CCR10 are predominantly expressed on lymphocytes, monocytes and
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monocyte-derived dendritic cells (Murphy et al, 2000); while CCR3 is found on 
eosinophils, mast cells, basophils and Th2 lymphocytes (Rubbert et al, 1998; 
Sallusto etal, 1997).
One receptor that does not fulfil this nomenclature criterion is ‘duffy antigen 
receptor for chemokines’ (DARC), a seven-transmembrane domain receptor that 
does not contain the PRY motif found in other chemokine receptors. DARC is able 
to bind the majority of members of the CC chemokine family. It is thought that this 
receptor may act as a buffer enabling concentrations of chemokines to be regulated 
(Fukama etal, 2003).
Chemokine Receptor Expression on T-lymphocytes
Developing lymphocytes express different chemokine receptor profiles 
throughout the differentiation process (O'Garra et al, 1998). Naive T-lymphocytes 
express receptors which traffic them to secondary lymphoid organs and promote 
their interaction with dendritic cells, such as CXCR4 and CCR7. Polarisation of 
naive T-lymphocytes into effector cells results in selective expression of chemokine 
receptors at the cell surface, depending on the cytokines present. Priming of T- 
lymphocytes in the presence of IL-12 promotes production of Th1 cells; these cells 
preferentially express CCR1, CCR5 and CXCR3. CCR5 and CXCR3 are present on 
the majority of peripheral blood memory T-lymphocytes; however they are 
expressed at much higher levels on Th1 cells than Th2 cells (Sallusto et al, 1998). 
The presence of IL-4 during polarisation drives development of Th2 cells which 
selectively express CCR3, a receptor originally described on eosinophils and 
basophils (Gerber etal, 1997). Th2 cells also express CCR4; however this receptor 
is not a faithful marker of Th2 cells, being expressed on cells which do not produce 
IL-4, a key feature of Th2 cells (Sallusto et al, 1998). It has become clear that 
although these profiles are accurate for the majority of cells, there are cells which 
do not conform to the functional characterisation afforded to them by this 
chemokine receptor profile.
Chemokines and Disease
The use of chemokine receptor knockout animals has provided insight into 
the specific roles of these receptors in normal and disease models (Table 2). The 
role of chemokines and their receptors in the trafficking and activation leukocytes 
suggests the possibility that they may play a role in a number of inflammatory
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diseases. It is clear that the correct functioning of these receptors is maintained in 
order for the immune system to respond effectively.
Chemokine
Receptor
Phenotype of knockout References
CCR1
Reduced lung eosinophil infiltration in a 
murine model of asthma 
Resistance to EAE development
Blease et al, 2000; 
Khan et al, 2001; 
Rottman ef al, 2000.
CCR2
Reduced macrophage recruitment to 
inflammatory stimuli 
Increased resistance to atherosclerosis 
Attenuation of bronchial hyper-reactivity in 
a murine asthma model
Blease et al, 2000; 
Boring etal, 1998; 
Gaupp et al, 2003; 
Peters etal, 2001.
CCR3
Absence of eosinophil trafficking to 
intestinal mucosa
Failure of eosinophil migration in a model 
of skin allergic inflammation
Humbles et al, 2002; 
Ma et al, 2002.
CCR4
Reduced airway hyper-responsiveness 
during chronic pulmonary allergic 
responses to Aspergillus
Schuh et al, 2002; 
Reiss ef al, 2001.
CCR6 Reduction in airway resistance, eosinophil 
migration and IL-5 production in the lung
Lukacs et al, 2001.
CXCR2 Protection from septic injury Ness et al, 2003.
CXCR3 Resistance to the development of acute 
allograft rejection
Hancock et al, 2000
CXCR4
Embryonic lethal
Defective development of major organ and 
immune systems.
Plotkin et al, 2003; 
Tachibana etal, 1998; 
Zou etal, 1998.
CX3CR1 Decreased atherosclerosis Lesnik et al, 2003
Table 2. Phenotype of chemokine receptor knockout models.
This table summarises some of the effects observed in chemokine receptor knockout mice.
Chemokine receptors have been found to be important in the pathogenesis 
of some diseases. In rheumatoid arthritis, Th1 cells expressing CCR5 and CXCR3 
infiltrate into the rheumatoid synovium (Bonecchi etal, 1998); however it is unclear 
whether these chemokines are involved in the pathogenesis of the disease and 
what the trigger for the accumulation of these cells is. There are a number of other 
diseases in which a large number of lymphocytes expressing specific chemokine 
receptor profiles accumulate at the site of inflammation. In allergic diseases, such 
as asthma or contact dermatitis, predominantly Th2 cells expressing CCR3 are 
thought to be involved in the disease pathogenesis (Sallusto et al, 1997; Thomas et 
al, 2004). CCL25 has been identified as having a role in the pathogenesis of
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Crohn’s disease by recruiting CCR9+ T-lymphocytes to the small intestine 
(Konstantinos et al, 2001).
In the past decade the involvement of chemokines in pathogenesis of 
human immunodeficiency virus (HIV) infection has been widely studied. In 
conjunction with CD4, CXCR4 and CCR5 have been identified as co-receptors for 
the T-tropic and M-tropic strains respectively (Littman, 1998; Lusso, 2006). The 
chemokines that bind these receptors are able to inhibit viral entry into the cell; this 
is thought to occur because either the chemokine directly blocks the viral binding 
site, or that ligation of the receptor by the chemokine induces a conformational 
change in the receptor such that the virus is no longer able to bind the receptor 
(Arenzana-Seisdedos etal, 1996).
CXCR6 and its Ligand CXCL16
CXCR6 (BONZO/ STRL33 (seven-transmembrane domain receptor L33)/ 
TYMSTR (T-lymphocyte-expressed seven-transmembrane domain receptor)) was 
concurrently discovered by a number of groups in 1997 (Deng et al, 1997; Liao et 
al, 1997; Loetsher et al, 1997). It has 30% homology with other chemokine 
receptors and the gene is localised within the major cluster of other CXC 
chemokine receptors (Liao et al, 1997); and was officially classified as a novel 
chemokine receptor following identification of its ligand, the chemokine CXCL16 
(Matloubin et al, 2000; Murphy et al, 2002; Wilbanks et al, 2001). There has been 
some conflicting evidence about the expression of CXCR6 on cells types, it was 
suggested that CXCR6 could possibly be a marker of Th1 cells because CXCR6 
expression correlates with expression of IFN-y from cells (Calabresi et al, 2002; 
Heydtmann & Adams, 2002; Kim et al, 2001), however it has also been identified on 
other populations of activated T-lymphocytes (Matloubin et al, 2000; Sharron et al, 
2000; Wilbanks et al, 2001), intestinal epithelia cells (Brand, 2002) and aortic 
smooth muscle cells (Chandrasekar et al, 2004). Unlike a number of other 
chemokine receptors, CXCR6 has only one known ligand, CXCL16; currently 
thought to exclusively activate CXCR6 (Matloubin et al, 2000; Wilbanks et al, 2001). 
CXCL16, also identified as the scavenger receptor SR-PSOX, involved in the 
uptake of oxidised low density lipoprotein into macrophages (Minami et al, 2001). 
CXCL16 is expressed on a number of cell types, including dendritic cells, 
macrophages, B cells, vascular endothelial cells (Matloubin et al, 2000; Shaskin et 
al, 2003; Wilbanks et al 2001). CXCL16 shares similar sequence homology with a 
number of chemokines with closest homology, among CXC family members, to
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CXCL12 (18.8%) (Wilbanks et al 2001). CXCL16 exhibits the classic CXC motif in 
the amino-terminal consistent with other members of this family; however the 
predicted chemokine domain is followed by a structure predicted to be a mucin-like 
stalk similar in structure to CX3CL1 (Wilbanks et al, 2001). This allows them to be 
expressed on the cell surface and be released from cells in a soluble form; both of 
which are able to elicit a response from the receptor (Nakayama et al, 2003). The 
soluble form of this chemokine has been suggested to act as a chemoattractant, 
while the membrane-bound form may act as an adhesion molecule (Nakayama et 
al, 2003).
Initially identified as a simian immunodeficiency disease (SIV) co-receptor 
for specific T-tropic strains of the virus (Deng etal, 1997), further studies revealed 
that it has a similar role in the human form of the virus, HIV (Cilliers et al, 2003; Liao 
et al, 1997; Loetsher et al, 1997). While the majority of research into the functions 
of this receptor has been within this field, is has since been implicated in a number 
of other disease pathologies. CXCR6+ cells are enriched in the synovial fluid of 
rheumatoid and psoriatic arthritis patients (Kim etal, 2001); there are high levels of 
CXCR6+ T-lymphocytes present in the liver during end-stage hepatitis C disease 
(Boisvert et al, 2003; Wang et al, 2004); CXCR6+ T-lymphocytes reactive to myelin 
basic protein, a feature of multiple sclerosis, accumulate within the inflamed area of 
the central nervous system (Calabresi et al, 2002; Fukumoto et al, 2004). The role 
of CXCL16 and CXCR6 in the development of atherosclerotic plaques is also under 
investigation (Wdgsater et al, 2004; Wuttge et al, 2004).
1.3 Signal Transduction Pathways
Initiation of a cellular response following activation of a receptor requires the 
co-ordinated activity of many intracellular proteins. The GPCR family contains 
several hundred members which respond to a diverse range of stimuli 
(neurotransmitters, hormones, light). They consist of seven hydrophobic helices 
which span the cell membrane and interact directly with G proteins at the cytosolic 
surface of the cell membrane (Murphy, 2000). G proteins are heterotrimeric proteins 
containing a, p and y subunits which transduce the signal initiated by a ligand 
binding the receptor (Neer et al, 1995). There are a number of isoforms of each 
subunit enabling many potential combinations which can be selectively expressed 
in a given cell or tissue type. The a  subunit contains a binding site for guanine 
nucleotides, which in an inactive cell is occupied by guanine diphosphate (GDP).
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Ligation of the receptor induces a conformational change which enhances the 
exchange of GDP to guanine triphosphate (GTP), a process which causes the 
dissociation of the G protein into an a subunit and a py subunit both of which are 
able to modulate a number of effector molecules (al-Aoukaty et a/, 1996; Neer et al, 
1995). The hydrolysis of GTP to GDP promotes the dissociation of the Ga subunit 
from its effectors and allows reassociation with the Gpy subunit, effectively 
terminating the response.
The activation of chemokine receptors induces signalling pathways involved 
in the control of a variety of biological functions, including chemotaxis, proliferation, 
apoptosis and adhesion. These pathways are complex, often interlinked, and 
despite considerable advances in our understanding, they remain unclear.
1.3.1 Phosphatidylinositol Lipids
Many signalling pathways rely on the metabolism of plasma membrane 
phosphatidylinositol (PI) lipids. PI forms the basic structure for the inositol- 
containing lipids, which consist of a D-myo-inositol-1 -phosphate (InsIP) linked via 
its phosphate group to diacylglycerol (DAG) (Figure 5). Although the inositol head of 
PI has five free hydroxyl groups, only those at positions 3, 4, and 5 can be 
phosphorylated forming lipids collectively known as the phosphatidylinositols or PI 
lipids. There are currently 8 documented phosphatidylinositols; PI, the PI 
monophosphates, PI(3)P, PI(4)P and PI(5)P, the PI bis-phosphates, PI(3,4)P2, 
PI(3,5)P2 and PI(4,5)P2 and PI trisphosphate, PI(3,4,5)P3.
PI lipids reside within membranes and are substrates for kinases, 
phosphatases and lipases resident in or recruited to the membranes. The 
production of PI lipids enables the recruitment of signalling proteins to the plasma 
membrane through the binding of specific lipid binding domains, such as pleckstrin 
homology (PH), Phox homology (PX) and FYVE domains, contained within the 
structures of signalling molecules. While FYVE domains tend to selectively bind 
PI(3)P, PX and PH domains have individual lipid preferences (Simonsen et al,
2001) (Table 3).














Figure 5. Chemical structure of phosphatidylinositol (PI)
Phosphatidylinositol (PI) forms the basic structure of the inositol-containing lipids located 
within membranes. The inositol head group of PI has five free hydroxyl groups; positions 3, 
4, and 5 can be phosphorylated in different combinations (Sotsios et al, 2000).
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Table 3. Selectivity of lipid binding domain containing proteins.
This table describes the PH, PX and FYVE domain containing proteins that preferentially 
bind to PI(3)P, PI(3,4)P2  and PI(3,4,5)P3  (Maffucci et al, 2001; Lemmon et al, 2003).
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1.3.2 Phospholipase C and Calcium
Phospholipase C (PLC) metabolises Pi(4,5)P2 into DAG and inositol 1,4,5- 
trisphosphate (IP3), second messengers which leads to the activation of protein 
kinase C (PKC) and transient increases of intracellular calcium levels (described 
below) (Berridge, 2000). The isoform of PLC involved in the response is dependent 
on the activation mechanism. Of the members of the PLC family (p, y, 5, e), only the 
PLCp enzymes are regulated by heterotrimeric G proteins (Kelley era/, 2001).
Calcium is a pivotal second messenger implicated in the regulation of a 
broad range of cellular processes, including gene transcription, proliferation and 
muscle contraction, through regulation of a number of signalling molecules. 
Intracellular calcium levels are tightly regulated through channels located at the 
endoplasmic (ER) and sarcoplasmic reticulum (SR), as well as at the plasma 
membrane which control the supply of calcium from the stores and extracellular 
space respectively. IP3 is able to induce the release of intracellular calcium stores 
through activation of its receptor, IP3R, on the ER (Berridge et al, 1998). The 
release of calcium regulates the activation of calcium release activated channels 
(CRACs) allowing entry of extracellular calcium (Lewis, 2001). These channels are 
critical for correct functioning of lymphocytes; cells deficient of CRAC activity are 
unable to proliferate or activate transcription factors (Feske et al, 2001; Le Diest et 
al, 1995). There are also store-independent channels which operate distinct of 
CRACs activity, however the exact functioning of these has yet to be determined 
(Owsianik et al, 2006). The subsequent removal of calcium occurs through the 
combined actions of pumps (Ca2+-ATPase), exchangers (Na+/Ca2+ on mitochondria) 
and buffers (calmodulin) (Berridge et al, 2000). It is currently unclear how cells are 
able to decode the changes in calcium concentration; however it is thought that the 
specificity is determined by the amplitude and frequency of the elevation 
(Dolmetsch etal, 1998).
1.3.3 Diacylglycerol and Protein kinase C
DAG is a lipid mediator generated following the hydrolysis of PI(4,5)P2, it 
binds to the C1 domain of proteins, traditionally believed to be contained within 
members of the PKC family, but more recently found in a diverse array of proteins 
including, diacylglycerol kinases (DGKs), protein kinase D (PKD), chimaerin Rac 
GAPs (GTPase activating proteins) and RasGRP (Ras guanyl nucleotide releasing 
factor) (Kazanietz, 2002). DGKs are a family of kinases which may be involved in
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the negative regulation of DAG. DGKy has been shown to phosphorylate DAG 
resulting in phosphatidic acid, therefore reducing DAG levels (van Blitterswijk & 
Housa, 2000). The PKD family (PKD/PKCn, PKD2, PKD3/PKCu) contains two C2 
domains and a PH domain acts downstream of PKC and has been implicated in the 
activation of the mitogen activated kinase (MAP-kinase) cascade (Brandlin et al,
2002) and nuclear factor-KB (NF-kB) (Storz et al, 2003). Chimaerins, as well as the 
C1 domain required for activation by DAG, contain a carboxyl-terminal GAP domain 
which catalyses GTP hydrolysis (inactivation) from Rac1 (Caloca et al, 2003). 
RasGRPs (RasGRP-1, -2, -3, -4) translocate to the membrane following DAG 
generation and complexes with, and activates, Ras by promoting loading of GTP 
(Ebinu etal, 2000).
Although the effects of DAG are not entirely mediated by PKC isoforms, it is 
safe to say that PKC isoforms are important downstream effectors of DAG. The 
PKC family is divided into 3 subgroups based on structural similarities and 
activation requirements. Classical PKC isoforms (cPKC), a, pi, pll, and y can be 
activated by calcium, DAG or phorbol esters (natural compounds which bind the C1 
domain and mimic DAG signalling); PKC e, 5, q, and 0 are described as novel PKC 
isoforms (nPKC), these lack a C2 domain conserved in other isoforms and are able 
to function in a calcium-independent manner. The third PKC subgroup contains the 
atypical isoforms (aPKC), £ and X. This subgroup does not require DAG activity for 
its activation and is also insensitive to phorbol esters. Some PKC isoforms require 
phosphorylation by 3-phosphoinsotide-dependent kinase-1 (PDK1) within their 
catalytic domain to become activated by DAG/calcium binding (Sonnenburg et al, 
2001).
Functional responses are isozyme-, cell type- and stimuli-specific allowing 
selective regulation of signalling cascades. Some of this selectivity is conferred by 
the activation of distinct PKC-activating protein, such as RACKs (receptors of 
activated C kinases) and STICKS (substrates that interact with C kinases). PKC is 
able to directly modulate the MAP-kinase cascade; in general, PKC activates Raf1 
which in turn activates other members of the MAP-kinase pathway promoting 
proliferation, however PKCa activation of the MAP-kinase pathway results in growth 
arrest of human rhabdomyosarcoma cells (Mauro et al, 2002). The role of PKC 
isoforms in modulation of transcription factor activity has been widely studied. The 
main isoform involved in TCR activation of NF-kB and AP1 (activator protein-1) is 
thought to be PKC0. PKC0 can phosphorylate and activate IKK2 (IkB (inhibitor of
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kB) kinase) upstream of NF-kB (Coudronniere et al, 2000); it was thought that 
activation of SEK1 (stress-activated protein kinase-1), within the c-Jun NH2-terminal 
kinase (JNK) pathway, was responsible for PKC-mediated activation of AP1, 
however subsequent studies in PKC6 knockout mice revealed only partial inhibition 
of these factors suggesting involvement of other PKC isoforms (Pfiefhofer et al, 
2003). A recent study has shown that PKCa is required for activation of NF-kB by 
the TCR and has suggested that this isoform is upstream of PKCe (Trushin et al,
2003). PKC has also been shown to interact with components of the cytoskeleton 
including actin filaments, MARCKS (Alien etal, 1995), talin and vinculin (Hyatt etal, 
1994).
1.3.4 Phosphatidylinositol 3-kinase (PI3K)
Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases which 
phosphorylate the 3-position of the inositol ring of PI lipids PI(3)P, PI(3,4)P2 and 
PI(3,4,5)P3. The PI3K family is divided into 4 main classes based on structural 
similarities and substrate selectivity (figures 6 and 7)(reviewed in Deane & Fruman,
2004). The class I PI3Ks, divided into Class lA and Class lB isoforms according to 
their different activation processes, use PI, PI(4)P and PI(4,5)P2 as substrates. 
Class lA PI3Ks consist of a p110 catalytic unit (p110a, 0, 8) and an associated 
regulatory subunit (p85); there are 5 different regulatory units associated with class 
lA PI3K derived from different genes (p85j3 and p55y) or splice variants (p85a, p55a 
and p50a). p85 mediates protein-protein interactions via its Src (signal relating 
kinase) homology (SH2) domain, with phosphotyrosine residues of other proteins. 
The Class lB PI3K (p 11 Qy) lacks a p85 binding domain but has a unique regulatory 
unit, p101. p110y can be activated by the direct interaction with the dissociated G0y 
subunit following GCPR ligation (Brock et al, 2003).
Currently, less is known about class II and III PI3Ks. In mammals, there are 
three different isoforms of class II Pl3Ks, a, p and y which do not constitutively 
interact with a regulatory subunit. These contain a carboxyl-terminal C2 domain; 
they selectively use PI, and possibly PI(4)P, as substrates in vitro. The single class 
III PI3K (Vps34p) is evolutionary conserved among species and uses PI 
exclusively as its substrate. It has a unique regulatory unit (Vps15p) which in yeast 
is a serine/threonine kinase. It is thought to be involved in protein and vesicle 
trafficking (Stevens, 2002).
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Figure 6. Schematic diagram of mammalian PI3K classes. Each PI3K contains a C2 
domain and a catalytic domain connected by the PIK region (a helical section present in 
lipid, but not protein, kinases). C2 domains are responsible for binding phospholipids in a 
calcium dependent or independent manner. PX domains can bind PI(3)P and PI(3,4)P and 
may be involved in recruiting Class II PI3Ks to the membrane. BH, BCR homology domain; 
Pr, proline rich regions; PX, phox homology domain; Ras-B, Ras binding domain.
Metabolism of PI3K products is strictly controlled; primarily via PI(3)4)5)P3 
degradation by the lipid phosphatases SH2-containing inositol polyphosphate 5- 
phosphatase (SHIP) and phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) (Vanhaesebroeck et al, 2000; Weber et al, 2001; Xiu et al,
2002). PTEN hydrolyses the 3-phosphate position converting PI(3,4,5)P3 to 
PI(4,5)P2, whereas SHIP dephosphorylates the 5-phosphate converting PI(3,4,5)P3 
to PI(3,4)P2. PI(4,5)P2can be further metabolised by PLC into DAG and IP3. Failure 
to initiate these regulatory mechanisms results in immune defects, which range 
from hyper-proliferation (aberrant signalling is seen in many cancers), to debilitating 
autoimmunity (D'Ambrosio etal, 1996).

























Figure 7. Synthesis and metabolism of phsophoinositides.
PI3K classes have different specificities for phosphatidylinositols. The products of PI3K are 
involved in multiple signalling pathways, and are therefore tightly regulated by phosphatases 
(PTEN and SHIP). PI(4,5)P2 can be cleaved by PLC into two other second messengers, 
DAG and IP3. DAG, diacylglycerol; IP3l inositol(1,4,5)trisphosphate; PI3K, 
phosphatidylinositol 3-kinase; PLC, phospholipase C; PTEN, phosphatase and tensin 
homologue deleted on chromosome 10; SHIP, SH2-containing inositol polyphosphate 5- 
phosphatase
There is much evidence of chemokine receptors stimulating PI(3,4,5)P3 
accumulation through PI3Ky. The G* specific inhibitor, pertussis toxin (PTX) 
prevents accumulation of PI(3,4,5)P3 mediated by CXCL12 and CCL2 (Ward et al, 
1998a; Ward et al, 1998b). PISKy 7' leukocytes derived from genetically engineered 
mice also fail to produce PI(3,4,5)P3 in response to CXCL1 (Hirsch et al, 2000). 
PI3Ky does not appear to be the only isoform activated by chemokine receptors. 
CXCL12 and CCL5 have been shown to activate the p85/p110 heterodimer in T 
cells (Sotsios et al 1999; Turner et al, 1995) and CCL2/MCP-1 in THP-1 cells 
(Turner et al, 1998). This study also reports the activation of PI3K-C2a in CCL2 
stimulated THP-1 cells (Turner et al, 1998).
1.3.5 Downstream Effectors of PI3K
Numerous studies using chemical PI3K inhibitors, overexpression of 
mutated forms of PI3K and gene knockout experiments have revealed that PI3K is 
involved in a wide range of cellular processes mediated by multiple effectors (figure
8).
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PI(4,5)P2
MAPK
Figure 8. Simplified overview of some PI3K signalling pathways.
PI3K can be activated following ligation of GPCRs and receptor tyrosine kinases resulting in 
the generation of PI(3,4,5)P3. This localises PH domain containing proteins to the plasma 
membrane. PTEN hydroyses PI(3,4,5)P3 to PI(4,5)P2 which in turn is hydrolysed by PLC to 
IP3 and DAG resulting and increase of intracellular calcium and the activation of PKC. PDK- 
1 phosphorylates PKB resulting in its activation. PKB phosphorylates a number of 
substrates resulting in either activation or inhibition (described in detail below). Rac1 
associates with, and can be activated downstream of, class IA and IB isoforms of PI3K 
however in a feedback mechanism, Rac1 can increase the activity of the p85 regulatory 
subunit of class IA PI3Ks. Following ligation of RTKs, Ras can activate PI3K and Raf, which 
activates the MAP-kinase pathway; also involved in the activation of p70S6K.
DAG, diacylglycerol; elF4E, eukaryotic initiation factor 4E; FKHR, forkhead transcription 
factor; GSK3J3, glycogen synthase kinase 3p; IKK, inhibitor of k B  kinase; IP3, 
inositol(1,4,5)trisphosphate; MAPK, mitogen activated protein kinase; mTOR, mammalian 
target of Rapamycin; p70S6K, S6 kinase of 70kDa; PDK1, phosphatidyl inositol-dependent 
kinase-1; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKC, protein kinase C; 
PLC, phospholipase C; PTEN, phosphatase and tensin homologue deleted on 
chromosome 10.
PKB
PKB is a key mediator of PI3K functions. PKB is a member of the AGC 
(cAMP-dependent protein kinase N  protein kinase G/ protein kinase C) superfamily 
of protein kinases which share sequence homology within their catalytic domain. All 
three PKB isoforms, PKBot (AKT1), PKBp (AKT2) and PKBy (AKT3), have a similar 
structure consisting of a carboxyl-terminal regulatory domain, a catalytic kinase 
domain and an amino-terminal PH domain. The PH domain of PKB binds the PI3K
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products PI(3,4,5)P3 and Pl(3,4)p2 with equal affinity (Freeh et al, 1997); this allows 
localisation of the protein to the membrane and induces conformational changes 
thought to expose the two main sites of phosphorylation, Thr308 and Ser473 
(Cantrell, 2002; Scheid & Woodgett, 2003). In recent years there has been much 
discussion about how PKB is activated. Currently, it is thought that PDK1 
phosphorylates Thr308, located within the activation loop of the kinase domain, 
instigates partial activation of the enzyme (Anderson et al, 1997; Stephens ef al, 
1998). PDK1 is another AGC kinase containing a PH domain that binds the 3- 
phosphoinositol lipids. In order to become fully activated, PKB needs to be 
subsequently phosphorylated on ser473 within the regulatory domain however, the 
pathway leading to this remains controversial. Ser473 phosphorylation always 
parallels the activation of PI3K and full activation of PKB however the mechanism 
by which this occurs is not completely understood. Initially it was assumed that 
PDK1 was responsible for phosphorylation of both residues because 
phosphorylation of ser 473 is dependent on both PI3K activation and 
phosphorylation of Thr308 (Andjelkovic et al, 1999). However, phosphorylation of 
ser473, but not Thr308, occurs in PDK1 knockout cells (Williams et al, 2000). It has 
been reported that under certain conditions, PKB is able to autophosphorylate 
ser473 (Toker et al, 2000). Integrin-linked kinase (ILK) has been shown to be 
involved in the phosphorylation of ser473 (Persad et al, 2000); alternatively, ser473 
may be phosphorylated by an as yet unidentified kinase. Transient regulation of 
PKB activation by proteins which interact with it has been reported. Both actin and 
keratin are able to sequester PKB within the cytoskeleton (Cenni et al, 2003; 
Paramio etal, 2001).
PKB is involved in many cellular processes via a number of effector 
molecules (figure 8). One of the main functions of PKB is the control of cell survival 
by regulation of pro- and anti-apoptotic mediators and transcription factors. Bad is a 
pro-apoptotic member of the Bcl-2 family of proteins, which binds Bcl-X or Bcl-2 
inhibiting their anti-apoptotic activity. Phosphorylation of Bad by PKB releases it 
from the complex with Bcl-2/  Bcl-X inactivating its pro-apoptotic ability (Datta et al,
1997). The Forkhead (FoxO/ FH) family of transcription factors can all be directly 
phosphorylated by PKB leading to activation of their target genes, which include 
both pro-and anti-apoptotic proteins (Burgering et al, 2003). Another important 
family of transcription factors is the NF-kB family; dysregulation of these proteins 
has been found in a number of cancers and autoimmune diseases (Li et al, 2000).
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Most NF-kB proteins are activated following phosphorylation of IkB, an inhibitor of 
NF-kB, by an IKK complex, leading to the degradation of IkB, and allowing NF-kB 
to translocate to the nucleus and activate its target genes (this is discussed in detail 
in 1.3.8). PKB has been reported to be involved in the activation of the IKK complex 
(Kane etal, 1999).
PKB has implicated in the regulation of protein synthesis via pathways 
which include mammalian target of Rapamycin (mTOR/ FRAP/ RAFT) (Scott et al,
1998). mTOR is a serine/ threonine kinase involved in regulating the availability of 
cellular levels of adenosine triphosphate (ATP) and nutrients required for protein 
synthesis. PKB can directly phosphorylate mTOR at ser2448 resulting in the 
inactivation of 4E-BP1, releasing elF4E (eukaryotic initiation factor 4E) which 
complexes with other proteins and activates translation; mTOR also phosphorylates 
p70S6K (S6K1). p70S6K activation is regulated by multi-site phosphorylation; 
including the phosphorylation at Ser411, Thr421 and Ser424 which is thought to 
activate p70S6K by relief of an auto-inhibitory mechanism (Pullen & Thomas,
1997). p70S6K phosphorylates the 40S ribosomal subunit protein, S6-ribosomal 
protein at multiple sites, which include Ser235, Ser236, Ser240 and Ser244 
(Ferrari, S. et al, 1991). This phosphorylation is thought to initiate the translational 
activity induced by S6-ribosomal protein.
PKB is able to regulate cell metabolism through phosphorylation and 
inhibition of GSK3p, which results in increased storage of glucose as glycogen 
(Cross et al, 1995). GSK3p is also connected to other signalling pathways; it has 
been reported to phosphorylate the adaptor protein and transcription factor, p- 
catenin leading to its subsequent degradation and inhibition of transcription (Yost et 
al, 1996).
Rho and Rac family of Small GTPases
Of particular importance in PI3K signalling are the small G proteins of the 
Rac and Rho families. PI3K can activate the small GTPases, Rho, Cdc42 and Rac 
to initiate several cascades which result in a number of processes including the 
reorganisation of the actin cytoskeleton and therefore cell polarisation and 
chemotaxis (Ma etal, 1998; Narumiya etal, 1997). In an active form, these proteins 
are GTP bound and they alternate between this and an inactive GDP-bound form. 
This process is highly regulated by guanine nucleotide exchange factors (GNEFs) 
and GAPs which catalyse activation or inactivation of the protein respectively.
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There are numerous studies, using pharmacological inhibitors and knockout 
models, which indicate these proteins are activated downstream of PI3K in 
mediating changes in actin organisation (Han etal, 1998; Reif et al, 1996)
Interactions between PI3K and Rac1 are complicated; following TCR ligation 
p85 has been shown to associate with Rac1 as well as the intracellular signalling 
domains of the TCR (Kane et al, 2003). Rad and Rho have both been shown to be 
activated downstream of class 1A and 1B PI3K via the GEF Vav (Han et al, 1998; 
Wennstrom etal, 1994). There is evidence that both GTP-Rac and GTP-Cdc42 can 
increase the activity of p85 (Weiner et al, 2002), but the exact mechanism for this is 
currently unknown. However, since PI(3,4,5)P3 can also induce dissociation of GDP 
from Rad and preferentially binds and stabilises the nucleotide free form of the G 
protein, there is a possible negative regulatory mechanism (Missy, 1998). There is 
also evidence that Rac1 can act upstream of Class I PI3K (Genot et al, 2000; 
Keely, 1997). The role of these proteins in chemotaxis is discussed in detail later.
1.3.6 Mitogen Activated Protein Kinase
The MAP-kinase cascade is another of the major signalling pathways 
involved in signal transduction that is conserved within many organisms. MAP- 
kinase pathways are a family of serine/threonine protein kinases involved in a 
number of physiological processes such as cell survival, growth, differentiation, 
development and death. While the individual pathways differ in their upstream 
activation sequences and downstream substrate specificities, they consist of a 
series of kinases in which a MAPKK-kinase phosphorylates and activates a MAPK- 
kinase, which in turn activates MAP-kinase (figure 9). There are several MAP- 
kinase which include the extracellular signal-regulated kinase (ERK1/2), JNK and 
p38 (p38-a, -p, -y, -5).
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Figure 9. Mammalian MAP-kinase pathway.
MAP-kinase pathways are organized in a three-tier kinase cascade consisting of a MAPKK- 
kinase that phosphorylates and activates a MAPK-kinase, which in turn activates MAP- 
kinase, and ultimately leads to activation of transcription factors.
Activation of GPCRs initiates a complex series of signalling events leading 
to the activation of MAP-kinase cascades (figure 10). G^-linked receptors can 
activate MAP-kinases through the py subunit in a PKC independent, but Ras 
dependent manner (Crespo et al, 1994). Ras is a membrane bound guanine 
nucleotide-binding protein (GTPase) regulated by GAPs (p120Ras) and adaptor 
proteins (SOCS3) (Cacalano et al, 2001). Tyrosine phosphorylation has been 
proposed to play a key role in mediating MAP-kinase signalling. The tyrosine kinase 
Src can be activated through a direct interaction with either Goi- or Gaq-coupled 
receptors (Ma et al, 2000); py-induced phosphorylation of She (Src homology and 
collagen) is mediated by Src (Luttrell etal, 1996). Tyrosine phosphorylation of She 
leads to the subsequent formation of She, Grb2 (growth factor receptor bound-2), 
Sos (son of sevenless) complexes which can promotes GTP loading of Ras (van 
Biesen et al, 1995). Non-receptor tyrosine kinases, which include C-terminal Src 
kinase (Csk), Lyn, Bruton’s tyrosine kinase (Btk) and proline-rich tyrosine kinase 2 
(PYK2), have been proposed to activate the Ras following ligation of G«i- and G«q- 
coupled receptors in a variety of cell types. PI3Ky, activated by py subunits can 
activate Src and therefore the Shc-Grb2-Sos mediated activation of Ras; another
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PI3K isoform, PI3Kp, can increase Ras activation of Raf through Cdc42- and PAK 
(Sun et al, 2000). and G* which can activate, or inhibit, adenylyl cyclase can 
mediate MAP-kinase signalling through production of cyclic adenosine 
monophosphate and activation of PKA, which can activate Rap. Rap is able to 
activate MAP-kinase through Raf-B. G^ can also stimulate MAP-kinase via a Ras- 
independent, PKC-dependent pathway through direct phosphorylation of c-Raf; 
however this phosphorylation may not be enough to induce full activation 
(Macdonald et al, 1993). The exact mechanism of Ras activation of Raf is currently 
unclear, however it is thought to be necessary for localisation plasma membrane 
(Avruch et al, 1994). Activated Raf, a serine/threonine kinase, can phosphorylate 
and activate Mek (MAP-kinase and ERK kinase). Following LPS activation of TLR4, 
tumour progression locus-2 (TPL-2), a MAPKKK, present in a cytosolic complex 
with NF-kB1 p105, is released and can phosphorylate and activate Mek-1 and -2. 
Mek, a dual specificity kinase, phosphorylates ERK1/2 on both tyrosine and 
threonine residues within the activation loop; phosphorylation of these residues 
results in activation of ERK1/2. ERK1/2 translocates to the nucleus where it can 
mediate activation of expression of transcription factors. ERK1/2 has been shown to 
phosphorylate a number of residues on p90RSK (p90 ribosomal S6 kinase), 
thought to be important in the activation of this kinase; however full activation 
requires phosphorylation by PDK-1. Known substrates of p90RSK include S6 
ribosomal protein, GSK3|3, and it has been linked to NF-kB activation. ERK1/2 has 
also been shown to phosphorylate autoinhibitory sites on p70S6K inducing a 
conformational change crucial for allowing phosphorylation of the catalytic domain 
inducing activation.
JNK and p38 are MAP-kinases primarily activated in response to 
environmental stress and inflammatory cytokines. Ga12 and Gai3 and py subunits 
have been shown to activate JNK in a Rac1 and Cdc42 dependent manner 
(Gudermann et al, 2000); while Gaq as well as py have been linked to activation of 
p38 (Yamauchi etal, 1997).





Figure 10. Activation of MAP-kinase pathways by GPCRs
Py-subunits can activate Ras via receptor and non-receptor tyrosine kinases, which results 
in the recruitment of the GEF Sos to the membrane and the exchange of GDP for GTP 
bound to Ras. Gaq activates protein kinase C (PKC) which can directly stimulate Raf1 or 
activate Ras via RasGRF and tyrosine kinases acting on Sos. Gai, Ga0 and Got* activate 
MAP-kinase through pathways which regulate Rap and B-Raf. Mek can also be activated 
by Tpl2. Activated MAP-kinase translocates to the nucleus and phosphorylates nuclear 
proteins, including transcription factors, thereby regulating gene expression.
AC, adenylyl cyclase; cAMP, cyclic adenosine triphosphoate; ERK1/2, extracellular-related 
kinase; MEK, MAPK kinase; PI3K phosphatidylinositol 3-kinase; p90RSK, p90 ribosomal S6 
kinase; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PLC, 
phospholipase C; PYK2, proline-rich tyrosine kinase 2; RTK, receptor tyrosine kinase; Sos, 
son of sevenless; Tpl2, tumour progression locus-2.
1.3.7 T Cell Polarisation and Directed Cell Migration
Chemokines and their receptors are important regulators of the trafficking 
and activation leukocytes in both a normal environment and in response to an 
inflammatory stimulus. This is a complex process involving the co-ordinated 
activation of a number of molecules. Inflammatory stimuli initiate the trafficking of 
leukocytes from the microvasculature to the site of inflammation by activating the 
expression of selectins, integrin ligands and chemokines on the endothelium. 
Selectins, involved in the initial tethering of the leukocyte to the endothelium,
Chapter 1: Introduction 37
provides the leukocyte to ‘roll’ along the endothelial surface. Firm adhesion is under 
the control of molecules presented on the surface of the endothelium, such as 
chemokines, lipid and other pro-inflammatory mediators. These activate adhesion 
molecules, an important example being the integrin ligands (ICAM-1, VCAM-1), 
which lead to firm adhesion. The leukocytes are then able to migrate across the 
endothelium into the tissue, known as diapedesis. This is a complex process in 
which the leukocyte elongates and extends a pseudopod through the endothelium; 
dependent on the disassembly and subsequent reassembly of its cytoskeleton. 
Diapedesis also requires an increase in intracellular free calcium within the 
endothelial cells between which the cells are passing (Huang et al, 1993; Su et al,
2000). This rise in intracellular calcium is able to induce retraction of the endothelial 
cells through activation of myosin light chain kinases (MLCK). (Hixenbaugh et al, 
1997; Saito et al, 1998). Following extravasation, leukocytes are susceptible to 
chemokine gradients in tissues which allow directed migration directs to a specific 
site, a process known as chemotaxis.
Chemotaxis is the result of the convergence of multiple signal transduction 
pathways which cells detect the direction and concentration of, and move toward, 
an extracellular chemoattractant gradient, some of which have been summarised in 
figure 11. When cells detect a chemoattractant gradient, they dramatically change 
their shape, polarizing in the direction of the gradient with the formation of a leading 
edge and a tail (uropod) (Lauffenburger etal, 1996; Sanchez-Madrid etal, 1999). At 
the leading edge of cells, there is an accumulation of chemokine receptors, F-actin, 
actin-binding proteins and adhesion receptors. Whereas the uropod contains 
molecules such as myosin II, golgi apparatus and adhesion molecules, such as 
intercellular adhesion molecules (ICAM)-1,2 and 3, CD43 and CD44. Ezrin, radixin 
and moesin (ERM family) are linker proteins between the plasma membrane and 
actin; also found to be localised in the uropod with the adhesion molecules following 
polarisation of the cell (Serrador etal, 2002). This localisation of cell components is 
partially due to the reorganisation of the actin skeleton which pushes the leading 
edge forwards and consequently allows actin filaments to move backwards.
The actin cytoskeleton is a flexible system which can be manipulated in 
order to initiate cell shape change. This involves actin polymerisation on one side of 
the cell, and depolymerisation on the other. Actin filaments are built up from 
adenosine 5’-triphosphate (ATPy  actin monomers which bind profilin, an ATP- 
exchange factor for actin, allowing them to associate with the WASP (wiskott- 
aldrich syndrome protein) /Arp2/3 (actin-related proteins) complex and form actin
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filaments (F actin). Depolymerisation of actin filaments is also important in 
reorganisation of the actin skeleton, and is mediated mainly by cofilin/actin 
depolymerising factor proteins. These proteins are activated by dephosphorylation 
and bind to ADP-actin within the actin filaments, causing them to depolymerise. The 
cofilin associated-ADP actin is then recycled to ATP-actin by profilin. In this 












Figure 11. Overview of some signalling pathways involved in the chemotactic 
response.
Directed cell migration is the culmination of activation of a number of signalling molecules 
activated downstream of surface receptors.
CaM, calmodulin; DAG, diacylglycerol; FAK, focal adhesion kinse; IP3, inositol 1,4,5- 
trisphosphate; LAT, linker for activated T cells; MAPK, mitogen activated kinase; MLC, 
myosin light chain; MLCK, myosin light chain kinase; PAK, p21 activating kinase; Pax, 
paxillin; PDK1, phosphatidylinositol kinase-1; PI3K, phosphatidylinositol 3-kinase; PKA, 
protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C, 
Src, signal relating kinase; WASP, wiskott-aldrich syndrome protein.
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It has become dear over the past few years that PI3K is one of the major 
players in chemokine mediated chemotaxis. Studies involving PI3K-knockout 
mutants indicate PI3K-y is important in neutrophil chemotaxis (Li et a/, 2000) which 
is supported by experiments using the PI3K inhibitors LY294002 and wortmannin 
(Cumock et al, 2003; Turner et al, 1995; Sotsios et al, 1999). Further studies 
indicate that class 1A PI3Kp and PI3K5 are also involved in directional sensing. 
Following exposure to a chemoattractant, PI3K is localised at the leading edge of 
cells causing an increase of PI(4,5I6)P3; this localises proteins containing PH- 
domains to this area (Meriot & Firtel, 2003). Specific PI3K effectors have been 
identified as being important in aspects of cell migration. PKB is localised at the 
leading edge of cells (Meili et al, 1999) and cells lacking PKB display reduced 
chemotaxis. While PKB is found at the leading edge of chemotaxing cells, by an 
unknown mechanism, it can activate PAK1 which is localised at the rear of the cell 
(Chung et al, 2001). The lipid phosphatase, PTEN is also localised to the side and 
rear of a polarised cell (Lacalle et al, 2004) further outlining the requirement for the 
PI lipids in this process.
The Rho-GTPases Rho, Rac and Cdc42 have been shown to be critical for 
directed cell migration. Cdc42 is important in determining correct cell polarity with 
respect to the external signal (Etienne-Manneville, 2004), while Rac is important in 
formation of the extracellular laminin and orientation of the cell (Sun et al, 2004). 
Both Rac and Cdc42 are thought to be involved in the formation of lamellapodia 
and the contact these protrusions have with neighbouring cells. Inhibition of Rho 
disrupts formation of the junctions which are involved in this cell-cell contact, 
possibly by preventing assembly of the actin filaments required to stabilise them 
(Takaishi et al, 1997). Some of the known Rac-GEFs are PI3K dependent, for 
example Vav and Sos, and it is thought that binding of PI(4,5,6)P3 to the PH domain 
of these molecules causes release of an intramolecular inhibition allowing activation 
(Han et al, 1998). DOCK180, while not a conventional Rac-GEF, is known to be an 
upstream regulator of Rac (Cote & Vuori, 2002); nucleotide-free Rac can bind to 
DOCK 180 causing increased GTP-loading in the presence of GTP; however there 
is a requirement of an additional enzyme to remove GDP before this can occur 
(Kobayashi et al, 2001). DOCK180 is a member of a class of Rho-GEFs, called 
CDMs (Ced15/Dock/Myoblasticity), which also includes DOCK2 and ZIZIMIN1. 
They contain domains which indicate that they may be directly regulated by 
PI(4,5,6)P3; indicating that PI(4,5,6)P3 is involved in the regulation of this family of
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GEFs at the leading edge of chemotaxing cells. p70S6k has also been implicated in 
the activation of these GTPases; it was recently shown to associate with Rac1 and 
Cdc42 (Berven, et al, 2005).
However, activation of PI3K is not necessarily required for chemotaxis, in 
fact, recent evidence suggests that in vivo cell migration to the chemokines 
CXCL12 or CCL19 is unaffected by PI3K inhibitors (Cinamon et al, 2001). While 
ultimately important in most chemotactic responses, it Is possible to bypass PI3K to 
activate the GTPases, in fact the Gpy subunit could directly activate Rho-GEFs 
leading to activation of Cdc42, Rac and Rho (Rickert et al, 2000). DOCK2 has been 
found to be important in T lymphocyte migration and more specifically in activation 
of Rac during chemokine mediated chemotaxis, possibly in a mechanism 
independent of PI3K (Fukui etal, 2001).
Myosin II is localised in the rear of the cell and is thought to be one of the 
contractile forces in cell movement. Myosin II is a double-headed molecule which 
can self assemble into filaments which can produce ATP-dependent movement by 
pulling actin filaments against each other. In non-muscle cells, myosin II has an 
important role in controlling actomyosin contractility; it can promote tension in the 
interactions between cell surface integrins and the actin cytoskeleton or their 
extracellular ligands causing them to break (Arthur, 2002). Activation of myosin II by 
phosphorylation is regulated by a balance of between MLC phosphatase and MLC 
kinase in a calcium dependent manner. There are other known molecules which 
may be involved in activation of myosin, such as p160ROCK. ROCKs (Rho 
kinases) can phosphorylate a number of substrates, such as myosin light chain 
(MLC) phosphatase therefore negatively regulating myosin contractility, and the 
ERM proteins. Other molecules such as LIM kinases (LIMK1, LIMK2), 
serineAhreonine kinases, are also involved in regulating cytoskeletai interactions via 
phosphorylation of cofilin which inhibits its ability to break up actin filaments. LIMK 
can not only be activated by ROCKs, but also by Cdc42 and PAK (Yang et al,
1998).
Tyrosine phosphorylation of FAK (focal adhesion kinase), a non-receptor 
tyrosine kinase, following integrin activation creates a binding site for Src family 
kinases (Schaller et al, 1994). FAK can also recruit DOCK180 and the adaptor 
protein Crk leading to the activation of Rac (Hsia et al, 2003). Both FAK and Src 
can phosphorylate p130Cas, a linker protein involved in mediating a number signals 
from FAK (Polte et al, 1995). FAK, Src and p130Cas are able to complex with
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paxillin, an adaptor protein containing a several binding domains enabling 
interaction of a number of molecules. The F-actin binding protein, vinculin, ILK 
(integrin linked kinase) and PAK can all directly bind the LIM domains in paxillin 
(Brown et al, 1996; Hasimoto et al, 2001; Nikolopolous & Turner, 2001); other 
proteins are able to link paxillin to PIX, a RAC/Cdc42 GEF (West et al, 2001). 
Paxillin has also been found to localise with LIMK further underlining its importance 
in regulation in motility (Foletta etal, 2004). ILK is also important in the formation of 
protein complexes which act upstream to affect actin dynamics and has also been 
implicated in the regulation of PKB and GSK3p (Delcommenne et al, 1998).
Further evidence of the complexity of this process is the involvement of 
protein kinase A (PKA) which is able to interact with a number of molecules which 
regulate actin and cell migration. PKA phosphorylation of VASP (vasodilator 
stimulated protein) disrupts its interaction with Abl therefore indirectly regulating 
WAVE-Abl complex formation (Stuart et al, 2006). Abl, an oncoprotein is able to 
bind actin via binding sites which preferentially bind either G- or F- actin (Van Etten 
et al, 1994). VASP is also able to bind directly to profilin and promote actin 
polymerisation (Reinhard et al, 1995; Walders-Harbeck et al, 2002). Through its 
regulation of PLC and IP3 receptors, PKA can also regulate the calcium dependent 
activation of MLCK activity (Garcia et al, 1997). PKC Isoforms are also found 
localised within the actin structure following activation. PKCJ3II is activated following 
F-actin binding (Blobe et al, 1996); while other isoforms, a, e and £ appear to have a 
requirement for F-actin binding to elicit certain effects (Gomez et al, 1995; Prekeris 
etal, 1995; Schmalz etal, 1996).
Activation of the T cell receptor causes activation and recruitment of ZAP-70 
(C-chain associated protein 70kDa), to the plasma membrane. This induces 
phosphorylation of LAT (linker for activated T cells) and SLP-76 (SH2 domain- 
containing Leukocyte Protein of 76 kDa), and links the actin skeleton to TCR 
activation through Vav1 and the WASP/Arp2/3 complex (Badour et al, 2004). Vav is 
a Rho family GEF and can catalyse activation of Rho, Rac1 and Cdc42; it has 
recently been shown to be important for CXCR4-mediated chemotaxis in 
lymphocytes (Vicente-Mazanares et al, 2005). It is the direct interaction of Vav with 
Cdc42 that causes WASP to activate the Arp2/3 complex (Zeng et al, 2003). Ras is 
a GTPase, upstream of the Rho-GTPases, which has been shown to be involved in 
regulation of cofilin activity through both PI3K- and Mek-dependent pathways (Nebl
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etal, 2004). This study suggests that Ras-dependent dephosphorylation of cofilin is 
partially accountable for the actin destabilising abilities of Ras.
1.3.8 Nuclear Factor-icB (NF-kB)
There are a number of inducible transcription factors responsible for a cell’s 
adaptive responses to environmental changes. NF-kB is an evolutionary 
conserved protein important in the control of the immune and inflammatory 
responses. Following receptor ligation by stimuli including lipopolysaccharide (LPS), 
interleukin 1 (IL-1), tumour necrosis factor a (TNFa) and y-irradiation, NF-kB 
translocates to the nucleus where it binds to the activation site on the target gene. 
NF-kB is involved in the regulation of the genes of pro-inflammatory cytokines (eg. 
TNFa, IL-1 and IL-6), chemokines (MIP1a and RANTES) and adhesion molecules 
required for recruitment of cells to sites of inflammation. However, NF-kB can also 
regulate a number of genes not involved in the immune response and can therefore 
affect normal cellular functions. The NF-kB family consists of several proteins 
including p65 (RelA), RelB, c-Rel, NF-kB1 (p105/p50) and NF-kB2 (p100/p52) 
(figure 12); usually present in resting cells as either a homo- or hetero-dimers. Both 
NF-kB 1 and NF-kB2 are synthesised as precursors of 105 and 100 kDa 
respectively and are proteolysed by the proteasome forming the active NF-kB 1 p50 
and NF-kB2 p52 subunits. This processing requires the glycine-rich region in the 
central portion of the protein (Orian et al, 1999). The NF-kB family contain a 
conserved Rel homology domain where the dimerisation, nuclear localisation and 
DNA binding domains are located. The Rel proteins (p65, RelB and c-Rel) also 
contain a c-teminal transactivation domain which can strongly activate transcription 
when bound to the NF-kB binding site on the target genes. RelB can only activate 
transcription when complexed with NF-kB1 p50 or NF-kB2 p52; RelB/p65 
hetrodimers cannot bind DNA and are therefore inhibitory (Marienfeld et al, 2003). 
Since NF-kB 1 p50 or NF-kB2 p52 lack the transactivation domain, they can only 
activate transcription when complexed with one of the Rel proteins. In resting cells, 
NF-kB is normally sequestered in the cytoplasm as an inactive dimer by a member 
of the inhibitor of NF-kB (IkB) family (kBa, kBp, kBe) (figure 12).
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Figure 12. Human NF-kB and IkB family members The five members of the mammalian 
NF-kB family, p65 (Rel A), c-Rel, Rel B, p105/p50 (NF-kB1) and p100/p52 (NF-kB2) contain 
a structurally conserved amino-terminal Rel homology domain (RHD). The RHD is 
comprised of the dimerisation, nuclear localisation (N) and DNA-binding domains. p65, o  
Rel and Rel B contain a transactivation domain (TD) and RelB also contains a leucine- 
zipper (LZ) motif. p65 contains several residues which can be phosphorylated and may be 
important for activation. Proteolytic processing of p105 and p100 (indicated by arrows), 
results in the p50 and p52 NF-kB family members. The glycine rich region (GRR) is required 
for processing p105 and p100. The inhibitor of NF-kB (IkB) family consists of kBa, kBp, 
IkBe (which has 2 transcripts shown by the dotted line) and BCL-3. They can be identified 
by the presence of several ankyrin repeats. p105 and p100 also contain carboxy-terminus 
ankyrin repeats. The number of residues in each protein is indicated on the right.
IkBs are characterised by the presence of multiple ankyrin repeats which 
interact with the nuclear localisation sequence in the Rel homology domain of the 
NF-kB protein to inhibit nuclear translocation. The c- terminal section of NF-kB1 
and NF-kB2 also contain multiple ankyrin repeats and can therefore function as an 
IkB molecule. Messenger RNA encoding only the c-terminal of NF-kB1 has been 
reported in murine cells and has been termed kBy (Moorthy & Ghosh, 2003). 
Phosphorylation of the N-terminal of IkB induces degradation of the molecule by the 
protea so me.
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There are three recognised signalling cascades leading to NF-kB activation: 
the canonical pathway, the alternative (non-canonical) pathway and the p105 
pathway (figures 13 & 14). The most characterised is the canonical NF-kB pathway 
in which the classical IKK complex, composed of the two catalytic proteins IKK1 
(IKKa) and IKK2 (IKKp) and a regulatory subunit, NEMO (NF-kB essential 
modulator; IKKy), is recruited to the plasma membrane. It is subsequently activated 
by phosphorylation by an upstream kinase such as NF-kB Inducible kinase (NIK), 
MEKK1 or PKB (Factor et al, 2001; Luftig et al, 2004; Zhou et al, 2003). The 
activated classical IKK complex then phosphorylates kBa on ser 32 and ser36 
resulting in its polyubiquitination and degradation via the proteasome pathway. The 
released NF-kB hetrodimer, typically p65/p50 or c-Rel/p50, translocates to the 
nucleus where it binds to specific consensus sequences on the target genes to 
promote transcription. The IKK complex can also phosphorylate kBp and \kBs 
resulting in ubiquitination and degradation (Heilker et al, 1999). Post-translation 
modifications of p65 have been shown to affect its transcriptional activity; 
acetylation of p65 can facilitate retention of the NF-kB complex in the nucleus 
(Ashbumer et al, 2001). Phosphorylation of p65 is important for transactivation as 
translocation alone is not enough to affect transcription. It has however been 
suggested that phosphorylation of p65 is required for optimum transcriptional 
activity. There are several sites for phosphorylation (figure 11) and their individual 
effects on transcription are currently not fully understood. Phosphorylation of ser 
276 in the Rel homology domain by PKA (Zhong et al, 1997) or mitogen-and stress- 
activated protein 1 (MSK1) (Vermeulen et al, 2003) has been reported to enhance 
transcriptional activity. Ser 468 can be phosphorylated following TCR activation 
however the result of this on transcription is unknown (Mattioli et al, 2004). GSK3p 
is also able to phosphorylate 4 sites within the amino adds sequence 354-551 in 
the transactivation domain (Buss, H. et al, 2004). There are currently a number of 
candidates for the kinase that phosphorylates ser536 within the transactivation 
domain: IKK1 (O’Mahony et al, 1999), IKK2 (Jeong et al, 2005), NIK (Jiang et al, 
2003) and PKB (Mattioli et al, 2004) have all been shown to be capable and there 
has been much debate about whether phosphorylation of this residue is necessary 
for full transcriptional activity.
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Figure 13. Schematic diagram of the canonical and alternative NF-kB pathways.
The canonical nuclear factor-KB (NF-kB) pathway involves activation of the classical IKK 
complex, composed of the two catalytic proteins IKK1, IKK2 and a regulatory subunit, 
NEMO, is recruited to the plasma membrane. The activated classical IKK complex 
phosphorylates kBa resulting in its polyubiquitination and degradation via the proteasome 
pathway. The released NF-kB hetrodimer then translocates to the nucleus. In the alternative 
NF-kB pathway activated IKK complex phosphorylates the NF-kB2 dimer, typically 
heterodimers of NF-kB2 p100 and RelB; NF-kB2 p100 is then ubiquitinated and degraded 
into NF-kB2 p52. The NF-kB2 p52/RelB dimer then translocates to the nucleus to influence 
transcription.
kBa, inhibitor of KBa; IKK1, inhibitor of kB kinase 1; IKK2, inhibitor of kB kinase 2; NEMO, 
NF-kB essential modulator, Ub, ubiquitin.
There is less known about the alternative pathway wherein partial 
processing of NF-kB2 p100 releases the p52 protein. The IKK complex containing 
an IKK1 homodimer, independent of both IKK2 and NEMO, is activated by NIK 
(Ling et al, 1998); it is currently unknown whether there are additional regulatory 
proteins in the complex. The activated IKK complex then phosphorylates the NF-
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kB2 dimer, typically heterodimers of NF-kB2 p100 and RelB. NF-kB2 p100, once 
phosphorylated, is then ubiquitlnated and targeted for degradation by the 26S 
proteasome (Xiao et al, 2004). The NF-kB2 p52/RelB dimer then translocates to the 
nucleus to influence transcription. It has been suggested that the NF-kB2 p52 
protein may be substituted for the NF-kB1 p50 protein following prior to 
translocation to the nucleus however the implications of this are not clear.
The kinetics of the NF-kB pathways differ depending on the activating 
stimuli; signal induced degradation of kBa through the TCR takes about 45 
minutes, where as ligation of the TNFR1 by TNFa results in kB a degradation after 
about 10 minutes (Heiiker etal, 1999). Processing of p100 is much slower than this 
taking several hours. Among the genes upregulated by NF-kB by TNFa via the 
canonical pathway are both NF-kB2 p100 and RelB, suggesting that the pathways 
are linked and have the ability for advanced regulation of NF-kB signalling. There is 
also possibly some overlap of genes regulated by the canonical and alternative 
pathways suggesting additional control of gene transcription by NF-kB.
In the third NF-kB pathway, NF-kB1 p105 is partially processed, in a similar 
way to NF-kB2 p100, resulting in the release of the NF-kB1 p50 protein (figure 14). 
Following receptor ligation, the c-terminus of p105 is phosphorylated by the 
classical IKK complex at ser927 and ser932 (Lang et al, 2003; Salmeron et al,
2001). Upstream kinases responsible for the activation of the IKK complex in this 
pathway have so far not been identified. NF-kB1 p105 is then ublquitinated and 
proteolysed releasing NF-kB 1 p50 which can then translocate to the nucleus. Since 
p50 lacks a transactivation domain, modifications, such as phosphorylation can 
alter its ability to bind DNA. Phosphorylation of p50 at ser337, within the Rel 
homology domain, by PKA can enhance p50 DNA-blndlng (Hou et al, 2003). NF- 
kB1 p105 is constitutively phosphorylated by GSK3(3 on ser903 and ser907 
inducing a stabilised conformation (Demarchi et al, 2003). NF-kB1 p105 also forms 
a complex with Tpl-2, a MAPKKK in macrophages and following LPS activation of 
TLR4, the released Tpl-2 can phosphorylate and activate Mek which subsequently 
phosphorylates ERK1/2 (Bienke et al, 2004). ERK1/2 can translocate to the nucleus 
where it can activate transcription of genes such as COX-2 and TNFa (Hoffmeyer 
etal, 1999).






Figure 14. The NF-kB1 p105 pathway
Following receptor ligation, the c-terminus of p105 is phosphorylated by the classical IKK 
complex, containing IKK1, IKK2 and NEMO. NF-kB1 p105 is then ubiquitinated and 
proteolysed releasing NF-kB1 p50 which can then translocate to the nucleus. NF-kB1 p105 
can be stabilised by the constitutive phosphorylation by GSK3JL NF-kB1 p105 is found 
complexed with TPL-2; which can phosphorylate and activate Mek which subsequently 
phosphorylates ERK1/2. ERK1/2 can also translocate to the nucleus where it can activate 
gene transcription.
ERK1/2, extracellular related kinase 1/2; GSK3p, glycogen synthase kinase 3[3; IKK1, 
inhibitor of k B  kinase 1; IKK2, inhibitor of k B  kinase 2; NEMO, NF-kB essential 
modulator NF-kB, nuclear factor-KB; PKB, protein kinase B; TPL2, tumour progression 
locus-2; Ub, ubiquitin.
1.3.9 Activation of the TCR
It is not only chemokine receptors which utilise these pathways. It has been 
recognised that full activation of the TCR requires additional co-stimulatory 
molecules, one of the most important of which is CD28, activated by the B7 family 
members on antigen presenting cells. Binding of the TCR by antigen peptide-MHC 
complex activates a series of complex signalling cascades within the cell (figure
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15). Activation of the TCR leads to members of the Src family of protein tyrosine 
kinases, such as Lck, being recruited to the TCR along with ZAP-70, which is then 
phosphorylated by the Src-kinases (Howe & Weiss, 1995). Tyrosine 
phosphorylation is a key mechanism of signal propagation in early TCR signalling. 
ZAP-70 then phosphorylates the adaptor protein LAT (Zhang et al, 1998) which 
forms a complex with the adaptor SLP-76 and Vav1 (Zhang et al, 1999). This 
complex is capable of activating a number of proteins, such as a complex 
containing Cdc42, WASP and Arp2/3, or Rac1 responsible for cytoskeletal changes 
or the MAP-kinase cascade (Salojin et a/,1999). PI3K is one of the major 
downstream signalling mediators involved in many of the functional effects elicited 
by TCR activation. As previously described, PI3K generates the lipid second 
messenger PI(3,4,5)P3 which is recognised by the PH domain of many proteins, 
allowing recruitment and activation of proteins like PKB. PKB activates many 
proteins such as GSK3p and the transcription factors Bad and forkhead 
transcription factors. Activation of PLC results in the metabolism of PI(4,5)P2 to 
DAG and IP3 which activates PKC and drives calcium flux resulting in regulation of 
NF-kB and nuclear factor of activated T cells (NFAT), transcription factors 
controlling gene regulation. TCR signalling is also mediated by inhibitory signals for 
example co-stimulation by CD28 represses the inhibitory signals initiated by Cbl-b 
allowing activation of further signalling mechanisms, like Vav1 or PI3K (Herndon et 
al, 2005; Li etal, 2004).








Figure 15. Simplified overview of signalling through the T cell receptor (TCR).
Activation of TCR by antigen results in recruitment and tyrosine phosphorylation of the 
adaptor proteins Lck and ZAP-70. This leads to activation of a protein complex containing 
LAT, SLP-76 and Vav. Subsequently, further signalling cascades are activated resulting in 
reorganisation of the cytoskeleton and regulation of gene transcription. Costimulation of 
CD28 releases the inhibitory signals of Cbl allowing activation of PI3K and its downstream 
effectors.
DAG, diacylglycerol; ERK1/2, extracellular-related kinase; FKHR, forkhead transcription 
factor; GSK30, glycogen synthase 3p; IP3, inositol 1,4,5-trisphosphate; LAT, linker for 
activated T cells; NFAT, nuclear factor of activated T cells; N F-kB , nuclear factor kB; PAK, 
p21 activating kinase; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKC, 
protein kinase C; PLC, phospholipase C; WASP, wiskott-aldrich syndrome protein; ZAP-70, 
^-chain associated protein 70kDa.
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1.4 Analysis of Signal Transduction Pathways
The activation of the pathways described here can be identified by a number 
of techniques. The generation of transgenic and knockout animals has enabled the 
identification of the role of specific molecules in embryonic development and normal 
functioning of cells, organs and animals; as well as their roles in disease 
progression of animal models. However, a more routine way of determining the 
interactions and roles of these molecules has been through use of selective 
inhibitors. There are many commonly available inhibitors reported to target specific 
molecules. Pertussis toxin is an exotoxin produced by the bacterium Bordetella 
pertussis. It is able to catalyze ADP-ribosylation of the a subunits of G proteins 
which then remain In their GDP-bound, Inactive state (Kaslow & Burns, 1992). This 
toxin selectivly acts on members of the Gai family and has been widely used in the 
invesigation of signalling events downstream of most GPCRs.
There are several inhibitors which target PI3K, the most commonly used 
ones include LY294002, a synthetic compound, and wortmannin, a fungal 
metabolite obtained from Penidllium fumiculosum. LY294002 is a cell permeable 
compound that acts on the ATP-binding site of PI3K and blocks the catalytic activity 
of the enzyme with an IC50 of 1.4pM (Vlahos et al, 1994). At this concentration it 
does not affect other known kinases including PKC, PKA, MAPK, S6 kinase or 
PI4K; however at about 100 fold higher concentrations this compound has been 
reported to inhibit MLCK, PLC and PI4K it has been shown to inhibit CK2 at similar 
concentrations used in inhibition on PI3K (Davies et al, 2000). in neutrophils, a 
concentration of 50pM LY294002 completely inhibits all PI3K activity (Vlahos et al, 
1994; Vlahos et al, 1995). Wortmannin has an IC50 of ~ 5nM in CCR2 activated 
THP-1 cells (Turner et al, 1998). Wortmannin has also been shown to inhibit 
neutrophil MAPK and MLCK activity at 200-300nM (Ferby et al, 1994; Cross et al,
1995) as well as PI4K and phospholipase D activity (Bonser et al, 1991; Nakanishi 
et al, 1992; Nakamura et al, 1995). IC87114 is reported to be a selective inhibitor of 
p1105 with an IC50 of 0.5 pM for p1105 inhibition compared to the IC50 values for 
p110a, p110p and p110y which were >100, 75, and 29 pM, respectively (Sadhu et 
al, 2003). IC87114 was also demonstrated to have no significant effect on other 
kinases including p38 MAPK, PKB, PKCa or PKCpil (Sadhu et al, 2003).
There are a number of PKC inhibitors available with reported specificities to 
different isoforms. Ro320432 a cell permeable inhibitor of PKC, reported to inhibit 
PKCa and PKCpI with IC 5 0  values of 9nM and 28nM in rat brain. This compound
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has also been shown to inhibit other PKC isoforms at higher concentrations 
(Wilkinson et al, 1993). G66796 is another widely used PKC inhibitor which targets 
PKCa and PKCpI with IC50 of 2.3nM and 6.2nM in rat brain (Gschwendt et al,
1996) and PKC(i with an IC50 of 20nM in neutrophils (Wenzel-Seifert et al, 1994). It 
has no reported activity for PKC8, s or £ isoforms. Although rottlerin is reportedly a 
selective PKC8 inhibitor with an IC50 of 3-6(jM for purified human PKC8 and 
PKC0 (Gschwendt et al, 1994). It is also able to inhibit PKCa, PKC|3, and PKCy 
isoforms at IC50 values of 30-42|jM, and 80-100 pM for PKCe, PKCr|, and PKC£. 
Further studies of this inhibitor have revealed that it is also a potent inhibitor of 
MAPKAPK2, CaM kinase III, p38 MAPK, PKA, and GSK3J3 (Davies et al, 2000) 
indicating that its status as a selective inhibitor may not be wholly accurate.
Toxins are widely used pharmacological tools in the determination of 
signalling pathways. Inhibition of members of the small G-protein families by lethal 
toxin B, from Clostridium difficile IP82, preferentially inhibits RhoA over Cdc42 and 
Rac, and Lethal toxin 82, from Clostridium sordellii, preferentially inhibits Rac1 over 
Cdc42 and Rho. The proposed mechanism of action of these toxins is through the 
glucosylation or isoprenylation of the target proteins (Just et al, 1995). Y27632 is a 
reported inhibitor of Rho kinase (ROCK) with an IC50 of 140nM; it also inhibits 
ROCKII, PRK2, MSK1 and MAPKAPKip with IC50 values of 800nM, 600nM, 8.3mM 
and 19mM respectively in purified human kinases (Davies et al, 2000; Ishizaki etal, 
2000).
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Aims
As described, chemokine signalling within cells is highly complex and is 
involved in initiating and regulation of multiple effects. Since CXCR6 and CXCXL16 
were discovered 9 years ago, little has been reported regarding the nature of 
signalling through this chemokine receptor and ligand. The presence of the receptor 
on activated T lymphocytes suggests an involvement in immune responses and 
since the receptor has been shown to be up-regulated in a number of disease 
states, it is important to understand the reason for this. Investigation of signal 
transduction events following activation of CXCR6 may help to identify the possible 
importance of this receptor on T lymphocytes. Since this chemokine has a unique 
structure within its class, and has been identified as a scavenger receptor, we were 
unsure if it would mediate the same pathways utilised by other chemokines and 
there receptors. The project aims were therefore two-fold:
1. To identify biochemical targets activated by CXCR6 in T lymphocytes and 
determine whether it utilises the same signal transduction pathways as other 
chemokine receptors.
2. To characterise the role of these molecules in functional responses. Is 
CXCL16/CXCR6 an inflammatory chemokine, can it mediate chemotaxis or 
gene transcription?
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Chapter 2: Materials and Methods
Methods
2.1 Cell Types
The following cell lines were used in this study (descriptions from ECACC or ATCC 
websites):
• CEM - human Caucasian acute T lymphoblastoid leukaemia cell (purchased 
from ATCC)
• HUT-78 - Leukaemic T lymphoblast cell (purchased from ATCC)
• Jurkat J6 - Leukaemic T lymphoblast cell (obtained from ICRF)
The following cells were generated from peripheral blood mononuclear cells 
(PBMCs):
•  previously activated human peripheral blood derived T-lymphocytes (PBLs)
- super antigen-activated T cells or CD3-CD28 activated T cells
• Th1 lymphocytes - T helper 1-like cells
2.2 Culture of Suspension Cell Lines
Suspension cell lines (CEM, HUT-78, Jurkat) were cultured in humidified 
incubators in 5% C02, at 37°C in complete media (RPM11640 media supplemented 
with 10% foetal bovine serum (FBS) (v/v), penicillin (100U/ml) and streptomycin 
(100pg/ml)). Cells were maintained at a confluency of 1-2x106 cells/ml.
2.3 Freezing and Thawing of Cell Lines
Cell lines were stored frozen in liquid nitrogen tanks to provide a continuous 
stock of cells of a particular age and to minimise transformation of cell lines. Cells at 
low confluency were resuspended at 5x106cells/ml in ‘freeze mix’ (90% (v/v) FBS, 
10% (v/v) dimethylsulphoxide (DMSO)) and aliquoted into cryovials at 1 ml/vial. The 
vials were frozen at '80°C overnight and then transferred to the liquid nitrogen tanks 
for storage. Cells were thawed by placing the cryovial in a 37°C water bath to 
rapidly defrost the cell suspension. The cells were quickly mixed with pre-warmed 
complete media and centrifuged (5 minutes, 400g). Cells were then resuspended in 
complete media, seeded into an 80cm2 tissue culture flask and maintained as 
described above.
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2.4 Isolation of Peripheral Blood Mononuclear Cells
100ml venous blood was taken from a healthy human volunteer into a 
heparinised syringe (2U/ml). The blood was diluted 1:1 v/v with RPMI 1640 media 
and 35mls of the mixture was layered over 15mls Lymphoprep in clear 50ml falcon 
tubes. The tubes were centrifuged at 400g, 20°C for 30minutes (no brake). The 
milky interface containing the PBMCs (figure 16) was removed into clean tubes and 
the cells were subsequently washed 3 times in RPMI 1640 medium by centrifuging 
at 400g for 5 minutes, removing the supernatant and resuspending the cells in 
RPMI medium. Cells were resuspended in 100mls complete RPMI 1640 medium 
(supplemented with 10% FBS, 50pg/ml penicillin and 50pg/ml streptomycin). 
PBMCs were then used to create activated T-lymphocytes.
Plasma
Milky layer containing 
lymphocytes
Lymphoprep
Cell pellet containing erythrocytes, 
granulocytes and other cells
Figure 16. Isolation of mononuclear cells from blood.
Whole blood, diluted with RPMI 1640 media, was layered over 15ml Lymphoprep and 
centrifuged at 400g for 20 minutes (without brake). The milky interface, containing 
mononuclear cells, between the plasma and Lymphoprep was removed and cells were 
cultured.
2.5 Expansion of previously activated human peripheral blood derived 
T-lymphocytes
Following isolation from blood, PBMCs were then expanded in culture by 
one of two methods. Either the PBMCs were transferred to a 175cm2 tissue culture 
flask with 1pg/ml staphylococcus enterotoxin B (SEB) for 72hrs at 37°C, 5% C 02. 
The cells were then washed 3 times in RPMI 1640 (400g, 5 minutes) and 
resuspended in 100mls complete RPMI 1640 medium with IL-2 (50U/ml) and
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transferred to a dean 175cm2 tissue culture flask. Cells were maintained at a 
confluency of 1-2x106 cells/ml and lL-2 (50U/ml) added every 2 days for up to 14 
days. These cells will be referred to as SEB-activated PBLs. Alternatively, PBMCs 
were transferred to a 175cm2 tissue culture flask for 3 hours where most adherent 
cells would be removed from the cell mixture. Suspension cells were removed and 
seeded at 1x106 cells/ml in complete RPMI media with IL-2 (50U/ml) and CD3- 
CD28 microbeads (1 bead/cell) in an 80cm2 tissue culture flask. Cells were 
maintained at a confluency of 1-2x106 cells/ml and IL-2 (50U/ml) added every 2 
days for up to 20 days. These cells will be referred to as CD3-CD28-activated 
PBLs. Prior to use in experiments, SEB-activated PBLs were washed free of IL-2, 
and for CD3-CD28-activated PBLs the CD3-CD28 microbeads were removed, and 
ceils maintained in complete media overnight.
2.6 In Vitro Generation of Human T Helper 1 (Th1) Cells
Preparation of Discontinuous Percoll Gradients
NaCI (9.00g) was dissolved in 100ml MilliQ water to make a 10x isotonic 
solution. Isotonic Percoll was prepared by diluting mixing Percoll with the 10x 
isotonic saline solution (9:1). This stock solution (“100%” Percoll) was used to 
prepare dilutions of 55%, 70% and 81%. Each gradient consisted of 5ml 81% 
Percoll, 3ml 70% Percoll and 2.5ml 81% Percoll. 1 discontinuous Percoll gradient 
was prepared for each 20ml whole blood.
Isolation of CD4+/CD45RA+ Cells
100ml venous blood was taken from a healthy human volunteer into a 
heparinised syringe (2U/ml). The blood was mixed with an equal volume of Hespan 
plasma expander and left to stand for 30 minutes. The supernatant was removed 
and centrifuged (400g, 5 minutes). The supernatant was removed and the 
leukocyte pellet was resuspended in 55% Percoll. The cell suspension was layered 
over the discontinuous Percoll gradients and centrifuged (1600g, 30 minutes, room 
temperature). The lymphocytes were removed from the 55% Percoll phase and the 
55%/70% Percoll interface (figure 17). Cells were washed twice in phosphate 
buffered saline (PBS) and CD4/CD45RA+ cells were isolated using a MACS CD4+ 
T call isolation kit II and MACS CD45RO microbeads (Miltenyl Biotec, Auburn, CA, 
USA) in accordance with manufacturer’s instructions. Cells were resuspended at 
2.5x10® cells/ml In buffer (PBS pH 7.2, 0.5% bovine serum albumin (BSA), 2mM 
EDTA). 10pJ/1x107 cells Biotin-Antibody Cocktail was added and the cells were
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incubated for 10 minutes at 4°C. 30pl/1x107 cells buffer and 20^1/1 x107 cells Anti 
Biotin Microbeads were added and the cells were incubated for 15 minutes at 4°C. 
The cells were washed and resuspended in buffer at 2x108 cells/ml. Cells were 
separated using the ‘deplete’ programme of an autoMACS™ Separator (Miltenyl 
Biotec, Auburn, CA, USA). The negative fraction eluted contained the CD4+ T cells. 
Cells were resuspended in buffer at 80 1^/1 x107 cells and 5pl/1x107 cells MACS 
CD45RO microbeads was added. Cells were incubated for 15 minutes at 4°C. The 
cells were washed and resuspended in buffer at 2x108 cells/ml. Cells were 
separated using the ‘deplete’ programme of an autoMACS™ Separator (Miltenyl 







Figure 17. Isolation of lymphocytes from whole blood.
Isotonic Percoll was prepared by diluting mixing Percoll with 10x saline solution. This stock 
solution (‘,100%B Percoll) was used to prepare dilutions of 55%, 70% and 81% and 
discontinuous Percoll gradients were prepared. Whole blood was mixed with an equal 
volume of Hespan plasma expander and left to stand for 30 minutes. The supernatant was 
removed and centrifuged (400g, 5 minutes). The leukocyte pellet was resuspended in 55% 
Percoll, layered over the Percoll gradients and centrifuged (1600g, 30 minutes, room 
temperature). Lymphocytes were removed from the 55% Percoll phase and the 55%/70% 
Percoll interface.
Generation of Th1 cells
6-well plates were incubated overnight (37°C, 5% C 02) with 1.5ml PBS 
containing 1mM MgCI2, 1mM CaCI2, anti-CD3 (5^g/ml) and anti CD28 (5pg/ml). The 
wells were washed with PBS prior to addition of cells. CD4+CD45RO' T cells were 
resuspended at 1x106 cells/ml in growth media (see Appendix 1) with IL-2
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(10ng/ml), IL-12 (5ng/ml) and anti-IL-4 (5ng/ml). 3mls cell suspension was added to 
each well and incubated for 4 days (37°C, 5% C 02). Cells were combined and 
washed in resting medium (see Appendix 1) and resuspended at 1x106 cells/ml in 
resting medium containing IL-2 (10ng/ml) and IL-7 (1ng/ml). cells were incubated 
for 4-7 days (37°C, 5% CO2). Cells were resuspended at 5x105 cells/ml in growth 
media with IL-2 (10ng/ml), IL-12 (5ng/ml), anti-IL-4 (5ng/ml) and anti-CD95L 
(ipg/ml) and incubated for a further 4 days (37°C, 5% C 02). IFN-y production, as a 
Th1 marker, was measured prior to use.
2.7 Cell Counting and Viability
Cells were resuspended in 50ml media and 100pl was transferred to a 0.5ml 
centrifuge tube containing I00pl 0.4% trypan blue (a negatively charged 
chromophore which is able to bind cellular proteins if the membrane is damaged; 
therefore staining non-viable cells blue). The tube was gently mixed and 10pJ was 
transferred to a haemocytometer. The number of viable cells was counted using a 
light microscope.
2.8 Cell Stimulation and Lysis
Preparation of Whole Cell Lysates
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPMI 1640 medium. Cells were resuspended in 1.5ml centrifuge tubes at 
5x106 cells/500pl in RPMI 1640 medium and allowed to rest for 1 hour at 37°C. 
Where used, inhibitors were added at the appropriate concentration after 30 
minutes. Agonists were added for appropriate times and the stimulations terminated 
by aspiration of the supernatant and addition of 500pl lysis buffer (see Appendix 1 
for recipe). Cells were then lysed by rotating at 4°C for 10 minutes and centrifuged 
(400g, 10 minutes 4°C). 400pl of each lysate was transferred to a clean tube 
containing 100pl 5x reducing sample buffer (see Appendix 1 for recipe) and boiled 
for 10 minutes. Samples were stored at ^0°C until used for SDS-PAGE and 
western blotting (described below).
Preparation of Samples for Flow Cytometric Analysis of Phosphorylation and 
Actin Polymerisation
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPM11640 medium. Cells were resuspended in 1.5ml centrifuge tubes at
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5x106 cells/500^1 in RPMI 1640 medium and allowed to rest for 1 hour at 37°C. 
Where used, inhibitors were added at the appropriate concentration after 30 
minutes. Agonists were added for appropriate times and the stimulations terminated 
by fixing the cells in 3.7% formaldehyde. Samples were incubated at room 
temperature for 10 minutes and washed twice in PBS. Cells were permeabilised in 
PBS containing 0.1% (w/v) triton and 0.1% (w/v) BSA on ice for 5 minutes. Samples 
were washed twice and resusupended in cold PBS.
Preparation of Samples for Measurement of TNFa and IFNy
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPMI 1640 medium. Cells were resuspended in 24-well tissue culture 
plates at 2x106 cells/500pl in RPMI 1640 medium/0.1%BSA and allowed to rest for 
1 hour at 37°C. Agonists were added for appropriate times and the stimulations 
terminated by centrifugation (13000g, 10 minutes, 4°C). The supernatant was 
transferred to a clean tube and stored at '80°C until used.
Preparation of Nuclear and Cytosolic Fractions
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times In RPMI 1640 medium. Cells were resuspended in 1.5ml centrifuge tubes at 
1x107 cells/500pl in RPMI 1640 medium and allowed to rest for 1 hour at 37°C. 
Where used, inhibitors were added at the appropriate concentration after 
30minutes. Agonists were added for appropriate times and the stimulations 
terminated by aspiration of the supernatant, addition of 400jil buffer 1 (see 
Appendix 1 for recipe) and incubation on ice for 15 minutes. 15pl 10% NP40 was 
added and the tubes were mixed and then centrifuged (13000g, 5 minutes, 4°C). 
The supernatants (containing cytosolic proteins) were transferred to clean tubes 
and the pellets (containing nuclear proteins) were washed in bulTer 1, and then 
resuspended in 50^1 buffer 2 (see Appendix 1 for recipe). The tubes were rotated 
for 30 minutes at 4°C and centrifuged (13000g, 5 minutes, 4°C). The supernatants 
(containing nuclear proteins) were transferred to clean tubes. Samples were then 
analysed to determine protein concentration (described below). 320pl of each 
cytosolic fraction was transferred to a clean tube containing 80^1 5x sample buffer 
and 40pl of each nuclear fraction was transferred to a clean tube containing 10^15x 
sample buffer. Samples were boiled for 10 minutes and stored at ‘20°C until used 
for immunoblotting (described below).
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2.9 Bradford Assay for Protein Concentration
To measure the amount of protein in each sample the Bio-Rad protein 
assay was used. For each sample to be analysed, 5pl lysate/supernatant was 
added to a 1.5ml centrifuge tube containing 995^1 20% Bradford solution and 
vortexed. 100pl was transferred to a 96 well plate in duplicate. A standard curve 
was also constructed using BSA and the plate was read at 595nm (figure 18) 
(Versamax, Molecular Devices Corporation, CA, USA). The amount of protein was 




0 5 10 15 20
protein concentration (pg)
Figure 18. Standard curve for determining protein concentration.
A standard curve of bovine serum albumin (BSA) was constructed to calculate protein 
concentration in samples. Appropriate concentrations of BSA were added to 20% Bradford 
solution. 100pJ was transferred to a 96 well plate in duplicate and the plate was read at 
595nm (Versamax, Molecular Devices Corporation, CA, USA).
2.10 SDS-PAGE & Western Blotting
Using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE), proteins from whole cell lysates can be identified and measured. The 
process of boiling samples in the presence of SDS and a reducing agent (2- 
mercaptoethanol) denatures the proteins into their polypeptide subunits. This allows 
separation, according to their molecular weight, of individual proteins on a gel when 
voltage is applied.
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SDS-PAGE
SDS-PAGE mini gels were made using BioRad Mini Protean III equipment 
in accordance with manufacturer’s instructions (Bio-Rad Laboratories, Hemel 
Hempsted, UK). Stacking geis were always 5% bis-acrylamide and resolving gels 
varied between 7.5% and 12% bis-acrylamide (see appendix 1 for recipes) in 
accordance with the size of the protein of interest. Glass plates were cleaned 
before use and 4.5ml resolving buffer was poured in between the plates. MilliQ 
water was carefully overlaid to ensure a smooth flat gel. The buffer was left to 
polymerise for 30 minutes and the MilliQ was completely removed. Stacking buffer 
was poured on top of the resolving gel and a comb was inserted. Following 
polymerisation of the stacking gel (~ 15 minutes) the comb was removed and the 
wells were washed with MilliQ water and filled with Running Buffer (see appendix 1 
for recipe). Samples were loaded into the appropriate well and a molecular weight 
marker was also included to aid protein band identification. Gels were 
electrophoresed at 80V until the samples had passed through the stacking gel and 
the voltage was then increased to 180V until the samples reached the bottom of the 
gel. The apparatus was then disassembled and the gel removed from the glass 
plates and washed in semi-dry transfer buffer (see appendix 1 for recipes). A stack 
containing 4 pieces of 3MM filter paper and nitrocellulose membrane pre-soaked in 
semi-dry transfer buffer was assembled on the anode plate of the transfer 
equipment (Pharmacia-Biotech Multiphor II) and the gel was placed on the top of 
this. A further 4 pieces of 3MM filter paper pre-soaked in semi-dry transfer buffer 
were added on top and air bubbles were gently removed. The cathode was placed 
on top of the stack and the proteins were then transferred from the gel onto the 
nitrocellulose membrane for 1 hour at 0.8mA/cm2 of gel.
Western Blotting (Immunoblotting)
Following transfer of the proteins onto nitrocellulose membrane, the 
membranes were washed in tris-buffered saline (TBS) (see appendix 1 for recipes) 
and stained with Ponceau S solution. This enabled visualisation of the protein 
bands to ensure equal transfer had occurred. The Ponceau S solution was removed 
by washing the membranes in TBS and they were then blocked for 1 hour in 5% 
(w/v) non-fat milk powder in TBS. Membranes were washed briefly in TBS and 
incubated on a rocking platform in the primary antibody overnight The membranes 
were washed 4 times (for 5 minutes) in TBS/0.01 %Tween (TBST) and incubated 
with the appropriate horse radish peroxidase (HRP) conjugated secondary antibody
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diluted in TBS for 2 hours. Membranes were washed 4 times in TBST and once in 
TBS before visualisation of the protein bands using Amersham Enhanced 
Chemiluminescence (ECL) reagent, in accordance with the manufacturer’s 
instructions. Membranes were incubated in the reagent for 1 minute and wrapped in 
cling film and exposed to autoradiography film.
Membrane Stripping and Reprobing
To verify that the samples were equally loaded on the membranes, 
membranes were incubated in stripping buffer for 30 minutes at 60°C to remove the 
antibodies. Membranes were then washed in TBST before being blocked and 
reprobed in appropriate primary and secondary antibodies as previously described.
2.11 Flow cytometry
A flow cytometer uses the deflection of light to analyse the physical 
properties of a single cell. Cells in suspension flow through the instrument in a 
single stream which allows each cell to be analysed. Light, from a laser source, is 
focused through a lens into a beam of approximately 50pm, perpendicular to the 
cell stream. As the light crosses the stream of cells, light is deflected and focused 
onto photodetectors, either in front of or at right angles to the source of light, which 
convert the light signal into an electrical impulse proportional to the intensity of the 
light which reaches the detector. Each photodetector is preceded by a filter, the 
filter ensures that the detector is only exposed to light of a specific colour. One of 
the detectors to the side of the illuming beam will be fitted with a filter of the same 
colour as the laser (usually blue); because it is at the side, light will only reach the 
detector if it has been deflected from the cell. The rougher the cell surface or more 
granular the cell, the more light will scatter and therefore reach the detector, this 
signal is known as the side scatter. Other detectors to the side of the laser beam 
will be preceded by coloured filters which enable detection of cells stained with 
fluorescent tags (usually fluorescein (FITC) (green) or phycoerythrin (PE) 
(red/orange)). The flow cytometer also has a detector directly in front of the light 
source; this is fitted with a metal bar in front of it. Light can only reach the detector if 
it is bent passing through a particle, this forward scatter is indicative of the size of 
the particle; a larger cell can refract more light and the signal reaching the detector 
will be more intense. Some flow cytometers, able to sort cells according to these 
physical properties, are known as fluorescence activated cell sorters (FACS).
















Figure 19. Simplified schematic diagram of a flow cytometer.
Light from the laser deflects from the stream of cells, passes through coloured filters onto 
photodetectors. The greater the light intensity, the larger the electrical impulse it is 
converted into. The forward scatter indicates the size of the cell, while the side scatter 
indicates the granularity. Orange and green filters allow the detection of fluorescent tags on 
cells.
Analysis of Receptor Expression
Cells were washed twice in PBS and aliquoted into polypropylene FACS 
tubes at 1x106 cells/tube in 80pl PBS/20% FCS. For measurement of CD3, CD28, 
CXCR4 and CXCR6, 20pJ of PE-conjugated mAb or corresponding PE-conjugated 
isotype control was added to the appropriate tubes. For CD4 and CD8 
measurement, 20jJ of FITC-conjugated mAb or corresponding FITC -conjugated 
isotype control was added to the appropriate tubes. A negative control was also 
included which had 20pl of PBS/20% FCS added in place of antibody to give a 
reading for the cell’s autofluorescence. Cells were incubated for 30 minutes on ice, 
in the dark with regular mixing. Cells were washed twice in PBS and resuspended 
in 500|jJ PBS and immediately analysed by a FACS Vantage (BD Biosciences, San 
Jose, CA).
Analysis of IL-4 and IFN^y Production (Th1)
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPMI 1640 medium. Cells were resuspended in polypropylene FACS tubes 
at 1x106 cells/500pl in RPMI 1640 medium and allowed to rest for 1 hour at 37°C.
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Cells were stimulated with PMA (Phorbol 13-myristate 12-acetate) (50ng/ml) and 
ionomycin (500ng/ml) for 2 hours at 37°C. One aliquot of the cells was left 
inactivated as a control. Following stimulation, 1(Vg/ml Brefeldin A was added to all 
cells and they were incubated for a further 2 hours at 37°C. The cells were washed 
in 3ml FACS staining buffer (PBS containing 1% BSA) and resusupended at 5x105 
cells/ml. Cells were fixed in 3.7% formaldehyde. Samples were incubated at room 
temperature for 10 minutes and in FACS staining buffer. Cells were permeabilised 
in PBS containing 0.1% (w/v) triton on ice for 5 minutes. Samples were washed 
twice in FACS staining buffer and resusupended in 80)jJ FACS staining buffer. 20*aI 
Alexa Fluor® 488-conjugated anti-IFNy or Alexa Fluor® 488-conjugated anti-IL-4 was added 
and the cells incubated for 30 minutes at room temperature in the dark. Samples 
were washed twice in FACS staining buffer and resusupended in 500pl cold PBS 
before analysis by a FACS Vantage (BD Biosciences, San Jose, CA).
Analysis of Protein Phosphorylation
Measurement of protein phosphorylation by flow cytometry has recently 
become more widely used. It enables analysis of the phosphorylation status of 
individual cells; the use of different coloured fluorescent tags could potentially allow 
measurement of phosphorylation of multiple molecules in the same cell at a given 
time point. It also requires fewer cells and is therefore useful when cell numbers are 
limited.
Following fixing and permeabilisation, cells were incubated in 0.2pg 
phospho-specific antibody or 0.2pg isotype control for 30 minutes at room 
temperature. Samples were washed twice in PBS and incubated in FITC- 
conjugated secondary antibody (1:250 final dilution) for 30 minutes at room 
temperature. Cells were washed twice in PBS and resuspended in 500pl PBS, 
transferred to polypropylene FACS tubes and immediately analysed by a FACS 
Vantage (BD Biosciences, San Jose, CA).
Analysis of Actin Polymerisation
Actin polymerisation occurs in response to a number of cell stimuli; actin 
monomers, through interaction with a number of proteins, are joined together 
forming actin filaments (F-actin). Phalloidin is a fungal toxin which binds F-actin 
monomers in a 1:1 ratio; fluorescently-labelled phalloidin can therefore be used to
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measure the concentration of actin in the cytoskeleton because the intensity of the 
signal will be proportional to the concentration of actin.
Following fixing and permeabilisation, cells were incubated in 0.6pM FITC- 
conjugated phalloidin for 30 minutes in the dark. Cells were washed twice in PBS, 
resuspended in 200pJ PBS and transferred to polypropylene FACS tubes. To 
measure autofluorescence of the cells, one sample was fixed and permeabilised 
but left without phalloidin. Samples were immediately analysed by FACS Vantage 
(BD Biosciences, San Jose, CA).
2.12 Chemotaxls Assays
There are two methods for analysing cell migration described below. The 
Neuroprobe disposable Chemotx plates required fewer cells and lower volumes of 
the chemoattractants, however the individual plates are expensive and it was not 
possible to use them in all assays. The Neuroprobe reusable chemotaxis chambers 
were therefore used to measure chemotaxis of cell types in which numbers were 
not limited.
Neuroprobe Reusable MB Series 96 Well Chemotaxis Chambers (Cell lines 
and activated PBLs) (figure 20)
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPMI 1640 medium. Cells were resuspended at 1x106 cells/ml in RPMI 
1640 medium/0.1% BSA and where used, inhibitors were added at the appropriate 
concentration. The 96-well reusable chemotaxis chamber (Neuroprobe, 
Gaithersburg, MD, USA) was prepared in accordance with the manufacturers 
instructions. The appropriate agonists were placed in the lower 96 well plate 
(disposable) within the lower chamber and a 5p.m polyvinylpyrrolidine-free 
polycarbonate membrane was carefully fitted on top. The chamber lid was gently 
closed and 200pl of the cell suspension was added to each well of the upper 
chamber. The chamber was left for 3 hours at 37°C (5% C 02). At the end of the 
Incubation period, cells remaining In the upper chamber were aspirated ofT and 
200pi versene was added to each well. The chamber was incubated at 4°C for 20 
minutes and the versene was aspirated off. The chamber was dismantled and the 
96-well plate in the lower chamber was centrifuged (400g, 10 minutes). The 
membrane was detached and the media was the aspirated off and the cells were 
resuspended in 100pl RPMl/0.1% BSA. Cell numbers were determined from
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standard curves of cells from the same experiment using 20pl/well Cell Titer 96 
AQueous reagent. Plates were incubated at 37°C until the colour developed. 





Figure 20. Neuroprobe reusable chemotaxis chambers.
Chemoattractants were added to the 96 wells of the lower plate and a membrane 
(filter) was fitted over the top. The lid (forming the upper 96-well plate) was closed ensuring 
air bubbles did not form and that the upper and lower wells were aligned. Cells were added 
to the upper wells and the chamber was left for 3 hours at 37°C (5% C02). Cell numbers 
were determined using Cell Titer 96 AQueous reagent.
Neuroprobe Disposable Chemotx System (Th1) (figure 21)
Cells were harvested by centrifugation (400g, 5 minutes) and washed 3 
times in RPM11640 medium (without phenol red). Cells were resuspended at 1x107 
cells/ml in RPM11640 medium (without phenol red)/0.1% BSA. Cells were labelled 
with 5mg/ml calcein-AM (Molecular Probes, Leiden, Netherlands) for 30 minutes in 
the dark at 37°C. Cells were then washed twice and resuspended at 4x106 cells/ml 
in RPMI 1640 medium (without phenol red)/0.1% BSA. The 96-well disposable 
chemotaxis plates (Neuroprobe, Gaithersburg, MD, USA) was prepared in 
accordance with the manufacturers instructions. 29pl of the appropriate agonists 
were placed in the 96 well plate and a 5pm filter was carefully placed on top. 25pl of 
the cell suspension was then placed on top of the filter over each well and the plate 
was incubated at 37°C (5% C 02) for 1.5 hours. At the end of the incubation time 
cells remaining on the top of the filter were gently washed off with PBS and the filter 
top was scraped with 3MM chromatography paper. The plate was read using a 
fluorescent plate reader (Fluoroskan Ascent, Thermo Labsystems, Finland) at 
485nm (excitation) and 538nm (emission). Cell numbers were determined from 
standard curves of cells from the same experiment.




Figure 21. Neuroprobe Chemotx plates.
Chemoattractants were added to the 96-well plate and a membrane (filter) was 
fitted over the top. Calden-AM labelled cells were placed in the filter, over each well and 
were incubated for 1.5 hours at 37°C (5% C 0 2). Cells were washed off the filter and the 
fluorescence was read using a plate reader.
2.13 Measurement of IFNy and TNFa by ELISA
ELISAs (enzyme linked-immunosorbant assay) can be used for the 
quantitative detection of a variety of small biological assays. The principle of the 
assay is to capture the ‘antigen’ with immobilised antibody and then add a 
secondary antibody coupled to an enzyme. Unbound antibodies are removed and 
the activity of the enzyme can be measured.
Samples were thawed on ice and levels of cytokines were measured by 
ELISA in accordance with the manufacturer’s instructions. A standard curve was 
constructed from recombinant human TNFa or IFNy. 50pJ of sample diluent was 
added to each well of the 96-well plate precoated with anti-TNFa antibody (for 
measurement of IFNy this was not required). 50pJ sample or standard was added to 
the wells in duplicate; the plate was covered and incubated for either 1 or 2 hours at 
room temperature for or TNFa or IFNy resepctively. Following incubation, the plate 
was washed 3 times in wash buffer. 10OpJ biotinylated antibody reagent was added 
to each well and incubated for an hour at room temperature. The plate was washed 
3 times and 100pJ strepavidin-HRP solution was added to each well. The plate was 
covered and incubated for a further 30 minutes at room temperature. Following 
incubation, the plate was again washed 3 times in wash buffer. 100|J TMB 
substrate solution was added to each well and plate was incubated in the dark for 
30 minutes at room temperature to allow colour change to occur. IOOp.1 stop 
solution was added to each well and the plate was read on a plate reader at 450nm 
(Versamax, Molecular Devices Corporation, CA, USA) and TNFa concentrations 
were calculated by linear regression from the standard curves (figure 22).
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Figure 22. Examples of ELISA standard curves.
2.14 Statistical analysis
Statistical analysis was performed using ANOVA and Student’s t test, with 
Bonferroni correction where necessary.
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Lymphoprep (Ficoll-paque 1.077g/ml 
density)
Axis-Shield, Oslo (Norway)
Media Gibco BRL, Paisley (UK)
Mercaptoethanol Sigma Aldrich, Gillingham (UK)
Phosphate buffered saline (PBS) 
without Ca2+ and Mg2+
Gibco BRL, Paisley (UK)
Penicillin/Streptomycin Gibco BRL, Paisley (UK)
Percoll Sigma Aldrich, Gillingham (UK)
Plastics Nunc (UK)
RPM11640 media Gibco BRL, Paisley (UK)
Sodium heparin Sigma Aldrich, Gillingham (UK)
Sodium pyruvate Gibco BRL, Paisley (UK)
Staphylococcal enterotoxin 8 Sigma Aldrich, Gillingham (UK)
Trypan Blue Gibco BRL, Paisley (UK)
Trypsin/EDTA Gibco BRL, Paisley (UK)
Other:
Material Source
2-mercaptoethanol Sigma Aldrich, Gillingham (UK)
96-well plates for chemotaxis Greiner-bioone (Germany)
Acrylamide/bis acrylamide Bio-rad (UK)
Ammonium persulphate Sigma Aldrich, Gillingham (UK)
Aprotinin Sigma Aldrich, Gillingham (UK)
Bovine serum albumin (BSA) Sigma Aldrich, Gillingham (UK)
Brefaldin A Sigma Aldrich, Gillingham (UK)
Bromophenol blue BDH, Poole (UK)
Cell Titer 96® Aqueous One Solution 
Cell Proliferation Assay
Promega UK, Southampton (UK)
DMSO Sigma Aldrich, Gillingham (UK)
EDTA Sigma Aldrich, Gillingham (UK)
Enhanced chemiluminescence 
detection kit for Western blotting 
(ECL)
Amersham International (UK
Ethanol Fisher Scientific, Loughborough (UK)
Filter paper Whatman, Maidstone (UK)
Formaldehyde Sigma Aldrich, Gillingham (UK)
Glycerol Sigma Aldrich, Gillingham (UK)
Glycine Sigma Aldrich, Gillingham (UK)
G56976 Calbiochem, Nottingham (UK)
HEPES Sigma Aldrich, Gillingham (UK)
Human IFNy ELISA Kit Pierce Endogen, Rockford IL (USA)
Human TNFa ELISA Kit Pierce Endogen, Rockford IL (USA)
Hydrochloric acid BDH, Poole (UK)
IC87114 Tocris Cookson, Avonmouth (UK)
lonomycin Sigma Aldrich, Gillingham (UK)
Lethal toxin 82
Leupeptin Sigma Aldrich, Gillingham (UK)
LY294002 Tocris Cookson, Avonmouth (UK)
Marvel (fat-free dry milk) Supermarket
Methanol Fisher Scientific, Loughborough (UK)
Molecular weight protein markers Bio-rad (UK)
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Nitrocellulose BDH, Poole (UK)
Nonidet P-40 Sigma Aldrich, Gillingham (UK)
Pan T Cell Isolation Kit II (human) Miltenyi Boitec, CA (USA)
PD98059 Calbiochem, Nottingham (UK)
Pertussis toxin Sigma Aldrich, Gillingham (UK)
Plastics Greiner-bioone (Germany)
Phalloidin - FITC conjugated Sigma Aldrich, Gillingham (UK)
Phorbol 13-myristate 12-acetate 
(PMA)
Calbiochem, Nottingham (UK)
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich, Gillingham (UK)
Ponceau S Sigma Aldrich, Gillingham (UK)
Rapamycin Calbiochem, Nottingham (UK)
Recombinant human CXCL16 
(rhCXCL16)
R & D Systems, Abingdon (UK)
Recombinant human CXCL10 
(rhCXCLIO)
R & D Systems, Abingdon (UK)
Recombinant human CXCL12 
(rhCXCL12)
R & D Systems, Abingdon (UK)
RO-32-0432 Calbiochem, Nottingham (UK)
Rottlerin Calbiochem, Nottingham (UK)
Sodium azide Sigma Aldrich, Gillingham (UK)
Sodium chloride Sigma Aldrich, Gillingham (UK)
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Gillingham (UK)
Sodium fluoride Sigma Aldrich, Gillingham (UK)
Sodium molybdate Sigma Aldrich, Gillingham (UK)
Sodium orthovanadate Sigma Aldrich, Gillingham (UK)
TEMED Sigma Aldrich, Gillingham (UK)
Toxin B
Tris (Trizma base) Sigma Aldrich, Gillingham (UK)
Tween-20 Sigma Aldrich, Gillingham (UK)
Versene Gibco BRL (UK)
Wortmannin Calbiochem, Nottingham (UK)
X-OMAT film Amersham International (UK)
XTT Sigma Aldrich, Gillingham (UK)
Y27632 Calbiochem, Nottingham (UK)
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Chapter 3 - Results
Identification of a T cell model for investigation into signalling 
through CXCR6
CXCR6 messenger RNA was first identified in T-lymphocytes (Loescher et 
al, 1997; Deng et al, 1997) and has since been reported to be expressed on a 
number of other primary cell types (Chandrasekar et al, 2004; Deng et al, 1997; 
Sharron, M. et al, 2000). Despite this the majority of research into CXCR6 has 
remained focused on primary T-lymphocytes and T cell lines. In order to investigate 
signalling mechanisms following activation of CXCR6 it was necessary to develop a 
working T cell model which expresses a functional CXCR6 receptor on the cell 
surface.
Characterisation of functional CXCR6 on T cell lines
3.1 Expression of CXCR6 on T cell lines
Several leukaemic T cell lines were analysed for expression of CXCR6 in 
order to develop a working model for further experiments (Figure 23). The 
leukaemic T cell lines, Jurkat, HUT-78 and Cem cells, are widely used within the 
chemokine research field as a model T cell. Initial analysis of Jurkat ceils showed 
expression of CXCR6 on a small population of cells (figure 23A), as a T cell line, it 
would usually be expected that cells would be uniform in their phenotype, so the 
reason only a small population of cells express the receptor is therefore unclear. 
Unfortunately, CXCR6 was unable to be detected in future experiments (figure 
23B). Both of these samples originated from the same source however, they 
represent aliquots thawed at different times and CXCR6 was only detected in the 
first. Although some work into CXCR6 function has been carried out in Jurkats, it 
used cells transfected with CXCR6 in order to obtain a consistently high expression 
(Matloubin etal, 2000).
The lack of consistency of CXCR6 expression in Jurkat cells lead to the use 
of alternative T cell lines. HUT-78 cells are another commonly used T cell line, 
which have previously been reported not to express CXCR6 RNA (Deng et al, 
1997). However, analysis of these cells by flow cytometry indicated that CXCR6 
was expressed on the cell surface (figure 23C). Deng et al were also unable to
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detect CXCR6 RNA in Cem cells, figure 23D however shows that they also display 
a high level of expression over the entire population.
Figure 23. Flow cytometric analysis of CXCR6 expression on cell lines A Initial Jurkat 
sample showing a sub-population of cells expressing CXCR6 (green line). B Second Jurkat 
sample showing no CXCR6 expression (green line). C Expression of CXCR6 on the entire 
Hut 78 cell population (blue line). D High expression of CXCR6 on Cem. Blue shaded area 
represents isotype control (mouse lg G 2B) Cells were incubated with either 2.5p.g/ml 
phycoerythrin-conjugated anti-CXCR6 antibody or isotype control for 30minutes. Samples 
were then analysed by flow cytometry. (n=5)
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3.2 Analysis of signalling pathways coupled to CXCR6 in T cell lines
Although these cell lines express CXCR6 at the cell surface, it was 
important to verify that the receptor was coupled to signalling pathways. As has 
been previously described, ligation of CXCR6 by CXCL16 activates the MAPK 
pathway (Matloubin etal, 2000). Phosphorylation of ERK1/2 on Tyr204 and Thr202 
within the activation loop results in activation of ERK1/2. Figure 24a shows that in 
these Jurkat cells, CXCL16 initiates both a concentration-dependent and time 
dependent phosphorylation of ERK1/2, at Thr202 and Tyr204, which reaches a 
maximum at 5nM and 2 minutes respectively. CXCR6 expression on Jurkats was 
only detectable in the initial aliquot thawed; as would be expected, lack of 
detectable receptor expression correlated with loss of CXCL16-induced 
phosphorylation of ERK1/2. PI3K and PKB are components of another important 
signalling pathway whose activation following TCR engagement and chemokine 
receptor ligation has been widely reported. Although there has been much 
discussion about the exact requirement for phosphorylation of serine 473 for full 
activation of PKB, it has been shown to correlate with activation of PI3K. However, 
due to a lack of PTEN and SHIP in Jurkats (Astoul et a/, 2001; Shan et al, 2000), 
these cells have high basal levels of phosphorylated PKB, and in these initial 
experiments in Jurkats, PKB phosphorylation was not measured.
The HUT-78 express CXCR6 over a larger percentage of the population 
than seen in the Jurkat sample, however signalling experiments in this cell line were 
disappointing. There was high levels of basal ERK1/2 phosphorylation which 
decreased with increasing concentrations of CXCL16 (figure 24b). Basal ERK1/2 
phosphorylation decreased at 30 seconds and reappeared at 1 and 2 minutes and 
again after 30 minutes. Due to the complex signalling pathways leading to 
phosphorylation of ERK, the later activation of ERK1/2 is not surprising, however 
the high basal levels make analysis of stimuli-induced phosphorylation difficult to 
decipher.
Cem cells express high levels of CXCR6 however there was no detectable 
CXCL16 induced phosphorylation of ERK1/2 or PKB. CXCL12 did increase 
phosphorylation of these proteins suggesting that in these cells, CXCR6 is not 
functionally coupled to downstream effectors (figure 24c).
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Figure 24. CXCR6 is coupled to signal transduction pathways in some T cell lines.
a. concentration-dependent phosphorylation of ERK1/2 by CXCL16 (1nM-100nM) at 2 
minutes in Jurkats and time-dependent phosphorylation of ERK1/2 by CXCL16 (5nM) in 
Jurkats. b. concentration-dependent phosphorylation of ERK1/2 by CXCL16 (1nM-100nM) 
at 2 minutes in HUT-78 cells and time-dependent phosphorylation of ERK1/2 by CXCL16 
(5nM) in HUT-78 cells, c time-dependent phosphorylation of ERK1/2 and PKB by CXCL16 
(10nM) and CXCL12 (10nM) in cem cells. Following stimulation (5x106 cells/point), cells 
were lysed and the proteins separated on a 10% SDS-PAGE gel. Changes in 
phosphorylation were detected using anti-phospho ERK1/2 (thr42/tyr44) antibody. Equal 
loading of gels was verified using anti-ERK1 antibody. (n=3).
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Characterisation of functional receptor expression on primary T- 
lymphocytes 
Th1 cells
3.3 Expression of CXCR6 on Th1 cells
Following its discovery on T-lymphocytes, CXCR6 was described as a Th1- 
speciflc chemoklne receptor because expression of the receptor correlates with 
production of IFN-y from cells (Calabresi et al, 2002; Heydtmann & Adams, 2002; 
Kim et al, 2001). While CXCR6 is no longer thought to be exclusively expressed on 
Th1 cells, they were thought to be a more reliable cell type for the investigation into 
signal transduction through CXCR6. Polarisation of naive T-lymphocytes 
(CD4*/CD45RO~) into a Th1 phenotype using cytokine stimulation produced a 
population of cells which express CXCR6 (Figure 25 a & b). The percentage of cells 
which expressed the receptor was highly donor dependent and ranged from 5 - 
35%. These cells were characterised as TtYMike by their ability to produce iFN-y 
(figure 25c) and lack of IL-4 production (figure 25d); although there was some 
variation between donors, In all experiments, the percentage of cells producing IFN- 
y was above 80% and below 5% for cells producing IL-4 .
3.4 CXCL16 induces chemotaxis of Th1 cells
Following an inflammatory stimuli, chemokines are able to induce directed 
cell migration towards the site of inflammation. This is an important phenomenon in 
the immune response; although chemotaxis of cells is also important in the 
homeostatic roles of chemokines. Initiation of a chemotactic response involves the 
polarisation of the cell in which they become elongated and develop a wide 
lamallipod at the leading edge and a tail-like projection (uropod) at the trailing end. 
The cells generate filamentous actin at the leading edge and the uropod contracts 
driving the cell forwards.
CXCR6 and its ligand CXCL16 have been implicated in the trafficking of 
activated T-lymphocytes to areas of chronic inflammation (Boisvert et al, 2003; Kim 
et al, 2001; Wang et al, 2004). CXCR6 has been shown to induce directed 
migration towards CXCL16 in primary T-lymphocytes and Jurkat cells transfected 
with CXCR6 in vitro. Initial experiments in the polarised Th1 cells show that 
CXCL16 significantly increases cell migration in a concentration dependent manner 
which peaks at ~10nM (figure 26).
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Figure 25. Flow cytometric analysis of CXCR6 expression on Th1 cells.
a, b. A representative population of Th1-like cells express CXCR6. c, d. production of IFN-y 
and IL-4 from cells indicating the Th1-like phenotype. For CXCR6 measurement, cells were 
incubated with either 2.5ng/ml phycoerythrin-conjugated anti-CXCR6 antibody or isotype 
control for 30minutes. For analysis of IFN-y and IL-4 production, cells were activated with 
PMA (Phorbol 13-myristate 12-acetate) (50ng/ml) and ionomycin (500ng/ml) and incubated 
with 10jig/ml Brefeldin A. Cells were fixed in 3.7% formaldehyde, permeabilised in 0.1% 
(w/v) triton and incubated with Alexa Fluor® 488-conjugated anti-IFNy or Alexa Fluor® 488- 
conjugated anti-IL-4 antibody. Samples were then analysed by flow cytometry. Data 
corresponds to one donor (n=15)
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Figure 26. Chemotaxis of Th1 cells to CXCL16 and CXCL10. T cells (CD4*/CD45R0) 
were purified from whole blood and incubated with cytokines to induce a Th1-like 
phenotype. Cells were labelled with 5mg/ml calcein-AM and chemotaxis to CXCL16 and 
CXCL10 was measured using disposable chemotaxis plates in accordance with the 
manufacturer's instructions (Neuroprobe, Gaithersburg, MD, USA). Cell numbers were 
calculated from a standard curve. Data represents the mean +/- SD from 5 donors. * = p< 
0.05, ** = p< 0.01, *** = p< 0.001 compared to basal chemotaxis.
Th1 cells also express the receptor for the chemokine CXCL10, CXCR3; as 
a positive control for this experiment, chemotaxis towards CXCL10 was also 
measured. This produced a concentration dependent response which was highly 
significant. Although the response was statistically significant, the overall numbers 
of cells which migrated was low compared to the total number of cells used at the 
start of the assay, with a maximum of -4% and ~7% of cells migrating towards 
CXCL16 and CXCL10 respectively. This does correlate to a previous study in which 
-5%  of cells migrate towards CXCL16 (Wilbanks etal, 2001).
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3.5 Analysis of signalling pathways coupled to CXCR6 in Th1 cells
Isolation and polarisation of these cells is expensive, time consuming and 
does not result in the numbers required to carry out extensive investigations using 
SDS-PAGE western blotting techniques routinely used in determining the activation 
of signalling pathways. In the past few years the phospho-specific antibodies to a 
number of proteins used for western blotting have been validated for use in flow 
cytometry. This process uses fewer cells and would ultimately be useful in 
determining simultaneous phosphorylation of multiple proteins in a single cell. The 
antibodies used in this study were raised to recognise Mekl phosphorylated at 
ser217/221, p70S6K phosphorylated at thr421/ser424 and PKB phosphoriated at 
ser473. These antibodies were all obtained from New England Biolabs, UK, and 
have been validated by this company to demonstrate their specificity to the 
particular target, through use of specific blocking peptides. Recent experiments by 
the company and others, to validate these antibodies for flow cytometry have also 
been reported for Mek1/2 (Chow et al, 2001; Furuno et al, 2001), p70S6K (Perez et 
al, 2004) and PKB (Krutzik et al, 2004). Methodolgy for this technique has also 
been published (Krutzik & Nolan, 2003; Irish et al, 2004; Perez et al, 2004)
A method was developed in order to minimise the number of polarised Th1 
cells required; following stimulation with the relevant ligand, cells were fixed with 
formaldehyde and permeabilised with triton and incubated with a phospho-specific 
antibody. 10000 cells were analysed by flow cytometry and the median 
fluorescence was calculated. Traditional SDS-PAGE western blotting was also 
carried out using the same antibodies in order to detect whether these antiboies 
recognised other proteins.
Activation of the MAPK pathway is well characterised in T lymphocytes 
following activation of GPCRs and the TCR. Mek1 is a dual specificity MAPKK 
activated following phosphorylation by an upstream kinase. Ligation of CXCR6 by 
CXCL16 increases phosphorylation of Mek, however the extent of phosphorylation 
and kinetics were very variable (figure 27a). In general, CXCL16 induced an initial 
phosphorylation of Mek at between 1 and 1.5 minutes which then quickly 
diminished. PMA has been used in the validation of this phospho-Mek antibody for 
flow cytometry; is a potent activator of some PKC isoforms and has been shown to 
induce phosphorylation of Mek and ERK1/2 in several cell types. PMA also 
increased phosphorylation of Mek in a time dependent manner, but again the
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magnitude of the response was variable (figure 27b). Concurrent western blot 
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Figure 27. Flow cytometric analysis of MAPK signalling in Th1 cells.
a CXCL16 (10nM) -induced Mek (MAP-kinase and ERK kinase) phosphorylation 
(ser217/221). b PMA (Phorbol 13-myristate 12-acetate) (10nM) -induced Mek 
phosphorylation (ser217/221). c CXCL16 (10nM) -induced p70S6K phosphorylation 
(thr421/ser424). d PMA(10nM) mediated p70S6K phosphorylation (thr421/ser424). Donors 
exhibited different sensitivities to activation by CXCL16 and PMA which did not correlate to 
the level of CXCR6 expression. Cells were activated for the indicated times. Stimulations 
were terminated by fixing the cells in 3.7% formaldehyde and cells were permeabilised in 
0.1% (w/v) triton. Cells were incubated in 0.2^g phospho-specific antibody or 0.2 i^g isotype 
control and then in FITC-conjugated secondary antibody. Samples were analysed by flow 
cytometry. The median fluorescence was then used to calculate the increase above basal 
levels.
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Figure 28. Western blot analysis of MAPK signalling in Th1 cells
Concentration-dependent phosphorylation of Mek (MAP-kinase and ERK kinase) by 
CXCL16 at 2 minutes (top panel). Time-dependent phosphorylation of Mek and p70S6K by 
CXCL16 (10nM) or PMA (Phorbol 13-myristate 12-acetate) (10nM) (lower panel).
Following stimulation (5x10® cells/point), cells were lysed and the proteins separated on a 
10% SDS-PAGE gel. Changes in phosphorylation were detected using anti-phospho-Mek 
(Ser217/221), or -p70S6K (thr241/424) antibody and visualised by chemoluminescence. 
Equal loading of gels was verified using anti-ERK1 or anti-p70S6K antibodies. (Data shown 
is representative of one donor; n=3).
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CXCL16 phosphorylates Mek in a concentration-dependent manner which 
peaked at 10nM. Unlike the responses shown by flow cytometry, the time- 
dependent phosphorylation of Mek was later more sustained appearing at 1.5 
minutes and disappearing by 5 minutes; the response elicited by PMA was much 
greater than for CXCL16, as was seen with the flow cytometry.
One of the downstream effectors of the MAPK is p70S6K which it activated 
following by phosphorylation of a number of residues. Phosphorylation of threonine 
421 by ERK1/2 is required for the subsequent phosphorylation of the activation 
loop. An antibody specific for this phosphorylation site has been validated for use in 
flow cytometry; however unlike the phosphorylation of Mek, neither CXCL16 nor 
PMA produced any consistent trends in the phosphorylation of p70S6K between 
donors making analysis difficult (figure 27 c & d). Western blot analysis of p70S6K 
phosphorylation using the same antibody showed that CXCL16 can induce a time- 
dependent response which appears at 2 minutes and lasts until 5 minutes after 
stimulation (figure 28); although the strength of the response did vary between 
donors. PMA consistently activated a strong phosphorylation of p70S6k at Thr421 
in western blot experiments. This antibody also recognises a p70S6K homologue, 
p85S6K which displays a similar phosphorylation profile following cell stimulation by 
CXCL16 although it has higher basal activity.
PKB is another signalling molecule whose activation following TCR 
engagement and chemokine receptor ligation has been widely reported. 
Phosphorylation of PKB has been reported in T cells following CXCL16 ligation of 
CXCR6 (Wilbanks etal, 2001). Phosphorylation of ser473 is thought to be required 
for full activation of PKB and can be used as an indirect marker of this. Flow 
cytometric analysis of CXCL16-induced phosphorylation of PKB at ser473 showed 
a general trend of a maximum at 2 minutes in 3 out of the 5 donors tested, but the 
magnitude of the response varied (figure 29). Western blot analysis showed a 
concentration dependent increase of PKB phosphorylation in which phosphorylation 
was induced at 3nM and was maintained to 100nM, the maximum concentration 
used (figure 30). Jurkat cells have high basal levels of phosphorylated PKB, 
therefore unstimulated Jurkat cells were used as a positive control to verify the 
results of the western blot. A time dependent response was also seen in some 
donors that peaked at 2 minutes which correlates with the results seen from the 
flow cytometry. In all of these experiments, CXCR6 expression was measured but 
levels of receptor expression did not correlate with the magnitude of the response.
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Figure 29. Flow cytometric analysis of PKB signalling in Th1 cells
CXCL16 (lOnM) -induced protein kinase B (PKB) (ser473) phosphorylation. Cells were 
activated for the indicated times. Donor variation was observed with donors inducing 
different magnitudes of CXCL16 -induced PKB phosphorylation which did not correlate to 
the level of CXCR6 expression. Stimulations were terminated by fixing the cells in 3.7% 
formaldehyde and cells were permeabilised in 0.1% (w/v) triton. Cells were incubated in 
0.2pg phospho-PKB (ser473) antibody or 0.2jig isotype control and then in FITC-conjugated 
secondary antibody. Samples were analysed by flow cytometry. The median fluorescence 
was then used to calculate the increase above basal levels.
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Figure 30. Western blot analysis of PKB signalling in Th1 cells
Concentration-dependent phosphorylation of protein kinase B (PKB) (ser473) at 2 minutes 
(top panel). Time-dependent phosphorylation of PKB by CXCL16 (10nM) (lower panel). 
Following stimulation (5x10® cells/point), cells were lysed and the proteins separated on a 
10% SDS-PAGE gel. Changes in phosphorylation were detected using anti-phospho PKB 
(ser 473) antibody and visualised by chemoluminescence. Equal loading of gels was verified 
using anti-AKT1 antibody. (Data representative of 1 donor; n=3).
■ ° i r > T - i n < N < 0 ' « * i n ( 0  
€  d  -■3------------------------------
E CXCL16
*  (10nM)
Chapter 3: Results 85
SEB-activated PBLs
3.6 Expression of CXCR6 on SEB-activated PBLs
The availability and donor variation limited the use of the Th1 cells so a 
different type of T cell derived from PBMCs was cultured. These are PBLs activated 
using SEB and expanded in culture. Consistent with the reported expression on 
only activated T cells, at early stages in the culture, these cells have very low 
expression of GXCR6, but expression increases after 10 days to a maximum at day 
12 before levels decrease and disappear by day 14 (figure 31). As was seen with 
the Th1 cells, expression of CXCR6 did vary between donors but was typically 
between 15-30% on days 11 and 12.
Day 5 Day 10
Day 12





Figure 31. Flow cytometric analysis of CXCR6 expression on SEB-activated PBLs
CXCR6 expression on the surface of SEB-activated PBLs. Blue shaded area represents the 
isotype control (mouse lgG2B) the green line represents CXCR6 expression. Cells were 
incubated with either 2.5^g/ml phycoerythrin-conjugated anti-CXCR6 antibody or isotype 
control for 30 minutes. Samples were then analysed by flow cytometry. (Representative of 2 
experiments)
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3.7 Analysis of signalling pathways coupled to CXCR6 in SEB-activated 
PBLs
As has been shown in other cells, in these cells CXCR6 is coupled to the 
MAPK pathway (figure 32). CXCL16 induces a time dependent increase in 
phosphorylation of Mek1 which peaks at 1 minute and subsequently decreases. 
Activated Mek is known to phosphorylate ERK1/2 at Thr202 and Tyr204 and 
following CXCR6 ligation, ERK1/2 is also phosphorylated. This peaks at 1 minute 
and disappears by 4 minutes. CXCL12, the ligand for CXCR4, elicits a stronger and 
more sustained phosphorylation of both of these proteins than CXCL16, however 
typically -60% of these cells express CXCR4. Marginal phosphorylation of PKB at 
serine 473 is also observed following activation of CXCR6. This increases up to 2 
minutes and then decreases, again CXCL12 elicits a stronger response. 
Experiments to determine signal transduction were carried out on either day 11 or 
12 after isolation from blood because the cells expressed the highest levels of 
CXCR6 at this time point.
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Figure 32. CXCR6 is coupled to signal transduction pathways in SEB-activated PBLs.
Time-dependent phosphorylation of protein kinase B (PKB) (top panel), Mek (MAP-kinase 
and ERK kinase) (middle panel) and ERK (extracellular signal-regulated kinase) (lower 
panel) by CXCL16 (10nM). Following stimulation (5x10® cells/point), cells were lysed and 
the proteins separated on a 10% SDS-PAGE gel. Changes in phosphorylation were 
detected using anti-phospho-PKB (Ser473), anti-phospho-Mek (Ser217/221) or -ERK1/2 
(thr42/tyr44) antibody and visualised by chemoluminescence. Equal loading of gels was 
verified using anti-ERK1 or anti-AKT1 antibodies. (Data shown is representative of one 
donor; n=3).
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CD3-CD28-activated PBLs
3.8 Expression of CXCR6 on CD3-CD28-activated PBLs
Although SEB T-lymphoblasts express functional CXCR6, they are only able 
to be used for a limited time, because the receptor expression decreases. CD3- 
CD28-activated PBLs have a more sustained expression of CXCR6 (figure 33). 
Typical expression was ~20% at day 7 and increased and was maintained up to 
day 15, when expression was at ~35-40%. Oyer 95% of the cells expressed CD3 
and ~70% expressed CXCR4 (figure 33).
Chemotaxis of CD3-CD28-activated PBLs
3.9 CXCL16 induces Chemotaxis of CD3-CD28-activated PBLs
Since CXCR6 and its ligand CXCL16 have been implicated in the trafficking 
of activated T-lymphocytes, it was logical to investigate whether CD3-CD28- 
activated PBLs chemotax towards CXCL16. During the measurement of 
chemotaxis in CD3-CD28-activated PBLs, CXCL12 was used as a positive 
response because ~70% of the cells expressed its receptor, CXCR4, and CXCL12 
is known to mediate chemotaxis of T-lymphocytes. In CD3-CD28-activated PBLs, 
CXCL12 exhibits a highly significant concentration dependent response which 
peaks at 10nM with a chemotactic index of ~ 6 (the chemotactic index is calculated 
by the division of the raw data by the basal level of chemotaxis, therefore a 
chemotactic index of 1 represents no chemotaxis) (figure 34). CXCL16 only induces 
minimal chemotaxis which is statistically significant at 10nM; however the response 
is only weakly concentration-dependent and the maximum chemotactic index 
observed is under 2. The difference between CXCL12 and CXCL16 in their 
chemotactic responses is not solely due to the percentage of cells expressing the 
relevant receptor because the magnitude of the difference does not correlate, 
although this would be a contributing factor.


































Figure 33. Expression of surface receptors on CD3-CD28- activated PBLs.
a, c. Expression of CXCR6 on CD3-CD28 activated PBLs on day 7 after isolation. Data 
represented as a histogram (panel a) and on dot plot (panel c). b, d. Expression of CXCR6 
on CD3-CD28 activated PBLs on day 15 after isolation, e, Expression of CD3 on CD3-CD28 
activated PBLs on day 7 after isolation, f, Expression of CXCR4 on CD3-CD28 activated 
PBLs on day 7 after isolation. Levels of CD3 and CXCR4 were maintained through out the 
culture period. Data represented as a histogram (panel b) and on dot plot (panel d). Cells 
were incubated with either 2.5pg/ml phycoerythrin-conjugated anti-CXCR6 antibody, 
2.5|ig/ml phycoerythrin-conjugated anti-CD3 antibody or 2.5^g/ml phycoerythrin-conjugated 
anti-CXCR4 antibody or isotype control for 30minutes. Samples were then analysed by flow 
cytometry. (Data shown is representative of one donor; n=5)




Figure 34. Chemotaxis of CD3-CD28^activated PBLs to CXCL16 and CXCL12.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. 
Chemotaxis to CXCL16 and CXCL12 was measured using 96-well reusable chemotaxis 
chambers (Neuroprobe, Gaithersburg, MD, USA) in accordance with the manufacturer’s 
instructions. Cell numbers were determined using Cell Titer 96 AQue0Us reagent and the 
chemotactic index was calculated from basal levels of chemotaxis. Data represents the 
mean +/- SD from 3 individual experiments. * = p< 0.05, ** = p< 0.01, *** = p< 0.001 
compared to basal chemotaxis.
3.10 Inhibition of chemotaxis by PI3K inhibitors
PI3K has been widely demonstrated to be important in several aspects of 
cell migration; studies involving PI3K-knockout cells indicate PI3K-y is important in 
neutrophil chemotaxis (Li et al, 2000) this data is supported by experiments using 
the PI3K inhibitors LY294002 and wortmannin (Curnock et al, 2003; Turner et al, 
1995; Sotsios et al, 1999). Other studies have indicated that class 1A PI3Kf3 and 
PI3K8 are also involved in directional sensing. CXCR6 mediated chemotaxis is 
completely inhibited by the PI3K inhibitor, LY294002 (10pM) (figure 35). This 
inhibition is only significant at a CXCL16 concentration of 10nM. CXCL12 induced 
chemotaxis is only partially abrogated by LY294002, inhibiting chemotaxis to an 
index of -  2 and all concentrations of CXCL12 used. LY294002 preferentially 
inhibits class I PI3K isoforms, however at the concentration used, most isoforms 
would be inhibited; the results in CD3-CD28-activated PBLs suggest that CXCL12
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utilises pathways not inhibited by LY294002, which combine with PI3K to induce 
chemotaxis. The PI3K8 selective inhibitor, IC87114, does not significantly inhibit 
chemotaxis induced by either CXCL16 or CXCL12 (figure 35), indicating that this 





















Figure 35. Inhibition of chemotaxis of CD3-CD28-activated PBLs to CXCL16 and 
CXCL12 by PI3K inibitors.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with 10jxM LY294002 or 10^M IC87114 for 30 minutes. Chemotaxis to 
CXCL16 and CXCL12 was measured using 96-well reusable chemotaxis chambers 
(Neuroprobe, Gaithersburg, MD, USA) in accordance with the manufacturer’s instructions. 
Cell numbers were determined using Cell Titer 96 AQueous reagent and the chemotactic 
index was calculated from basal levels of chemotaxis. Data represents the mean +/- SD 
from 3 individual experiments. * = p< 0.05, *** = p< 0.001 compared to basal chemotaxis.
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Measurement of Actin Polymerisation - an indicator of 
chemotaxis?
Since migration of cells towards CXCL16 is difficult to assess using the 
available techniques, an alternative assay quantifying the amount of filamentous 
actin in a cell was used as a potential measure of chemotaxis. Phalloidin is a fungal 
toxin which binds to F-actin monomers in a 1:1 ratio. Fluorescent labelling of 
phalloidin allows levels of F-actin in individual cells to be measured using flow 
cytometry. Actin polymerisation occurs at the leading edge of chemotaxing cells, 
allowing the extension of lamellipodia and subsequent motility of the cell.
3.11 CXCR6-induced actin polymerisation
CXCL16 elicits both a time- and concentration dependent increase in actin 
polymerisation (figure 36). The response was almost instant with the maximum 
occurring at 15 seconds after stimulation of the cell with a concentration of 10nM 
CXCL16 and continually decreasing over 30 minutes. 10nM CXCL12 elicited a 
similar response which was maximal at 30 seconds and subsequently decreasing. 
The vehicle did not significantly induce actin polymerisation indicating that the 
responses observed following stimulation of the cells with CXC16 and CXCL12 
were due to receptor activation (figure 36).
3.12 Activation of heterotrimeric G-proteins
There are four main classes of G protein a subunit, G^, Gai, Gaq and Ga12 
which are coupled to downstream signalling cascades. Pertussis toxin (PTX) 
selectively inhibits activation of the God isoform and can therefore determine 
whether GPCRs are coupled to it.
F-actin polymerisation entirely mediated by CXCR6 and CXCR4 is 
mediated via Gd coupled receptors (figure 37a). The generation of F-actin is 
completely abolished following incubation of the cells with (pertussis toxin) PTX 
(100ng/ml) for 16 hours prior to stimulation. Incubation of these cells with the PTX 
vehicle did not affect the chemokine generated response (figure 37b). PTX slightly 
decreased the basal level of F-actin, however this was not significant.
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Figure 36. CXCL16 and CXCL12 increase actin polymerisation.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. CD3- 
CD28-activated PBLs were activated by CXCL16 or CXCL12 for appropriate times and fixed 
with 3.7% formaldehyde and permeabilised using 0.1% (w/v) triton. Actin polymerisation 
was measured using FITC-conjugated phalloidin. Data represented as the % change from 
basal fluorescence calculated from the median fluorescence +/- SD from 3 separate 
experiments. * = p< 0.05, ** = p< 0.01, *** = p< 0.001 compared to basal fluorescence.













Figure 37. Pertussis toxin (PTX) inhibits CXCL16 and CXCL12 mediated actin 
polymerisation.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. CD3- 
CD28-activated PBLs were incubated with PTX (100ng/ml) or vehicle (0.025% glycerol) for 
16 hours. Cells were activated with CXCL16 (10nM) or CXCL12 (10nM) for 30 seconds and 
fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) triton. Actin 
polymerisation was measured using FITC-conjugated phalloidin. Data represented as the % 
inhibition of the CXCL16 or CXCL12 response calculated from the median fluorescence +/- 
SD (a) or the % change from basal fluorescence calculated from the median fluorescence 
+/- SD (b). *** = p< 0.001 compared to CXCL16 or CXCL12 response. (n=3)
3.13 Actin polymerisation is abrogated by PI3K inhibitors
PI3K isoforms are localised at the leading edge of polarised cells, and have 
been linked to F-actin assembly in Dictyoostelium and mammalian fibroblasts 
through activation of Rac. In CD3-CD28-activated PBLs, LY294002 is able to 
completely abolish CXCL16 induced actin polymerisation with an IC50 of l.25|iM  
(figure 38a). A1 the concentration shown to inhibit CXCL16-mediated chemotaxis in 
these cells, actin polymerisation is inhibited by ~85% of the maximum. The vehicle 
controls do not significantly affect either the basal levels of F-actin or the CXCL16 
mediated increase (figure 38b).




















Figure 38. LY294002 inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were Isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with LY294002 for 30 minutes and were activated by CXCL16 for 30 
seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). ** = p< 0.01 compared to CXCL16 stimulated response, *** 
= p< 0.001 compared to CXCL16 stimulated response. (n=3)
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Wortmannin, another non-selective PI3K inhibitor, inhibits actin 
polymerisation in a concentration dependent response with an IC50 of 10.1nM 
(figure 39a). It reaches maximum inhibition at about 85% of the total actin 
polymerisation induced by CXCL16. The vehicle controls do not affect either the 
basal levels of F-actin or the CXCL16 mediated increase (figure 39b).
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Figure 39. Wortmannin inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with wortmannin for 10 minutes and were activated by CXCL16 for 30 
seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). * = p< 0.05 compared to CXCL16 stimulated response, *** 
= p< 0.001 compared to CXCL16 stimulated response. (n=3)
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IC87114, the selective PI3K5 inhibitor had no significant effect on the 
chemotactic response to CXCL16 (figure 40), however it is able to inhibit actin 
polymerisation Induced by CXCL16 to a maximum of ~70% with an IC50 of 2.3^M 
(figure 40a). This suggests that PI3K5 is possibly involved in cell polarisation, but 
does not have a significant role in chemotaxis. There is no significant effect of the 


















Figure 40. IC87114 inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with IC87114 for 30 minutes and were activated by CXCL16 for 30 
seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). * = p< 0.05 compared to CXCL16 stimulated response, ** = 
p< 0.01 compared to CXCL16 stimulated response. (n=3)
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3.14 mTOR is involved in actin polymerisation
Rapamycin inhibits mTOR, a protein phosphorylated by a number of 
proteins including PKB; phosphorylation of mTOR results its inactivation. 
Experiments in smooth muscle cells and fibroblasts have found that rapamycin is 
able to inhibit cell migration (Poon etal, 1996) and stress fibre formation (Crouch et 
al, 1997). Rapamycin partially inhibits F-actin formation in CXCL16 stimulated CD3- 
CD28-activated PBLs (figure 41a); it also slightly increased basal F-actin, but this 









Figure 41. Rapamycin inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with rapamycin for 60 minutes and were activated by CXCL16 for 30 
seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). * = p< 0.05 compared to CXCL16 stimulated response. 
(n=3)
Rapamycin (log M)
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3.15 Actin polymerisation is inhibited by PKC inhibitors
PKC isoforms have been found to be localised with various cytoskeletal 
proteins, including F-actin. These associations are isoform-, stimuli- and cell type 
specific allowing complex regulation of the responses. PKC activity has been 
identified in the cytoskeleton of both resting and activated cells. There are a number 
of pharmacological inhibitors of protein kinase C isoforms with varying specificities. 
RO320432 inhibits cPKC and nPKC isoforms, whereas G06976 and rottlerin are 
described as selective inhibitors of cPKC and PKC6, respectively, although there 
are reports suggesting that rottlerin is also able to inhibit PKC@. in CD3-CD28- 
activated PBLs, Ro320432 significantly inhibits CXCL16 mediated actin 
polymerisation in a concentration dependent manner with a maximum inhibition of 

























Figure 42. RO320432 inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with RO320432 for 30 minutes and were activated by CXCL16 for 
appropriate times. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% 
(wN) triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). * = p< 0.05 compared to CXCL16 stimulated response, ** = 
p< 0.01 compared to CXCL16 stimulated response. (n=3)
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At 3nM, G66976 inhibits actin polymerisation by ~40%, but at 30nM this decreases 
slightly (figure 43a) suggesting a role for cPKC isoforms in actin polymerisation by 
CXCL16. Rottlerin, at 1-1 O^M, inhibits F-actin polymerisation by -70% indicating 
that nPKCs are possibly more potent at inducing actin polymerisation. The vehicle 
controls do not significantly affect either unstimulated or stimulated actin 
polymerisation (figures 42b & 43b).
Figure 43. PKC Inhibitors reduce actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with either G06976 (Go) or rottlerin (Rott) for 30 minutes and were activated 
by CXCL16 for 30 seconds. Cells were fixed with 3.7% formaldehyde and permeabilised 
using 0.1% (w/v) triton. Actin polymerisation was measured using FITC-conjugated 
phalloidin. Data represented as the % inhibition of the CXCL16 response calculated from 
the median fluorescence +/- 3D (a) or the % change from basal fluorescence calculated 
from the median fluorescence +/- SD (b). * = p< 0.05 compared to CXCL16 stimulated 
response, *** = p< 0.001 compared to CXCL16 stimulated response. (n=3)
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3.16 MAPK pathway is linked to actin polymerisation
The MAPK pathway can be activated downstream of numerous, complex 
signalling cascades; some of which are involved in actin polymerisation, for 
example PKC can activate Raf1, a MAPKKK, which activates Mek and ERK1/2.
Inhibition of Mek, by PD98059, induces a highly significant concentration 
dependent inhibition of CXCL16 mediated actin polymerisation with an IC50 of 
3.8|xM (figure 44a). PD98059 slightly inhibits basal polymerisation of actin, but this 
was not significant (figure 44b). The inhibitor vehicle did not affect either stimulated















Figure 44. PD98059 inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with PD98059 for 60 minutes and were activated by CXCL16 for 30 
seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). ** = p< 0.01 compared to CXCL16 stimulated response, *** 
= p< 0.001 compared to CXCL16 stimulated response. (n=3)
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3.17 Rho, Rac and Cdc42 are involved in actin polymerisation
Small GTPases of the Rho family (including Rho, Rac and Cdc42) are 
critical many aspects of cell behaviour, such as lamellipod formation, gradient 
sensing and gene transcription. In the pseudopod, PI3K and PI(3,4,5)P3 colocalise 
with the small GTPase Rac1 (Huang et a/, 2003; Gardiner et al 2002). Rac1 and 
Cdc42, and their downstream effectors, PAK, WASP and WAVE stimulate a 
complex containing Arp2/3 which induces actin polymerisation. While Rad is 
important in polymerisation, Cdc42 is important in determining correct cell polarity 
with respect to the external signal. Rho is also critical in cytoskeletal reorganisation, 
via its downstream effectors, ROCK and mDia.
It is therefore not surprising that, inhibition of ROCK by Y27632 decreases 
actin polymerisation mediated by CXCR6 (figure 45a). The maximum CXCL16 
mediated actin polymerisation is inhibited by Y27632 at an ICso of 389nM, however 
this inhibition of ROCK only elicits a maximal inhibition of ~60%, indicating the 
requirement of the other proteins in initiating actin polymerisation.
Lethal toxin B (LT-B) from Clostridium difficile preferentially inhibits RhoA 
over Cdc42 and Rac. LT-B inhibits CXCL16-activated actin polymerisation in a 
concentration dependent manner, which produces ~75% inhibition of the stimulated 
response at 10ng/ml, the hightest concentration of toxin used (figure 46a). Lethal 
toxin 82 (LT-82) from Clostrictium sordellii preferentially inhibits Rad over Cdc42 
and Rho. At 10ng/ml, LT-82 completely inhibits actin polymerisation induced by 
CXCL16 (figure 47a). The IC50 values for Tox B and LT-82 are 0.12ng/ml and 
0.11ng/ml respectively. The vehicle did not significantly affect actin polymerisation 
however both of the toxins reduced basal levels of F-actin (figure 46b & 47b).











Figure 45. Y27632 inhibits actin polymerisation in CD3-CD28-actlvated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with Y27632 for 60 minutes and were activated by CXCL16 for 30 seconds. 
Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) triton. Actin 
polymerisation was measured using FiTC-conjugated phalloidin. Data represented as the % 
inhibition of the CXCL16 response calculated from the median fluorescence +/- SD (a) or 
the % change from basal fluorescence calculated from the median fluorescence +/- SD (b). 
** = p< 0.01 compared to CXCL16 stimulated response, *** = p< 0.001 compared to 
CXCL16 stimulated response. (n=3)
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Figure 46. Lethal toxin-B inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with lethal toxin-B (LT-B) for 60 minutes and were activated by CXCL16 for 
30 seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% (w/v) 
triton. Actin polymerisation was measured using FITC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). ** = p< 0.01 compared to CXCL16 stimulated response, *** 
= p< 0.001 compared to CXCL16 stimulated response. (n=3)














Figure 47. Lethal toxin-82 Inhibits actin polymerisation in CD3-CD28-activated PBLs.
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. Cells 
were pretreated with lethal toxin-82 (LT-82) for 60 minutes and were activated by CXCL16 
for 30 seconds. Cells were fixed with 3.7% formaldehyde and permeabilised using 0.1% 
(wN) triton. Actin polymerisation was measured using FlTC-conjugated phalloidin. Data 
represented as the % inhibition of the CXCL16 response calculated from the median 
fluorescence +/- SD (a) or the % change from basal fluorescence calculated from the 
median fluorescence +/- SD (b). *** = p< 0.001 compared to CXCL16 stimulated response. 
(n=3)
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Analysis of signalling pathways coupled to CXCR6 in CD3-CD28- 
activated PBLs
CD3-CD28-activated PBLs express CXCR6 which is coupled to signal 
transduction mechanisms that can regulate actin polymerisation. Further 
investigation to elucidate the interactions between these pathways indicated that 
CXCR6 is coupled to pathways utilised by other receptors, however it also revealed 
that CXCR6 may be coupled to pathways not currently reported for other 
chemokine receptors in these cells.
3.18 CXCR6 induces phosphorylation of PKB and MAPK
The MAPK pathway and PKB, as an indirect marker of PI3K activation, are 
acknowledged as two of the major signal transduction pathways in most cells. Their 
activation can regulate a number of functional responses conserved within cells. 
The full activation of a number of these molecules requires the phosphorylation of 
specific residues; this may induce a conformational change, releases an inhibitory 
mechanism or exposes further activation sites.
As described for some of the other cell types used so far, in CD3-CD28- 
activated PBLs CXCR6 can mediate phosphorylation of both the MAPK and PKB 
signalling pathways (figure 48). CXCL16 phosphorylates ERK1/2 and PKB in both a 
concentration and time dependent manner detectable at 1 and 2 minutes and then 
declines; it is maximal at 10nM. This response is initiated by the ligand, indicated by 
the vehicle control which did not elicit any response.
Further evidence of the activation of these pathways is the phosphorylation 
of downstream effectors. In CD3-CD28-activated PBLs, CXCL16 elicits a greater 
and more sustained phosphorylation of PKB than CXCL10 but the response at 
10nM is maximal at 1 minute, unlike the response from CXCL12 which peaks at 2 
minutes (figure 49). GSK3p can be phosphorylated by PKB at sei9 following ligation 
of chemokine receptors or the TCR. CXCL16 stimulation increases phosphorylation 
of GSK3J3 in a time-dependent manner, a response seen with both CXCL12 and 
CXCL10 (figure 49). Phosphorylation of GSK3p induced by CXCL16 is not as great 
as the response from both CXCL12 and CXCL10 however the kinetics display a 
similar pattern reaching a maximum at 2 minutes.
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Figure 48. CXCR6 is coupled to signal transduction pathways in CD3-CD28-activated 
PBLs
Time-dependent phosphorylation of protein kinase B (PKB) (top panel) and ERK 
(extracellular signal-regulated kinase) (lower panel) by CXCL16 (0.1-10nM). Following 
stimulation (5x10® cells/point), cells were lysed and the proteins separated on a 10% SDS- 
PAGE gel. Changes in phosphorylation were detected using anti-phospho-PKB (Ser473) or 
-ERK1/2 (thr42/tyr44) antibody and visualised by chemoluminescence. Equal loading of gels 
was verified using anti-ERK1 or anti-AKT1 antibodies. (Data shown is representative of one 
donor; n=3).
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Figure 49. Chemokine receptor activated signal transduction pathways in CD3-CD28- 
activated PBLs
a, Time-dependent phosphorylation of protein kinase B (PKB) (ser473) and glycogen 
synthase 3p (GSK3(3) (ser9) by CXCL16 (10nM), CXCL10 (10nM) and CXCL12 (10nM). b, 
Time-dependent phosphorylation of ERK (extracellular signal-regulated kinase) 
(tyr202/thr204) and p38 MAPK (thr180/tyr182) by CXCL16 (10nM), CXCL10 (10nM) and 
CXCL12 (10nM). c, Time-dependent phosphorylation of p70S6K (thr421/ser424) by 
CXCL16 (10nM), CXCL12 (10nM), UCHT-1 (10pg/ml) and PMA (Phorbol 13-myristate 12- 
acetate) (10nM). This antibody also possibly recognises the p70S6K homologue, p85S6K. 
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. CD3- 
CD28-activated PBLs were washed and left to rest overnight prior to stimulation with the 
appropriate agonist. Following stimulation (5x10® cells/point), cells were lysed and the 
proteins separated on a 10% SDS-PAGE gel. Changes in phosphorylation were detected 
using anti-phospho-specific antibody to the relevant residues and visualised by 
chemoluminescence. Equal loading of gels was verified using anti-AKT1, anti-ERK1 or anti- 
p70S6K antibodies. (Data shown is representative of one donor; n=3).
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As discussed, CXCL16 activates the MAPK pathway, shown by the phosphorylation 
of ERK1/2. In a similar pattern to that seen in the phosphorylation of PKB, the 
response from CXCL10 less sustained than that of CXCL16 and CXCL12; CXCL12 
also elicits a stronger phosphorylation than that of CXCL16 (figure 49). Another 
member of the MAPK family is p38, a protein involved in activation of gene 
transcription. CXCL16 induced phosphorylation of this protein is more prolonged 
than that of CXCL12 and CXCL10 (figure 49).
One of the proteins that can be activated downstream of MAPK and PI3K is 
p70S6K. As shown in Th1 cells, PMA is a potent activator of this protein and has 
been used as a positive control along with the UCHT1 antibody which activates 
CD3 (figure 49). CXCL16 phosphorylation of p70S6K at Thr421 and Ser424 peaks 
at 2 minutes; these are residues known to be phosphorylated by ERK1/2 and this 
phosphorylation enables the activation of p70S6K following phosphorylation of 
other residues. CXCL12, like UCHT1 generates a weaker signal which appears at 5 
minutes.
3.19 CXCR3 is coupled to Goi
Actin polymerisation induced by CXCL16 and CXCL12 was completely 
abrogated following incubation of cells with PTX; CXCR6 mediated signal 
transduction is also dependent on G^. PTX completely abolishes the 
phosphorylation of ERK1/2 and PKB induced by CXCL16 (figure 60). Cells were 
incubated with either PTX or the vehicle for 16 hours prior to stimulation; cells 
incubated with the vehicle slightly increased basal levels of PKB phosphorylation in 
unstimulated cells. This was not observed with the addition of the CXCL16 vehicle 
or with cells treated with PTX.
Chapter 3: Results 109
phospho ERK 1/2 (thr202/tyr204)




X « O O X < D ® X C M X
3 r  2’ 5' 2’
Figure 50. Pertussis toxin (PTX) inhibits CXCL16 and CXCL12 mediated signal 
transduction.
Pertussis toxin (PTX) inhibits the time-dependent phosphorylation of ERK (extracellular 
signal-regulated kinase) (tyr202/thr204) and protein kinase B (PKB) (ser473) induced by 
CXCL16 (10nM) and CXCL12 (10nM). PBMCs were isolated from whole blood and 
activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were incubated with 
pertussis toxin (100ng/ml) or vehicle (0.025% glycerol) for 16 hours and cells were activated 
with CXCL16 (10 nM) or CXCL12 (10 nM) for indicated times. Whole cell lysates were 
separated by gel electrophoresis, transferred to nitrocellulose membrane and probed using 
appropriate antibodies. Membranes were stripped and reprobed with indicated antibodies to 
verify equal loading of samples. Data representative of 3 separate experiments.
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3.20 CXCL16 induces phosphorylation of down stream effectors of 
PI3K
There are a number of signalling molecules activated downstream of PI3K; 
of these, PKB is sometimes used as an indirect measure of PI3K activation. As has 
been previously reported, CXCL16 induces phosphorylation of PKB in T- 
lymphocytes. In CD3-CD28-activated PBLs inhibitors of PI3K, LY294002, 
wortmannin and IC87114, are all able to completely inhibit phosphorylation of PKB 
at ser473 in a concentration dependent manner (figures 51, 52 & 53). IC87114, a 
selective PI3K5 inhibitor is only able to mediate complete inhibition of PKB 
phosphorylation at the maximum concentration used; the specificity for this 
compound at this concentration is not known and may therefore indicate that the 
PI3K5 isoforms is only partially responsible for phosphorylation of PKB.
These PI3K inhibitors partially inhibit CXCL16-induced ERK phosphorylation 
in CD3-CD28-activated PBLs (figures 51, 52 & 53). Phosphorylation of ERK1/2 is 
more sensitive to inhibition by wortmannin, than by LY294002 or IC87224. This 
contradicts a recent report in which CXCL16-induced activation of ERK in intestinal 
epithelial cells was independent of PI3K, but dependent on Mek (Brand et al, 2002); 
however this could be due to differences in cell types.
LY294002, wortmannin and IC87114 are able to reduce phosphorylation of 
GSK3p to basal levels at 10p.M, 100nM and 30|xM respectively (figures 51, 52 & 
53); at this concentration the IC87114 may inhibit other PI3K isoforms. S6- 
ribosomal protein is a substrate downstream of PKB and ERK1/2, all three inhibitors 
decrease CXCL16-induced phosphorylation of S6-ribosomal protein in a 
concentration dependent response although none of them completely inhibit the 
phosphorylation (figures 51, 52 & 53). However, S6 ribosomal protein can be 
activated down stream of a number of pathways, not all of which are PI3K- 
dependent.
Chapter 3: Results 111
# N ( D ' r n » - n o ^ N g  
^ !  O O> & *  -----------------------  x  —
>  °  uM LY294002 0
phospho PKB (ser473)
AKT1
phospho ERK 1/2 (thr202/tyr204)
ERK1
phospho GSK3p (ser 9)
ERK1





♦ CXCL16 (10nM) ?  LY294002 
c  + CXCL12 
°  (10nM)
Figure 51. LY294002 inhibits CXCR6 signal transduction CD3-CD28-activated PBLs
The PI3K inhibitor LY294002 (0.1-30)iM) attenuates the time-dependent phosphorylation of 
protein kinase B (PKB) (ser473), glycogen synthase 3p (GSK3p) (ser9), ERK (extracellular 
signal-regulated kinase) (tyr202/thr204) and S6-ribosomal protein (ser235/236) induced by 
CXCL16 (10nM) and CXCL12 (10nM). PBMCs were isolated from whole blood and 
activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were washed and left to 
rest overnight prior to stimulation. CD3-CD28-activated PBLs (5x10® cells/point) were 
incubated with LY294002 or vehicle for 30 minutes and cells were activated with CXCL16 
(10nM) or CXCL12 (10nM) for indicated times. Whole cell lysates were separated by gel 
electrophoresis, transferred to nitrocellulose membrane and probed using appropriate 
antibodies. Membranes were stripped and reprobed with indicated antibodies to verify equal 
loading of samples. Data representative of 3 separate experiments.
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Figure 52. Wortmannin inhibits CXCR6 signal transduction CD3-CD28-activated PBLs
The PI3K inhibitor wortmannin (1-300nM) attenuates the time-dependent phosphorylation of 
protein kinase B (PKB) (ser473), glycogen synthase 3p (GSK3P) (ser9), ERK (extracellular 
signal-regulated kinase) (tyr202/thr204) and S6-ribosomal protein (ser235/236) induced by 
CXCL16 (10nM) and CXCL12 (10nM). PBMCs were isolated from whole blood and 
activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were washed and left to 
rest overnight prior to stimulation. CD3-CD28-activated PBLs (5x106 cells/point) were 
incubated with wortmannin or vehicle for 10 minutes in the dark and cells were activated 
with CXCL16 (10nM) or CXCL12 (10nM) for indicated times. Whole cell lysates were 
separated by gel electrophoresis, transferred to nitrocellulose membrane and probed using 
appropriate antibodies. Membranes were stripped and reprobed with indicated antibodies to 




§  wortmannin 
5  +CXCL12 
C  (1 OnM)
Chapter 3: Results 113
T> O - ^ t D i - C O T - M O Q M Q
f i  1  I  5  o  ci -  ft ^ ?5
1 ? S §
phospho PKB (ser473)
AKT1
phospho ERK 1/2 (thr202/tyr204)
ERK1
phospho GSK3p (ser 9)
ERK1







5  IC87114 
<§ + CXCL12 
C. (10nM)
Figure 53. IC87114 inhibits CXCR6 signal transduction CD3-CD28-activated PBLs.
The PI3K inhibitor IC87114 (0.1-30nM) attenuates the time-dependent phosphorylation of 
protein kinase B (PKB) (ser473), glycogen synthase 3p (GSK3{J) (ser9), ERK (extracellular 
signal-regulated kinase) (tyr202/thr204) and S6-ribosomal protein (ser235/236) induced by 
CXCL16 (10nM) and CXCL12 (10nM). PBMCs were isolated from whole blood and 
activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were washed and left to 
rest overnight prior to stimulation. CD3-CD28-activated PBLs (5x106 cells/point) were 
incubated with IC87114 or vehicle for 30 minutes and cells were activated with CXCL16 
(10nM) or CXCL12 (10nM) for indicated times. Whole cell lysates were separated by gel 
electrophoresis, transferred to nitrocellulose membrane and probed using appropriate 
antibodies. Membranes were stripped and reprobed with indicated antibodies to verify equal 
loading of samples. Data representative of 3 separate experiments.
Chapter 3: Results 114
3.21 CXCL16 Activates Rapamycin-Sensitive Signalling Pathways
mTOR is a protein which can be phosphorylated by PKB resulting in its 
activation. mTOR has been reported to phosphorylate Thr389 on p70S6K, required 
for full activation. Inhibition of mTOR by rapamycin completely abolishes the 
phosphorylation of p70S6K at thr421 and ser424 induced by CXCL16 in a 
concentration-dependent manner (figure 54). CXCL12 induced phosphorylation of 
p70S6K is only partially inhibited by rapamycin, indicating that the chemokines may 
be linked to this protein through different mechanisms. Further evidence of this 
comes from S6-ribosomal protein, a downstream target of p70S6K, although it can 
be phosphorylated by p90RSK downstream of MAPK. The CXCL16 induced 
phosphorylation of S6-ribosomal protein is inhibited by rapamycin in a concentration 
dependent manner, however rapamycin has no effect on CXCL12 induced S6- 
ribosomal protein phosphorylation (figure 54).
3.22 CXCL16 activates cPKC and nPKC dependent signalling pathways
PKC isoforms can be activated by a number of stimuli and can regulate 
different signalling pathways; downstream effectors of PKC include members of the 
MAPK family although these can be either activated or inhibited depending on the 
activating stimuli, cell type and isoform activated. cPKCs can activate Raf which 
ultimately leads to phosphorylation of ERK, PKC5 has also been shown to activate 
ERK1/2. CXCL16 induced phosphorylation of ERK1/2 is inhibited by G66976 and 
rottlerin, but not RO320432 (figure 55). G66976 inhibits ERK1/2 more strongly at 
30nM than 300nM, while rottlerin is able to completely inhibit phosphorylation of 
ERK1/2. PKC can also phosphorylate p70S6K via either MAPK dependent or 
independent pathways. All three inhibitors decrease CXCL16 mediated 
phosphorylation of p70S6K. Again, G56976 mediated inhibition of p70S6K is 
stronger at 30nM than 300nM, while rottlerin and RO320432 are able to completely 
inhibit phosphorylation. RO320423 inhibition of p70S6K phosphorylation therefore 
appears to function independent of MAPK signalling. A substrate of p70S6K is S6- 
ribosomal protein, unlike its inhibition of phosphorylation of ERK1/2 and p70S6K or 
inhibition of actin polymerisation, G66976 inhibits S6-ribosomal protein more 
strongly at 300nM than at 30nM indicating that one of the isoforms it inhibits is able 
to activate S6-ribosomal protein independently of MAPK and p70S6K (figure 54). 
Ro320432 and rottlerin completely inhibit S6-ribosomal protein phosphorylation at 
10pM and 30pM respectively.
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Figure 54. Rapamycin inhibits CXCR6 signal transduction in CD3-CD28-activated 
PBLs.
Rapamycin (0.3-100nM) attenuates the time-dependent phosphorylation of p70S6K 
(thr421/ser424) and S6-ribosomal protein (ser235/236) induced by CXCL16 (10nM) and 
CXCL12 (10nM). The p70S6K antibody also possibly recognises the p70S6K homologue, 
p85S6K. PBMCs were isolated from whole blood and activated using CD3-CD28 
microbeads. CD3-CD28-activated PBLs were washed and left to rest overnight prior to 
stimulation. CD3-CD28-activated PBLs (5x106 cells/point) were incubated with rapamycin or 
vehicle for 60 minutes and cells were activated with CXCL16 (10nM) or CXCL12 (10nM) for 
indicated times. Whole cell lysates were separated by gel electrophoresis, transferred to 
nitrocellulose membrane and probed using appropriate antibodies. Membranes were 
stripped and reprobed with indicated antibodies to verify equal loading of samples. Data 
representative of 3 separate experiments.
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Figure 55. inhibition of CXCR6 mediated signal transduction by PKC inhibitors in 
CD3/CD28 lymphoblasts
The PKC inhibitors G66976, rottlerin and RO320432 attenuate the time-dependent 
phosphorylation of ERK (extracellular signal-regulated kinase) (tyr202/thr204), p70S6K 
(thr421/ser424) and S6-ribosomal protein (ser235/236) induced by CXCL16 (10nM). PMA 
(Phorbol 13-myristate 12-acetate) (10nM) was used as a positive control to verify 
phosphoryaltion of the proteins. The p70S6K antibody also possibly recognises the p70S6K 
homologue, p85S6K. RO320432 inhibits cPKC and nPKC isoforms, whereas G66976 and 
rottlerin are described as selective inhibitors of cPKC isoforms and PKC8, respectively. 
PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. CD3- 
CD28-activated PBLs were washed and left to rest overnight prior to stimulation. CD3- 
CD28-activated PBLs (5x106 cells/point) were incubated with G66976 (30-300nM), rottlerin 
(1-10fiM), R0320432 (3-30pM) or vehicle for 30 minutes and cells were activated with 
CXCL16 (10nM) or CXCL12 (10nM) for indicated times. Whole cell lysates were separated 
by gel electrophoresis, transferred to nitrocellulose membrane and probed using appropriate 
antibodies. Membranes were stripped and reprobed with indicated antibodies to verify equal 
loading of samples. Data representative of 3 separate experiments.
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3.23 CXCL16 Activates MAPK
As has been previously mentioned, CXCL16 can mediate phosphorylation of 
MAPK pathways. The phosphorylation of ERK1/2 has been shown in other cells to 
be independent of PI3K, but dependent on Mek (Brand et al, 2002). In CD3-CD28- 
activated PBLs, CXCL16 mediated phosphorylation of ERK1/2 completely 
abrogated by inhibition of Mek with PD98059 (figure 56). Phosphorylation of GSK30 
is also sensitive to inhibition of Mek in CXCL16 or CXCL12 stimulated cells (figure 
56).
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Figure 56. PD98059 inhibits CXCR6 signal transduction in CD3-CD28-activated PBLs
The Mek1/2 inhibitor PD98059 (0.1-30^M) attenuates the time-dependent phosphorylation 
of ERK (extracellular signal-regulated kinase) (tyr202/thr204) and glycogen synthase 3p 
(GSK3P) (ser9) induced by CXCL16 (10nM) and CXCL12 (10nM). PBMCs were isolated 
from whole blood and activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs 
were washed and left to rest overnight prior to stimulation. CD3-CD28-activated PBLs 
(5x10s cells/point) were incubated with PD98059 or vehicle for 60 minutes and cells were 
activated with CXCL16 (10nM) or CXCL12 (10nM) for indicated times. Whole cell lysates 
were separated by gel electrophoresis, transferred to nitrocellulose membrane and probed 
using appropriate antibodies. Membranes were stripped and reprobed with indicated 
antibodies to verify equal loading of samples. Data representative of 3 separate 
experiments.
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3.24 CXCR6 can induce NF-kB phosphorylation
A large number of signal transduction pathways ultimately have an effect on 
transcription factors. CXCL16 activates a number of these pathways (PKB, MAPK, 
and Cdc42/Rac1) and CXCR6+ T-lymphocytes are upregulated in many chronic 
inflammatory conditions. It has recently been published that CXCL16 has pro- 
inflammatory properties and can activate the transcription factor NF-kB and induce 
production of TNF-a in smooth muscle cells (Chandresakaar, et al, 2005). It is 
therefore possible that CXCR6 may be coupled to transcription factor activation in 
T-lymphocytes.
The canonical NF-kB pathway involves degradation of the inhibitory 
molecule IkB which allows phosphorylation of p65 NF-kB at a number of residues. 
The significance of phosphorylation of these sites in determining transcriptional 
activity of p65 NF-kB has been widely discussed. Okazaki et al suggests that ser 
276 is the most important marker of p65 NF-kB activation in murine embryonic 
fibroblasts; however in T cells it is thought that phosphorylation of ser536 is the 
most accurate marker of p65 NF-kB activation (Mattioli et al, 2004). Although 
CXCL12 has previously been shown to activate NF-kB in murine astrocytes (Han Y 
et al, 2001), in CD3-CD28-activated PBLs, neither CXCL16 nor CXCL12 induce 
phosphorylation of p65 NF-kB on ser276 or induce degradation of kBa (figure 57 a, 
b, c). Costimulation of CD28, with 9.3 antibody, and PMA, in the same cells, 
induces both degradation of kBa and phosphorylation of ser 276 in a time- 
dependent manner (figure 57 a & b). However, CXCL16 but not CXCL12, induces a 
time dependent phosphorylation of p65 NF-kB at ser536 which is maximal at 30 
minutes (figure 57d). This phosphorylation is not as strong as the response elicited 
by stimulation of cells with PMA and 9.3 antibody. Phosphorylation of ser536 was 
measured in cytosolic and nuclear fractions separately (figure 57e). Cytosolic 
phosphorylation of p65 increased up to 120 minutes following CXCR6 activation; an 
increase of phosphorylated p65 was also seen in the nucleus after 90 minutes. This 
activation of p65 indicates that CXCR6 is possibly coupled to the canonical 
pathway, although iKBa is not degraded, activation of p65 complexed with other 
members of the IkB may occur following CXCR6 ligation.
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Figure 57. Does CXCL16 activate the canonical NF-kB pathway?
a, PMA (Phorbol 13-myristate 12-acetate) (10nM) and 9.3 antibody (10p.g/ml) but not 
CXCL16 (10nM) induces time-dependent phosphorylation of p65 (ser276) and degradation 
of kBa. b, c, CXCL12 (10nM) does not induce phosphorylation of p65 (ser276) (b) or 
degradation of kBa(c). d, CXCL16 (10nM), but not CXCL12 (10nM) induces time- 
dependent phosphorylation of p65 (ser536). e, CXCL16 (10nM) induces translocation of 
phosphorylated p65 (ser536) from the cytosol to the nucleus. PBMCs were isolated from 
whole blood and activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were 
washed and left to rest overnight prior to stimulation with the appropriate agonist. Following 
stimulation (5x106 cells/point), cells were lysed and the proteins separated on a 10% SDS- 
PAGE gel. Changes in phosphorylation were detected using anti-phospho-specific antibody 
to the relevant residues and visualised by chemoluminescence. Equal loading of gels was 
verified using antibodies as described (Data shown is representative of one donor; n=3).
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The canonical NF-kB pathway is not the only mechanism of activating NF- 
kB dependent gene transcription. p105 NF-kB 1 is also known to be activated in T- 
lymphocytes. Following agonist stimulation, p105 is phosphorylated and degraded 
releasing the associated NF-kB proteins (p50, p65 or c-Rel), allowing them to 
translocate to the nucleus. CXCL16 induces a gradual increase in phosphorylation 
of p105 which reaches a maximum at 30 minutes and has disappeared by 60 
minutes (figure 58a). By contrast, costimulation with PMA and 9.3 antibody induces 
phosphorylation of p 105 after 5 minutes and is sustained for at least 30 minutes. 
Using an antibody for p105 it was possible to see the degradation of p105 in the 
cytoplasm following activation of CXCR6 (figure 58b). By 45 minutes there was 
complete degradation of p105 and levels did not return by 90 minutes. In 
conjunction with this, there was a concurrent sustained increase of nuclear p50 
after 15 minutes which correlates with the phosphorylation and degradation of p105 
Levels of p50 in the cytoplasm also decreased slightly after 30 minutes it is not 
clear whether this has recognised the N-terminal of the p105 protein which is 
degraded or if it is translocation of p50 proteins to the nucleus. This antibody also 
recognises a protein of ~75kDa which is possibly the product of p50 cleavage from 
p105, although it is present in both the cytoplasm and nucleus, which indicates it 
may be a longer form of the p50 molecule.
3.25 CXCR6 mediates production of proinflammatory cytokines from 
CD3-CD28-activated PBLs
Dysregulation of NF-kB signalling has been linked to the overproduction of 
pro-inflammatory cytokines associated which chronic inflammatory conditions in 
which numbers CXCR6+ T-lymphocytes are also increased. Since CXCL16 may 
activate these NF-kB pathways it is possible that activation of CXCR6 on T- 
lymphocytes may contribute to the release of these cytokines. One of the most 
important pro-inflammatory cytokines regulated by NF-kB is TNFa. There is 
evidence that CXCL12 is able to induce TNFa production from murine astrocytes 
(Han Y et al, 2001), and CXCL16 has been reported to induce TNFa production 
from smooth muscle cells (Chandrasekar et al, 2004); although there are currently 
no reports of either of these chemokines promoting TNFa release from T- 
lymphocytes.
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Figure 58. Activation of the p105 NF-kB pathway.
a, CXCL16 (10nM) and PMA (Phorbol 13-myristate 12-acetate) (10nM) and 9.3 antibody 
induces time-dependent phosphorylation of p105 (ser932). b, CXCL16 increases nuclear 
concentrations of p50. PBMCs were isolated from whole blood and activated using CD3- 
CD28 microbeads. CD3-CD28-activated PBLs were washed and left to rest overnight prior 
to stimulation with the appropriate agonist. Following stimulation (5x10° cells/point), cells 
were lysed and the proteins separated on a 10% SDS-PAGE gel. Changes in 
phosphorylation were detected using anti-phospho-specific antibody to the relevant residues 
and visualised by chemoluminescence. Equal loading of gels was verified using antibodies 
as described (Data shown is representative of one donor; n=3).
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Both CXCL16 and CXCL12 significantly increase production of TNFa from 
CD3-CD28-activated PBLs (figure 59). At 48 hours, CXCL16 regulated TNFa 
production increased in a concentration-dependent manner up to 10nM. By 72 
hours, this TNFa production had decreased, however there was still a significant 
increase at 10nM CXCL16. CXCL12 induced production of lower concentrations of 
TNFa than CXCL16 however it demonstrated a concentration-dependent increase 
which was statistically significant. At 72 hours, CXCL12 induced production low 
concentrations of TNFa which was not statistically significant. At both 48 and 72 
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Figure 59. Chemokine induced TNF-a production from CD3-CD28-activated PBLs.
CXCL16 and CXCL12 induce production of tumour necrosis factor-a (TNF-a) from CD3- 
CD28-activated PBLs. PBMCs were isolated from whole blood and activated using CD3- 
CD28 microbeads. CD3-CD28-activated PBLs were activated with CXCL16 (0.1-10 nM) or 
CXCL12 (10 nM) for indicated times. The supernatants were removed and concentrations of 
IFN-y were measured by ELISA in accordance with the manufacturer’s instructions. Data 
represented as mean +/- SD. * = p< 0.05 compared to unstimulated control, ** = p< 0.01 
compared to unstimulated control. (n=2)
Chapter 3: Results 123
Activation of the TCR is Known to promote TNFa production from T- 
lymphocytes. Stimulation of CD3 with UCHT1 elicited a concentration dependent 
increase in TNFa production in CD3-CD28-activated PBLs at both 48 and 72 hours 
which was approximately double the concentration induced by CXCL16 (figure 60). 
Stimulation of these cells with both UCHT1 and CXCL16 produced an additive 
increase over stimulation with UCHT1 alone in the concentration of TNFa. At 1nM 
CXCL16, this increase was not significant at any time point or concentration of 
UCHT1. Using 10nM CXCL16, at 48 and 72 hours, with 1pg/ml UCHT1, the additive 
effect of the costimulation was statistically significant. It is possible that at 10pg/mi, 
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Figure 60. CXCL16 increases CD3-induced TNF-a production from CD3-CD28- 
activated PBLs.
CD3 alone and co-stimulation of CD3 with CXCL16 induce production of tumour necrosis 
factor-a (TNF-a) from CD3-CD28-activated PBLs. PBMCs were isolated from whole blood 
and activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were activated with 
either UCHT1 (0.1-10^g/ml) or UCHT1 (0.1-10ng/ml) and CXCL16 (1-10 nM) for indicated 
times. Where more than one agonist was used, UCHT-1 was added for 30minutes prior to 
addition of the chemokine. The supernatants were removed and concentrations of TNF-a 
were measured by ELISA in accordance with the manufacturer’s instructions. Data 
represented as mean +/- SD. * = p< 0.05 compared to UCHT1 alone stimulated response, ** 
= p< 0.01 compared to compared to UCHT1 alone stimulated response. (n=2)
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Although CXCL12 also increased TNFa production from these cells, 
costimulation with UCHT1 and CXCL12 did not induce the same additive effect as 
was found with CXCL16 and UCHT1 (figure 61).
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Figure 61. CXCL12 has no effect on CD3-induced TNF-a production from CD3-CD28- 
activated PBLs.
CD3 alone and co-stimulation of CD3 with CXCL12 induce production of tumour necrosis 
factor-a (TNF-a) from CD3-CD28-activated PBLs. PBMCs were isolated from whole blood 
and activated using CD3-CD28 microbeads. CD3-CD28-activated PBLs were activated with 
either UCHT1 (0.1-10ng/ml) or UCHT1 (0.1-10ng/ml) and CXCL12 (10nM) for indicated 
times. Where more than one agonist was used, UCHT-1 was added for 30minutes prior to 
addition of the chemokine. The supernatants were removed and concentrations of TNF-a 
were measured by ELISA in accordance with the manufacturer's instructions. Data 
represented as mean +/- SD. (n=2)
The signalling mechanisms behind this additive effect are unclear. There was no 
augmentation in phosphorylation of PKB or S6 ribosomal protein when CD3-CD28- 
activated PBLs were co-stimulated with 1(ig/ml UCHT1 and 10nM CXCL16 
compared to stimulation with either UCHT1 or CXCL16 (figure 62). There is 
however an increase in ERK1/2 phosphorylation; this experiment would need to be 
repeated to verify this.
Chapter 3: Results 125
UCHT1 (1fjg/ml) -  .  +  -  +  -  +  -  +  -  +
CXCL16 (1 OnM) -  -  -  +  +  -  -  +  +  - .  +  +
2’ 5’ 10’
phospho PKB (ser 473)
AKT1
phospho ERK1/2 (thr202/tyr204 )
ERK1
phospho S6 ribosomal protein (ser235/236) 
ERK1
Figure 62. Activation of signal transduction pathways by CD3 activation and CXCL16
CD3 and CXCL16 alone and in combination induce phosphorylation of a number of 
signalling molecules from CD3-CD28-activated PBLs. PBMCs were isolated from whole 
blood and activated using CD3-CD28 microbeads. CD3-CD28 T lymphoblasts were 
activated with either UCHT1 (1*ig/ml), CXCL16 (10nM) or UCHT1 (1fig/ml) and CXCL16 (1- 
10nM) for indicated times. Whole cell lysates were separated by gel electrophoresis, 
transferred to nitrocellulose membrane and probed using appropriate antibodies. 
Membranes were stripped and reprobed with indicated antibodies to verify equal loading of 
samples. (n=1)
Expression of CXCR6 on T-lymphocytes positively correlates with the 
production of IFNy, another proinflammatory cytokine, from cells. Ligation of this 
receptor significantly induces production of IFNy which increases in a concentration 
dependent manner at 48 and 72 hours (figure 63). At 48 hours, 10nM (the only 
concentration used) CXCL12 also induces a significant increase in IFNy production; 
as was found in the measurement of TNFa production, the concentration of IFNy 
produced was much lower for CXCL12 than CXCL16. Ligation of CD3 by UCHT1 
also elicits a concentration dependent production of IFNy in CD3-CD28-activated 
PBLs at 48 and 72 hours (figure 64). While costimulation CXCL12 did not 
significantly alter this response, costimulation with CXCL16 did (figure 64). At 48 
hours, 10nM CXCL16 significantly increased the concentration of IFNy produced by 
UCHT1 (0.1, 1, 10 pg/ml) above that produced by UCHT1 alone (0.1, 1, 10 pg/ml). 
At 72 hours there was also an additive effect with costimulation using 1pg/ml 
UCHT1 and 10nM CXCL16 which was statistically significant.





Figure 63. Chemokine-mediated IFN-y production from CD3-CD28-activated PBLs.
CXCL16 and CXCL12 induce production of interferon-y (IFN-y) from CD3-CD28-activated 
PBLs. PBMCs were isolated from whole blood and activated using CD3-CD28 microbeads. 
CD3-CD28-activated PBLs were activated with CXCL16 (0.1-10 nM) or CXCL12 (10 nM) for 
indicated times. The supernatants were removed and concentrations of IFN-y were 
measured by ELISA in accordance with the manufacturer’s instructions. Data represented 
as mean +/- SD * = p< 0.05 compared to CXCL16 stimulated response, ** = p< 0.01 
compared to unstimulated control. (n=2)
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Figure 64. C03 and Chemokine-mediated IFN-y production from CD3-CD28-activated 
PBLs.
CD3 alone and co-stimulation of CD3 with CXCL16 or CXCL12 induce production of 
interferon-y (IFN-y) from CD3-CD28-activated PBLs. PBMCs were isolated from whole blood 
and activated using CD3-CD28 microbeads. CD3-CD28 T lymphoblasts were activated with 
either UCHT1 (0.1-10^g/ml) or UCHT1 (0.1-10ng/ml) and CXCL16 (10 nM) or CXCL12 (10 
nM) for indicated times. Where more than one agonist was used, UCHT-1 was added for 
30minutes prior to addition of the chemokine. The supernatants were removed and 
concentrations of IFN-y were measured by ELISA in accordance with the manufacturer’s 
instructions. Data represented as mean +/- SD. * = p< 0.05 compared to CXCL16 stimulated 
response, *** = p< 0.001 compared to unstimulated control.
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Cell Lines vs Primary Cells
Identification of a T-cell model with which to investigate the activation of 
CXCR6 was a critical step in this project. Previous studies about CXCR6 used 
either primary T-lymphocytes or Jurkats transfected with CXCR6. There are a 
number of T cell lines routinely used in the chemokine field which were available 
for this study. Cell lines have the advantage over primary cells in that they offer a 
sustainable source of cells and are easy and cheap to culture. Analysis of Jurkat, 
HUT-78 and Cem cells identified that they all expressed the receptor CXCR6 and 
they were therefore a logical starting point. Unfortunately none of them provided a 
suitable model with which to continue; while the initial data from the Jurkat cells 
was good, further aliquots of cells from the same source, thawed at later time 
points did not express the receptor. The reasons for this are unclear. HUT-78 and 
Cem cells continued to express similar levels of the receptor each time receptor 
expression was measured, however the signalling data obtained from these cells 
was neither reliable nor consistent. The high basal levels of phosphorylated MAPK 
observed with HUT-78 cells were unexpected and therefore made these cells 
unsuitable for analysing further signal transduction pathways. Cem cells, while 
surface expression of CXCR6 was high, the receptor did not appear to be coupled 
to signal transduction pathways. The receptor CXCR4 was able to induce 
phosphorylation of both PKB and ERK1/2 demonstrating that the cells were 
functional. Ultimately, the cell lines available were not viable for investigating the 
signal transduction pathways activated by CXCR6.
Primary T-lymphocytes have been used in a number of studies looking at 
CXCR6, and for a time, CXCR6 expression was thought to be confined to Th1 
cells. Although receptor expression has now been reported on a number of cell 
types, CXCR6 is highly expressed on activated T cells and receptor expression 
correlates with the production of IFN-y from cells. Isolation of naive T-lymphocytes 
(CD47CD45RO), and their subsequent activation with several rounds of cytokines 
produced cells with a Th1 -like phenotype, identified by the ability to produce IFN-y, 
but not IL-4. Some of these cells expressed CXCR6, however the percentage was 
not very high and varied widely between donors. This variation in CXCR6 
expression did not correlate with the variation in the responses found when 
measuring phosphorylation of proteins making analysis of the results difficult to
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interpret. The inconsistency between donors in the receptor expression and 
response to CXCR6 ligation, the low numbers and the cost of generating the cells 
limited their use.
Activated PBLs were a source of primary T-lymphocytes which expand in 
culture and were easier and cheaper to generate that the Th1 cells. Cells activated 
with SEB express the receptor after several days in culture and expression 
increases to a peak at around day 10 or 11 before decreasing. This limited the 
period in which experiments can be performed. Cells activated with CD3-CD28 
microbeads express CXCR6 for longer time periods, with receptor expression on ~ 
20% of cells by day 7, a level that was maintained, and sometimes increased for 
over a week. The appearance of CXCR6 after several days in culture during which 
cells are activated, is consistent with reports of CXCR6 expression primarily on 
activated T cells. While there was some variation between donors in levels of 
receptor expression, the CD3-CD28-activated PBLs produced more consistent 
data and were therefore used in the majority of experiments.
Measurement of Signal Transduction
Phosphorylation is required by a number of signalling molecules in order for 
activation to occur, and the phosphorylation of certain residues can be used as a 
marker of protein activation. In general these phosphorylation events were 
detected using western blotting techniques. Since the availability of Th1 cells was 
limited, it was necessary to employ a method of detecting phosphorylation events 
that did not require as many cells as western blotting. In recent years some of the 
antibodies used in western blotting have been validated for flow cytometry; this 
presented a possibility for measuring phosphorylation in the Thi cells. Following 
stimulation of cells, they were fixed and permeabilised and incubated with 
antibodies specific for phosphorylated forms of the proteins. The addition of a 
fluorescent tag to the antibody allowed the quantitative measurement of changes in 
phosphorylation by flow cytometry. This would allow the simultaneous analysis of 
multiple phosphorylation sites/proteins in a single cell, with the use of different 
coloured tags. The data was analysed by using the light scatter to gate the 
population of cells, this removes dead or disrupted cells, which often fluoresce 
brightly, from the analysis. The fluorescence was then plotted on a histogram and 
the median florescence used in subsequent calculations. The principles of this 
technique mean that it sensitive enough to detect small changes in the
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phosphorylation status of proteins, which may not be detected by western blots, 
however it is very dependent on the specificity of the antibody. This limitation is 
demonstrated by the use of the phospho-p70S6K antibody which also recognises 
p85S6K; the western blot shows up an additional band to represent this protein, 
but it is not able to be distinguished from the p70S6K signal when using flow 
cytometry. Another factor to consider with the use of this technique is the cost of 
the antibodies used, because the volumes required for flow cytometric analysis of 
phosphorylation is greater than that required for western blotting.
Consistent with the activation of other chemokine receptors, ligation of 
CXCR6 induces the phosphorylation of a number of signalling molecules, 
consistent with their activation.
Comparison of CXCR6 mediated responses with those of other chemokine 
receptors was used to determine whether similar signalling pathways were utilised; 
CXCL10, the ligand for CXCR3 was used as a control for some of the Th1 and 
CD3-CD28-activated PBL data. CXCR3 is predominantly expressed on Th1 cells 
and activated T-lymphocytes; however CXCL12, through its receptor CXCR4, 
which is expressed on the majority of cells, elicited a greater response in signalling 
experiments in CD3-CD28-activated PBLs and was therefore also used to compare 
with CXCL16 responses.
The unique structure of CXCL16, compared to other CXC chemokines, and 
its presence as a soluble or membrane bound form suggested that it may have 
functions not performed by other chemokines. This study used a recombinant form 
of the soluble chemokine in all experiments, it is currently unknown whether this is 
able to elicit different responses through CXCR6 that the membrane bound form, 
however chimeric studies using CXCL16 and CXC3LI indicate that the membrane 
bound form of the chemokine is able to activate CXCR6 as well (Heydtmann et al, 
2005; Shimoaka etal, 2002)
CXCL16-induced Chemotatic Responses
Chemokine-induced regulation of lymphocyte migration is important for their 
development and the ability of correct inflammatory responses. CXCR4 is known to 
be important in the trafficking of T-lymphocytes throughout development and 
routine immune surveillance and the CD3-CD28-activated PBLs used here 
migrated towards CXCL12. In these experiments, CXCL16 was not a very strong
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chemoattractant and the levels of migrating cells observed were very low, although 
comparative to those seen in previous studies using the soluble form of the 
chemokine. It is therefore surprising, based on in vitro experiments, that CXCR6 
has been implicated in trafficking of T-lymphocytes. The difference in levels of cells 
migrating towards CXCL16 compared to CXCL12 is partly explained by the levels 
of their receptors on the cell surface. However, the variation in response is not 
solely due to the percentage of cells expressing the relevant receptor because the 
magnitude of the difference does not correlate; the percentage of cells expressing 
each receptor does not correlate to the percentage of cells which actually migrate. 
This may be due to the limitations of the assay used; these in vitro assays may not 
reflect the in vivo capabilities of a chemokine present in both soluble and 
membrane bound forms. Cell movement is an extremely complex phenomenon, 
requiring the protrusion of a leading edge, adhesion of that edge to the 
extracellular matrix, translocation of the cell and finally the retraction of the trailing 
edge. Chemokines provide a gradient important in the directional movement of the 
cell, however it is possible that the cell surface expression of CXCL16 also plays 
an active role in the adhesion of lymphocytes which would enable more effective 
movement of the cell (Heydtmann et al, 2005). Since in these assays only the 
soluble chemokine was used it is not possible to demonstrate whether this occurs, 
but it cannot be ruled out as a reason why only low levels of cells migrate towards 
CXCL16 in vitro when in vivo there is an accumulation of CXCR6+ cells at 
inflammatory sites.
The low levels of chemotaxis observed in CD3-CD28-activated PBLs to 
CXCL16 mean that the effects of inhibitors were difficult to detect. An alternative to 
chemotaxis was the measurement of F-actin following cell stimulation. This is not a 
direct measure of chemotaxis, but it demonstrates a functional mechanism 
required for chemotaxis. Polymerisation of F-actin occurs at the leading edge of 
migrating cells and can be quantitatively measured using phalloidin which binds F- 
actin monomers in a 1:1 ratio. This technique is easier and quicker than 
chemotaxis assays; the data produced allowed detection of small changes induced 
by inhibitors and was more repeatable than the chemotaxis assays. In these 
assays, while CXCL12 did not induce as much actin polymerisation as CXCL16, 
which is surprising considering the chemotactic responses, the response was 
highly significant for both chemokines. This difference may just reflect differential 
signalling mechanisms activated by the different receptors, or an ability of CXCL16 
to induce actin polymerisation for a function other than cell migration.
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Polymerisation of actin occurs following activation of a cell in order to induce shape 
change and cell polarity or formation of the immunological synapse as welt of a 
number of other cell processes.
The signalling mechanisms which result in movement of a cell are in the 
process of being unravelled, however it will be many years before the process is 
fully understood. The Involvement of PI3K Isoforms In the chemotactic response 
has been widely studied, but many questions remain unanswered. PI3K inhibitors 
have been shown to inhibit leukocyte chemotaxis and imaging of cells has revealed 
a concentration of PI(3,4,5)P3 at the leading edge of cells (Sadhu el al, 2003). 
Since chemokine receptors are GPCRs, it is not surprising that p110y knockout 
mice display reduced chemokine mediated neutrophil and macrophage 
chemotaxis; these ceils also indicate a requirement for this PI3K isoform in 
PI(3,4,5)P3 production, PKB and Rac activation and accumulation of F-actin at the 
leading edge of cells (Li et a/, 2000; Sasaki et al, 2000). Class IA isoforms have 
also been shown to be activated downstream of GPCRs. While the non-selective 
PI3K inhibitors reduced chemokine mediated chemotaxis, the selective p110d 
inhibitor had little effect on CXCL16 mediated chemotaxis. In contrast to the results 
found here, study of neutrophil chemotaxis showed a requirement for p1105, 
however actin polymerisation was not affected (Sadhu et al, 2003). This raises 
questions about the requirement of specific PI3K isoforms in chemotaxis, and how 
stimuli- and cell-specific these are. The lack of effect of IC87114 may indicate that 
other class IA isoforms are more important than p1108 in the chemotactic response 
to CXCL16. What was surprising about the role of p1108, is the reduction of F-actin 
polymerisation in response to CXCL16. Downstream of GPCR activation, pRex-1, 
a Rao-GEF, has been demonstrated to be important in the PI(3,4,5)P3-dependent 
GTP loading of Rac1 (Weiner et al, 2002; Welch et al, 2002). It has been 
postulated that p1105 is activated downstream of Rac1 following Gpy activation of 
Rac1 through pRex-1 (Deane & Fruman, 2004). This mechanism of p110d 
activation may allow an additional regulatory pathway, allowing differential 
activation of the PI3K isoforms in different functional responses. However it is also 
possible that the chemotaxis assay used in this study was not sensitive enough to 
detect a reduction of chemotaxis.
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A number of PKC isoforms have been shown to interact with actin and the 
cytoskeleton. Of the nPKC isoforms, PKCS has been shown to bind actin in airway 
epithelial cells (Liedtke etal, 2003). PKCe is involved in the spreading of fibroblasts 
through its interactions with actin filaments and myosin II (England et al, 2002). 
PKC0 can phosphoryfate WIP (WASP-interacting protein) and therefore directly 
regulate actin reorganisation (SaSahara et al, 2002). cPKC isoforms also 
potentially have a role in the reorganisation of the actin cytoskeleton; PKCpi is 
involved in cell polarity and has been associated with microtubufes (Volchov et al, 
1998; Volchov et al, 2001). Conversely, PKCa can directly bind fascin, a protein 
involved in bundling actin which localises at the leading edge of cells; inhibition of 
this interaction attenuates cell migration (Anilkumar et al, 2003). Through inhibition 
of actin polymerisation, using the chemical inhibitors, CXCL16 is able to activate 
members of cPKC and nPKC families, and these are involved in CXCL16-mediated 
actin polymerisation. Of the isofbrms within these sub-groups, rottlerin-sensitive 
isoforms appear to have most effect on actin polymerisation and phosphorylation of 
ERK1/2.
Since CXCR6 mediated phosphorylation of ERK1/2 is mediated via G*. 
indicated by the complete abrogation of the response by PTX, the upstream 
activation processes can be speculated from previous studies. Go, can be coupled 
to ERK phosphorylation via a number of pathways (described in the introduction), 
and in these celts, CXCL16 mediated phosphorylation of ERK occurs only partially 
through a PI3K-dependent pathway. Inhibition of ERK phosphorylation appears to 
be more dependent on PKC, with rottlerin having a much greater effect, implicating 
PKC8 and possibly PKC0 in the response. PKC has isoform-specific interactions 
with activation of ERK1/2, and in general, PKC activates Raf which is upstream of 
other MAPKs. Since PKCa appears to have opposite effects on ERK 
phosphorylation to other PKC isoforms, it is possible that PKCa in these cells is 
responsible for the lack of effect of RO320432 and GC6976, while rottlerin 
exhibited a stronger attenuation of ERK phosphorylation, ft also possibly explains 
the stronger inhibition of phosphorylation seen at lower concentrations of G66976.
The ability of G06976 to inhibit phosphorylation of S6-ribosomal protein 
without inhibiting either ERK phosphorylation or phosphorylation of p70S6K 
indicates several possibilities: the isoform responsible for attenuating the inhibition 
of ERK phosphorylation at the higher concentration is not involved in
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phosphorylation of S6 ribosomal protein or that this isofbrm is coupled to an ERK 
and p70S6K independent pathway.
The role of MAPK in chemotaxis is not well defined. In these cells the 
Mek1/2 inhibitor was able to inhibit F-actin polymerisation. A recent study has 
implicated MAPK as critical in the CXCL16-mediated recruitment of cells to 
rheumatoid arthritis synovial tissue (Ruth et al, 2006). Paxillin has an important role 
in the organisation of the actin cytoskeleton; it has been found to associate with 
Mek, Raf and ERK1/2 (Ishibe etal, 2003). ERK1/2 is able to phosphorylate paxillin, 
promoting the association with FAK and ultimately the activation of Rac which 
promotes actin polymerisation (Ishibe etal, 2004).
PD98059 was also able to inhibit CXCL16 mediated phosphorylation of 
GSK30. This is possibly through the MAPK effector p9QRSK which has been 
shown to be upstream of GSK3p (Ding et al, 2005). This interaction may also be 
involved in the inhibition of actin polymerisation by PD98059, since GSK3p has 
been shown to interact with Cdc42 (Etienne-Manneville & Hail, 2003).
The MAPK p38 is phosphorylated downstream of CXCL16 in activated- 
PBLs; while p38 is traditionally believed to be involved in gene transcription 
following stress-activated signals, it has also been linked to regulation of the actin 
cytoskeleton. Both ERK1/2 and p38 are able to activate MAPK-activated protein 
kinase 2 (MK2); MK2 deficient mice show abnormal migration of mouse embryonic 
fibroblasts and neutrophils (Hannigan et al, 2001; Kolyarov et al, 2002). p38 has 
also been shown to activate PAK6, a PAK family member not activated by Cdc42 
or Rac and whose functions are so far not determined (Kaur etal, 2005).
There are a number of signalling events which indicate that CXCL16 and 
CXCL12 may be able to regulate different cellular processes. The ability of 
rapamycin to inhibit CXCL16-induced, but only partially inhibit CXCL12 induced 
phosphorylation of p70S6K and S6 ribosomal protein, suggesting a potential role 
for CXCL16 in protein translation or glucose metabolism. CXCL16 induced 
phosphorylation events also appear to be more sensitive to IC87114 than those of 
CXCL12, indicating more of a role for p1105 in CXCL16 mediated responses. 
Since PI3K is potentially involved in most cellular functions, it is not really possible 
to say how this may affect the cellular responses to the different chemokines.
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Does CXCL16 activate NF-kB?
The canonical NF-kB pathway traditionally involves the phosphorylation, 
ubiquitination and degradation of IkB allowing phosphorylation of the NF-kB p65 
subunit which then translocates to the nucleus. CXCL16 does not affect kBa but 
induces phosphorylation of p65 at serS36 and translocation to the nucleus. This 
leads to a number of questions regarding whether the canonical NF-kB pathway is 
activated by CXCL16. The ability of phosphorylation of ser536 to determine the 
activation of NF-kB is debatable, with some studies suggesting it is important in 
p65 activation in T-lymphocytes, while other studies suggest this is not the case, 
Phosphorylation of p65 at serS36 is not always associated with degradation of 
IkBoc (Doyle et al, 2005; Sasaki et al, 2005). In macrophages Btk is involved in a 
pathway in which there is no degradation of IkB(x, but p65 is phosphorylated at ser 
536 and there is increased transcriptional activity (Doyle et al, 2005). In this study, 
it was suggested that phosphorylation of p65 at ser536 was responsible for the 
LPS induced increase in transcriptional activity. Previously this group had found a 
role for Btk in TLR4 signalling to NF-kB (Jefferies et al, 2003). Activation of NF-kB 
by LPS involves a pathway which includes the adaptors MyD88 and Mai which 
activate IKKs via IRAKs and TRAF6. Since over expression of the adaptor proteins 
has been shown to promote transactivation (Mansell et al, 2004) and Btk has been 
found in complexes with both of them (Jefferies et al, 2003) it is probable that 
interactions between the adaptor proteins and Btk are responsible for the effects of 
Btk on NF-kB. T cells do not contain Btk, but it is possible that an alternative 
member of the Tec family of kinases could be involved in the phosphorylation of 
p65 by CXCL16.
Redundency of individual IkB isoforms, shown by isoform deficient mice 
indicates that although kB a is traditionally viewed as the main isofbrm involved in 
the canonical NF-kB pathway, other IkB molecules are important in NF-kB 
signalling. Thus, it is possible that the p65 is complexed with kBp or kBe. kBp is 
able to strongly bind p65/p50 heterodimers and masks both of the NLS, functioning 
to retain NF-kB in the cytoplasm (Malek et al, 2001).
in T cells, the proteasome inhibitor MG132 has been shown to reduce 
translocation of total p65 but not p65 phosphorylated at ser536 (Sasaki et al, 
2005). This study found that this phospho-p65 was not dimerised with either p50 or 
associated with kBa, IkBP or IkBs. It also describes a possible selective effect for
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p65 phosphorylated on ser536 on gene activation, binding only the IL-8, not 1CAM- 
1 promoter region.
This all suggests that CXCL16 may be able to activate the canonical NF-kB 
pathway in a way which does not involve the degradation of IkBoc. It also leads to 
the possibility that the phosphorylation of p65 on ser536 by CXCL16 is not 
connected with the activation of the canonical pathway, but that the p65 is 
dimerised with p105.
Since phosphorylation does not always mean activation, further 
experiments will be required to verify if CXCL16 can activate NF-kB, or whether the 
phosphorylation events are independent of activation.
The production of TNFa can result from the activation of a number of 
transcription factors, one of which is NF-kB. CXCL16 alone was not able to induce 
significant amounts of TNFa from cells; however the additive effects of TCR and 
CXCR6 ligation provide an intriguing possibility for costimulation. The additive 
effect of co-stimulation of the TCR and CXCR6 can be the result of a number of 
explanations; the activation of differential transcription factors; enhanced 
transcription factor activation through different signal transduction pathways or the 
activation of a positive feedback loop.
TNFa, and other pro-inflammatory cytokines, have been shown to increase 
the expression of CXCR6 on the cell surface (van der Voort et alt 2005). The CD3 
mediated TNF-a produced from these cells may therefore upregulate the 
expression of CXCR6 on the surface of the cell. It may be possible that CXCL16 
can induce an autocrine positive feedback loop to enhance the expression of 
CXCR6 and therefore production of TNF-a; however in these experiments the 
concentration of TNF-a produced may not be enough to activate this.
Activation of NF-kB induces production of TNF-a, itself a potent activator of 
NF-kB, creating a positive feedback loop. Since the mechanisms by which CXCR6 
may activate NF-kB are currently unknown, NF-kB may be activated by several 
pathways following costimulation of these cells, which induces an additive effect on 
the production of TNF-a. For example, CARMA1, activated by PKC downstream of 
TCR ligation, is required for TCR, but not IL-1- or TNF-a -activation of NF-kB, 
indicating a potential mechanism by which activation of CD3 can induce 
transcription (Wang etal, 2002).
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Synergism between TCR and IL-1R in the activation of NF-kB has been 
shown to be dependent on PKC (U et at, 2005); in this study the NF-kB nuclear 
localisation was primarily mediated by IL-1R activation, but prolonged by TCR 
engagement, this was thought to antagonise proteins involved in the normally 
transient NF-kB nuclear localisation. It is therefore possible that TCR activation of 
transcription factors can be potentiated by the chemokine receptor which prolongs 
NF-kB activation through a similar mechanism.
Activation of the MAPK pathway may be a way in which the CD3 signal 
could be enhanced by CXCL16, since there is possibly an additive phosphorylation 
of ERK1/2 in cells which were stimulated with UCHT-1 and CXCL16. The activation 
of Ras isoforms is clearly an important upstream event in ERK activation, and a 
number of studies have shown the compartmentalisation of Ras within the cell is 
important for eliciting responses induced by different stimuli (Bivona et at, 2003; 
Chiu et al, 2002; Rocks et al, 2005). The ability of MAPK phosphatases to 
dephosphorylate only the tyrosine residue on ERK, creating a pool of primed 
proteins, leads to a possibility that inhibition of these phosphatases creates a more 
sustained ERK activation (Tonks et at, 2001). If CXCL16 was able to inhibit these 
phosphatases, there could be increased gene activation via CD3 activated ERK.
Another mechanism by which the MAPK pathway may affect TNF-a 
production is through GSK3(3. Inhibition of Mek by PD98059 inhibited 
phosphorylation of GSK3p, a protein recently implicated in the regulation of 
proinflammatory cytokines (Woodgett & Ohasi, 2005).
The activation of TLRs has recently been shown to induce activation of 
ERK1/2 through a mechanism dependent on NF-kB1 p105 (Dumitri et at, 2000; 
Waterfield etal, 2004). The degradation of p105 releases TPL-2 which can activate 
ERK1/2. The results here indicate that CXCL16 can induce phosphorylation of 
p105 which is degraded in the cytosol. This may allow the activation of ERK1/2 by 
TPL-2 which can then activate gene transcription. TCR activation of TNF-a is 
unaffected in TPL2-/- cells; however LPS-induced upregulation of TNF-a is 
dramatically reduced in TPL-2-/- macrophages (Dumitru et al, 2000). It is therefore 
possible that CXCL16 and the TCR are able to induce TNF-a production through 
different mechanisms.
p38 MAPK is crucial to production of proinflamatory cytokines, including 
TNF-a (Kyriakis etal, 2001). TNF-a gene regulation in mouse macrophages has 
been found to be mainly dependent on a promoter region which contains NF-kB
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binding motifs (Shakhov et at, 1990), however a more recent study has identified 
another two regions which are able to maximise the LPS induced activation of this 
gene (Yao et al, 1997). These regions are able to bind other transcription factors, 
some of which are activate by p38 allowing maximal activation of the TNF-a gene 
through the co-ordinated activation of a number of transcription factors. p38 is able 
to affect NF-kB -dependent gene expression, possibly through regulation of TATA- 
binding protein (Carter et al, 1999). Another way in which p38 is able to increase 
TNF -a production is through the stabilisation of its mRNA (Neiniger et al, 2002). It 
is therefore possible that the increase in TNF-a production seen by co-stimulation 
of CD3 and CXCR6 could be mediated by activation of p38, since CXCL16 was 
able to induce greater phosphorylation of p38 than CXCL12 and CXCL12 does not 
induce an additive production of TNF-a as seen with CXCL16.
Another protein through which GPCRs and the TCR may cooperate is in the 
activation of p70S6K. This protein, shown to be phosphorylated by CXCL16, has 
been identified as a mechanism by which receptor tyrosine kinases and GPCRs 
synergise in DNA synthesis (Billington et al, 2005). This study suggests that 
sustained PKB activity (4 hours) correlated with the increased DNA synthesis when 
cells following GPCR and receptor tyrosine kinase activation.
Since TNF-a production can be regulated through a number of 
transcription factors, most of which can be activated downstream of the TCR, it is 
possible that in these cells the TCR and CXCR6 activate different ones and can 
therefore co-operate to enhance gene activation; however without further 




The data obtained from this project has raised a number of questions which 
can only be explained following further investigation. In order to answer some of 
these questions, the immediate experiments I would have performed would include 
the following.
• Measurement of actin polymerisation using combinations of inhibitors, for 
example, PD98059 with a PI3K inhibitor or combined PKC and PI3K 
inhibition.
•  While CXCL16 does not induce degradation of hcBot, there are other IkB 
isoforms which may by complexed with NF-kB p65. Therefore measuring 
kBp or kBe degradation may help elucidate the pathway following CXCR6 
ligation.
•  Phosphorylation of NF-kB p65 does not necessarily confer activation; 
therefore the use of EMSA experiments would indicate whether CXCL16 
can activate NF-kB.
•  The use of inhibitors of PI3K, PKC and MAPK may shed light on the 
upstream effectors responsible for the phosphorylation of NF-kB p65 and 
NF-kB p105 byCXCL16.
• Co-stimulation of CD3 with CXCR6 induced increased TNF-a production, 
which is possibly partly regulated by MAPK family members therefore 
measurement of p38 and also NF-kB phosphorylation following co­
stimulation may help elucidate the mechanism.
• Since CXCR6 expression on cells may be upregulated by TNF-a, 
measurement of levels of CXCR6 expression following CD3 ligation may 
provide insight into a mechanism of costimulation or possibly an autocrine 
mechanism by which CXCR6 can increase its own surface expression.
• Since CXCL16 can induce production of TNFa and IFNy the activation of 




Since its identification on T-lymphocytes in 1997, little has been reported 
regarding the signal transduction mechanisms coupled to CXCR6 in these cells. 
The aims of this project were to identify biological targets linked to ligation of this 
receptor. By comparing some of the responses obtained in response to CXCL16 
with responses elicited by other chemokines it has become clear that CXCR6 is 
similarly coupled to many signalling molecules; however it may also activate 
pathways not utilised by these receptors.
The experiments carried out through the duration of this project have 
identified a number of signalling molecules activated downstream of CXCR6 which 
are involved in the polymerisation of actin and also possibly the induction of gene 









Figure 65. Summary of CXCR6 activated signalling pathways.
CXCR6 induces phosphorylation of key molecules involved in a number of signalling pathways. 
CXCR6 is a G cij coupled receptor which is able to activate PI3K and its downstream effectors. 
This receptor is also coupled to the MAPK pathway and can mediate functional responses 
through these and other molecules, including PKC, small GTPases and NFkB. The ability of 
CXCR6 to induce and increase CD3-mediated cytokine production occurs through an, as yet, 
unidentified pathway. Dashed lines represent possible interactions. ERK1/2, extracellular-related 
kinase; GSK30, glycogen synthase 3fJ; MEK, MAPK kinase; mTOR, mammalian target of 
rapamycin; PI3K phosphatidylinositol 3-kinase; PKC, protein kinase C.
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While CXCR6 is able to induce low levels of T cell migration in vitro, the 
increased number of T cells expressing CXCR6 found at sites of inflammation 
indicates that in vivo this receptor may have a more profound effect. As discussed, 
membrane bound CXCL16 may be involved not only as a gradient for directional 
purposes, but also have a role in events prior to extravasation, such as adhesion, 
which would enable greater levels of migration.
The ability of these CXCR6+ cells to produce pro-inflammatory cytokines 
raises new questions about their actual role in the disease states. In conditions in 
which an accumulation of CXCR6+ T-lymphocytes are found, there is often a high 
concentration of TNFa and IFN-y and suggesting the possibility that CXCR6 may 
be responsible for more than just trafficking the cells.
Ultimately, CXCR6 and its ligand, CXCL16, are coupled to complex signal 
transduction pathways which result not only in the reorganisation of the actin 
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Appendix 1: Recipes for buffers and solutions
1. Media for Th1 polarisation
Growth Media
500ml RPM11640 media
5% (v/v) Heat inactivated foetal calf serum








10% (v/v) Heat inactivated foetal calf serum









2.1 Lysis buffer for whole ceil lysates
20mM Tris pH 7.5 
137mM NaCI 
1 % (v/v) Nonidet P-40 
10% (v/v) glycerol
1mM EDTA
1 mM sodium vanadate *
1 mM sodium molybdate *
10mM sodium fluoride *
40|ig/ml phenylmethylsulfonyl fluoride * 
0.7pg/ml pepstatin A *
10|xg/ml aprotinin *
10|xg/ml leupeptide *
10pg/ml soyabean trypsin inhibitor * 
MilliQ H20
* added just before use 









1mM sodium molybdate * 
1mM sodium vanadate * 




1 mM sodium molybdate * 
1 mM sodium vanadate * 
10mM sodium fluoride * 
MilliQ H20
* added just before use
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3. Solutions and buffers used in immunoblotting
3.1 5x SDS-sample buffer
10% (w/v) SDS 
50% (v/v) glycerol 
200mM Tris pH 6.8 
Bromophenol blue 
5% (v/v) 2-mercaptoethanoi 
MilliQ H20
3.2 Resolving gel buffer
1.5M Tris pH8.8 
0.4% SDS
Stacking gel buffer
0.5M Tris pH6.8 
0.4% SDS




MilliQ H20 9.84ml 8.17ml MilliQ H20 6.85ml
Resolving gel buffer 5.0ml 5.0ml Stacking gel buffer 3.0ml




150 pi 150 pi 10% (w/v) ammonium 
persulphate *
150 pi
TEMED * 15pl 15pl TEMED * 15pl
* added just before use









0.0375 % (w/v) SDS 





20mM Tris pH7.5 
150mM NaCI 
MilliQ H20
Tris-buffered saline + tween (TBST)
TBS as above 
0.01% (v/v) Tween-20
Stripping buffer
62.5mM Tris pH6.8 
2% (w/v) SDS
0.0077% (v/v) 2-mercaptoethanol 
MilliQ H2Q
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